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Abstract 
Inhibition of kinase activities using small molecules for the treatment of various diseases, 
including lung cancer, is one of the most pursued therapeutic targets. Molecularly 
targeted therapy aimed at the inhibition of specific protein kinase signalling activities, 
e.g. epidermal growth factor receptor (EGFR), has changed the treatment landscape of 
clinical oncology into personalised medicine. Today, lung cancer patients are stratified 
according to tumour genetic mutations and are further profiled into kinase inhibitor 
treatment options. The 4-anilinoquinazoline class of small molecules are EGFR kinase 
inhibitors, used for the treatment of adenocarcinoma NSCLC. Therapeutic challenges 
affecting the efficacy of these molecules include low bioavailability, off-target reactive 
toxicities, and acquired drug resistance. 
The core objective of this study was to investigate the formulation of 4-anilinoquinazoline 
small molecules into polymer-drug conjugates. These conjugates were intended for use 
in a micellar drug delivery mechanism using poly(N-vinylpyrrolidone) (PVP) and pH-
responsive linker groups. The 4-anilinoquinazoline anti-tumour agents carrying Michael 
acceptor electrophiles (acrylamide and acrylates) were synthesised by assembling 
various quinazolin-4(3H)-one derivatives. The preparation of a PVP delivery carrier was 
achieved by means of triazole-based RAFT/MADIX polymerisation. The ɷ-end group 
transformation of PVP into a thiol functionality was realised by aminolysis and the 
polymer-drug conjugates were then developed by 1,4-conjugated Michael addition 
reaction. The conjugates were allowed to self-organise into characteristic micelles in 
aqueous solutions. Assessments of the drug release profiles under variable pH conditions 
showed that release is favoured in the acidic tumour microenvironment. Furthermore, 
the in vitro anti-tumour efficacy of the amide-linked conjugate was demonstrated to 
match the Gefitinib ATP-competitive EGFR kinase inhibitor against EGFR wild-type and 
EGFR L858R/T790M mutant. The overall anti-tumour efficacy suggests that the mode of 
EGFR kinase inhibition is a critical determinant of anti-tumour efficacy. Further 
developments related to the present formulation are however necessary to enhance 
bioactivities of the conjugates. 





Verskeie siektes, insluitend longkanker, word behandel deur die kinase-aktiwiteite te 
inhibeer met behulp van klein molekules en is daarom een van die mees gefokusde 
terapeutiese teikens. Molekulêr-geteikende terapie wat gefokus is op die inhibering van 
spesifieke proteïenkinase seinaktiwiteite, bv EGFR, het die manier waarop hierdie siektes 
behandel word verbeter. Pasiënte met longkanker word huidiglikglik geklassifiseer op 
grond van die genetiese mutasie van hul tumor en word verder gegroepeer in die 
behandeling wat beskikbaar is om die spesifieke kinase te inhibeer. 4-anilinoquinazoline 
is ‘n klas van klein molekules wat EGFR kinase inhibeer en word gebruik om 
adenokarsinoom nie-klein selkanker te behandel. Lae bio-beskikbaarheid, nie-
geteikende reaktiewe toksisiteite en die verworwe geneesmiddelweerstand is nog 
terpeutiese uitdagings wat die effektiwiteit van hierdie molekules beïnvloed. Die doel van 
hierdie studie was om die formulering van 4-anilinoquinazolin klein molekules in 
polimeer-dwelmkonjugate te ondersoek. Hierdie was bedoel vir 'n misellige 
geneesmiddelleweringsmeganisme wat PVP-polimeer en pH-sensitiewe verbindende 
groepe gebruik. Die 4-anilinoquinazoline anti-tumor middels wat die Michael-akseptor 
elektrofiele (akrielamied en akrelaat) vervoer, was gesintetiseer deur verskillende 
quinazolin-4 (3H)-oon derivate te verbind. Triasool-gebaseerde RAFT/MADIX-
polimerisasie is gebruik om die PVP-vervoer draer te berei. Aminolise is verder gebruik 
om die ɷ-eindgroepe van PVP om te skakel na die terminale tiol groepe waarna die 
polimeer-dwelmkonjugate ontwikkel was deur middel van ‘n 1,4- gekonjugeerde 
Michael-addisie reaksie. Hierdie konjugate vorm kenmerkende miselle in waterige 
oplossings. Evaluering van die geneesmiddel-vrystelling-profiel onder verskillende pH-
kondisies demonstreer dat die tumor mikro-omgewing verkies ‘n suur omgewing. Verder 
het ons gedemonstreer dat die in vitro anti-tumor effektiwiteit van die amied-
verbindende konjugate ooreenstem met die Gefitinib ATP kompeterende EGFR kinase 
inhibeerder teen EGFR wilde-tipe en EGFR L858R/T790M mutant. Die algehele anti-
tumor effektiwiteit diu daarop dat die metode van EGFR kinase inhibisie ‘n bepalende 
faktor is in die anti-tumor effektiwiteit. Verdere ontwikkelings op die huidige 
formulering is egter nodig om die bioaktiwiteite van die konjugate te verbeter. 
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List of abbreviations 
The following index describes various abbreviations and nonstandard acronyms used 





epidermal growth factor receptor 
ATP adenosine triphosphate 
EGFR TK epidermal growth factor receptor tyrosine kinase 
TKI(s) tyrosine kinase inhibitor(s)  
SMKI(s) small-molecule kinanase inhibitor(s) 
NSCLC non-small-cell lung cancer  
SCLC small cell lung cancer 
ICH immunohistochemistry  
HER/ ErbB human epidermal growth factor receptors 
RTKs receptor tyrosine kinases 
VEGFR vascular endothelial growth factor receptor 
FDA Food and Drug Administration 
PVP poly(N-vinyl pyrrolidone) 
NVP N-vinyl pyrrolidone 
PEG-PLA polyethylene glycol-polylactic acid 
PEG polyethylene glycol 
RDRP reversible deactivation radical polymerisation  
RAFT reversible addition-fragmentation chain transfer 
MADIX macromolecular design via the interchange of xanthates 
EPR enhanced permeability and retention 
NMR nuclear magnetic resonance 
DCM dichloromethane 
TLC thin layer chromatography  
DMAP 4-dimethylaminopyridine  
HSQC heteronuclear single quantum coherence  
HMBC heteronuclear multiple bond correlation 
UPLC-MS ultra-performance liquid chromatography-tanderm mass 
spectroscopy  
UV ultraviolet 
ADRs adverse drug reactions 
NMP nitrogen-mediated polymerisation 
ATRP atom radical transformation 
DPn degree of polymerisation  
Mn number average molecular weight 
SEC size-exclusion chromatography  
MS mass spectrometry 
MALDI-TOF MS matrix assisted laser desorption ionization-time of flight mass 
spectrometry 
PDI (Ɖ) polydispersity indices  
DRI differential refractive index 
Stellenbosch University  https://scholar.sun.ac.za
 
ix 




DLS dynamic light scattering 
STEM Scanning transmission electron microscopy 
CM confocal microscopy 
STEM scanning transmission electron microscopy 
AIBN α,α´-azobisisobutyronitrile 
ESI electrospray ionisation  

















Chapter 1: Introduction and 
research objectives 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: Introduction and research objectives 
1 
Abstract  
This chapter introduces cancer of epithelial origin and the role played by epidermal 
growth factor receptor (EGFR) kinase signalling activity in promoting tumour growth 
through sustained phosphorylation. The 4-anilinoquinazoline class of small molecules is 
used in clinical oncology to inhibit the kinase signalling activity by occupying the 
adenosine triphosphate (ATP) pocket. There are challenges in the clinical application of 
these molecules. Some illustrative shortcomings are discussed, along with possible 
solutions thereof. One possible solutions is the development of polymer-drug conjugates 
to form a micellar drug delivery system. The research objectives are then formulated, as 
outlined in the final section of this chapter. 
 
Cancer is a deadly disease that accounts for over 11% of global death cases annually. The 
prevalence of cancer is highest among Eastern Asians (55%), while the African continent 
represents 7% of this incoming pandemic blight.1 There are different types of cancer, but 
carcinomas of the lung are ranked the most lethal subtype.1b Morbidity and prevalence of 
cancer is statistically projected to escalate in the economically developing world, such as 
in South Africa, as per GLOBOCAN’s collective data.1 
 
The description of cancer is based upon the intricacies of genetic mutations and 
epigenetic changes within biological cells. Accumulation of these alterations in normal 
cells can stimulate the development of autonomous qualities that are permissive to 
sustained cell proliferation.2 The manifestation of malignant properties in biosynthetic 
activities of cells was examined in the early 1920s by Otto Warburg.3 ‘The Warburg effect’ 
is consistent with the increased metabolism in proliferative tumour cells, particularly 
enhanced aerobic glycolysis for generating ATP. To meet the energetic demands of cell 
proliferation, tumours ingest nutrients from their environment using growth factors.4 
The acquired mutations in growth factor receptors are then utilised to activate metabolic 
pathways to support tumour survival.4-5 In this way, the reprogrammed metabolic 
activities in tumours can be considered as consisting of a diversely arrayed crosstalk 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: Introduction and research objectives 
2 
between signalling pathways and protein phosphorylation processes, which are 
mediated by kinases.5b  
Thus, it can be cautiously emphasised that the biosynthetic pathways underlying the 
proliferative state of tumours are profoundly influenced by growth factors and 
phosphorylation. Protein phosphorylation is a widespread process,6 while a salient 
feature of the EGFR is that of fostering cell proliferation and chronically enhancing 
intracellular phosphorylation.7 The EGFR is a type of tyrosine kinase receptor that is 
frequently used as a therapeutic prognostic marker in numerous solid tumours, such as 
lung cancer.8 Its overexpression in most cells is known to indicate the manifestation of a 
malignant phenotype.9 A landmark discovery by the Nobel Laureates Fischer and Krebs, 
established protein phosphorylation as a key regulatory mechanism in biochemical 
signalling pathways.10 The catalytic role played by the kinases in transferring a γ-
phosphate group from ATP to the hydroxyl group of serine, threonine, or tyrosine amino 
acids is thus well known (see a shematic sketch in Fig. 1.2). Given the fact that metabolic 
activities and cellular growth are intertwined through signalling pathways, it is no 
surprise that mutant EGFR stimulates phosphorylation to regulate the biochemical 
activities.7a, 11 The cascaded biological reactions ensuing from phosphorylation (also 
known as downstream signalling) have been demonstrated in many human tumour cell 
lines and xenograft models.12 
 
Figure 1.2 Reversible protein phosphorylation between (i) kinase and phosphatase 
enzymes. (ii) Kinase phosphorylation prevented by exogenous compounds such as small-
molecule kinase inhibitors. 
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With the increased understanding of the key roles played by signalling pathways, a 
complementary theme to the Warburg phenomenon is called ‘oncogene addiction’.13 The 
subject outlines tumour dependency to a signal transduction network, which is activated 
by the oncogenic proteins.13b According to Volgestein et al.,14 between two and eight 
mutant oncogenic proteins can sufficiently promote selective tumour proliferation 
advantage in a cell with about 140 intragenic mutations. These tumour-selective 
proliferation oncogenes are known as ‘mutant driver genes’, which can be grouped into 
twelve signalling pathways which modulate, namely, (i) cell fate, (ii) survival, and (iii) 
genome consistency. The rest of the genetic mutations without identifiable biological 
flaws are classified as ‘passenger’ mutations.15 In view of the oncogene addiction aspect, 
tumours rely on one to several signalling pathways to execute their biochemical 
activities. Proof of this concept has been consolidated by disparate data sources from the 
literature and clinical practices using molecularly targeted therapy [inhibition of the 
EGFR tyrosine kinase (EGFR TK) signalling pathway].13-14, 16 
 
Recent perspectives in developing more differentiated cancer therapy encourage the use 
of molecules that target specific biological pathways in mutant cells. In line with this, the 
tyrosine kinase family has become one of the primary targets in cancer treatment, and 
more than 23 small-molecule kinase inhibitors (SMKIs) are now on the market.17 The ICI 
Pharmaceuticals Parke-Davies group (the present AstraZeneca) has demonstrated 
selective anti-tumour efficacies of 4-anilinoquinazoline compounds against EGFR TK 
activities.18 The combination of high potency and good selectivity offered by these 
compounds makes them ideal choices for long-term clinical use. In addition, these 
cytotoxic agents are effective against advanced non-small-cell lung cancer (NSCLC) 
adenocarcinoma.19 Examples include Gefitinib, which received an accelerated FDA 
approval after only two phase II trials in 2003, and Erlotinib, which was endorsed in 2004 
(structures are shown in Fig. 1.3). They were both approved for second-line and third-
line monotherapy for patients under chemotherapy.20 Today, few 4-anilinoquinazoline 
molecules are clinically used against NSCLC adenocarcinomas with EGFR activating 
mutations.21 The inventory of 4-anilinoquinazolines has since been diversely expanded 
with other quinazoline derivatives, the majority of which have failed in different stages 
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of the clinical trials. These compounds derive anti-tumour activity by occupying the ATP 
binding site, thereby blocking the EGFR kinase catalytic activity.22  
 
Figure 1.3 Small-molecule tyrosine kinase inhibitors based on the 4-anilinoquinazoline 
scaffold currently in clinical use for treatment of lung adenocarcinomas.  
 
Alluding to a universal problem of mutation development in cancer, 4-
anilinoquinazolines are clinically limited to NSCLC patients with EGFR activating 
mutations (EGFR L858R is a prominent mutation that positively activates signalling 
pathways in oncogenic proteins).23 Gefitinib and Erlotinib are 4-anilinoquinazoline drugs 
that were withdrawn, due to low clinical benefits, from the US and EU markets, but not in 
Asia. Lung cancer patients that received treatment with these compounds either 
exhibited an outstanding positive or a poor response.23 This impression has inspired 
genetic profiling of lung tumours according to EGFR mutations in clinical trials and has 
further paved the new era in the management of lung cancer. At present, lung cancer 
patients are tactfully stratified according to histomorphology and genetic differentiation 
of tumours. A compulsory screening of EGFR mutations prior to medical prescription has 
also been accepted as the standard clinical practice.24 As a result, Gefitinib and Erlotinib 
were thus recalled into clinical practice, in 2015 and 2013 respectively, as first-line 
treatment drugs.21, 25  
Because of EGFR mutations, there is a renewed interest in the clinical re-evaluation of 4-
anilinoquinazoline anti-tumour agents. A series of expanded phase III clinical trials 
examining the acquired drug resistance in lung cancer was launched in 2009. 
Approximately ten phase III clinical trials comparing 4-anilinoquinazoline kinase 
inhibitors with chemo-regimens have been completed on a single-arm data collection 
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basis.21, 25-26 There have been discrepancies across randomised clinical trial designs due 
to population selection criteria, study methodology and the primary end point of 
evaluation. Nonetheless, collective data emanating from these studies have presented 
improved overall tumour responses (60–80%) and progression-free survival of the 
patients in favour of 4-anilinoquinazolines.21, 26-27 Head-to-head phase III trial studies on 
different generations of EGFR tyrosine kinase inhibitors (TKIs) have also been 
conducted; they are still ongoing (the FLAURA is expected to end in 2018).21 The 
intention is to style a first-line therapy according to EGFR somatic mutations. 
The EGFR T790M is the secondary ‘gate-keeping’ mutation that modestly encumbers the 
ATP binding pocket against quinazoline-based kinase inhibitors, thereby reducing their 
target affinity and anti-tumour efficacy.28 To challenge the situation, 4-
anilinoquinazolines bearing an electrophilic group at the C-7 position [see Fig. 1.4 (a) for 
structures] were designed to irreversibly occupy the ATP binding pocket.29 The 
electrophilic functionality allows for the proximal covalent bond formation with the 
target nucleophile, cysteine thiol (Cys 797). This has permitted an effective therapeutic 
window for EGFR T790M in preclinical models.28a, b However, doses required to elicit 
favourable pharmacological responses have often been concomitant with adverse side 
effects under the clinical setting. The intrinsic reactivity of some of these electrophilic 
funtionalities (such as acrylamide) have been demonstrated to induce non-selective 
inhibition of the wild-type and mutant EGFR.28a Off-target reactive toxicities for this set 
of compounds continues to be a medically unmet challenge.  
 
Figure 1.4 (a) Quinazoline-based kinase inhibitors targeting the EGFR T790M. The first 
two compounds (PD 168393 and Canertinib) have failed at different phases of clinical 
trials and Afatinib is an experimental drug for adenocarcinoma patients. (The acrylamide 
moiety is highlighted in grey.) 
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A different molecular approach aimed at targeting EGFR T790M has pursued a 
pyrimidine-based chemical scaffold of irreversible inhibitors [see Fig. 1.4 (b)].30 The 
pyrimidines were intended to show the T790M mutant selectivity over the wild-type 
EGFR. However, the efficacy of pyrimidine-based compounds (third generation EGFR 
kinase inhibitors) was curtailed by the newly acquired EGFR C797S mutation, within 10 
months of clinical use.30-31 In EGFR C797S, the covalent bond formation between the 
electrophilic acrylamide group and the thiol is lost because of serine substitution of the 
cysteine. The next (being the 4th) generation of small molecules, which is intended for the 
allosteric inhibition of T790M and C797S, is in the discovery pipeline.32 Despite this 
evolving genetic mutations, the ATP affinity binding assays in tumours that accrue the 
EGFR T790M mutation have shown that Gefitinib can still achieve low nanomolar (nM) 
concentration efficacies.28a Therefore, revisiting 4-anilinoquinazoline compounds with 
the intention to improve their pharmacokinetics and the therapeutic efficacy was 
considered to be.an instructive recourse.  
 
Figure 1.4 (b) EGFR T790M selective irreversible aminopyridine-based kinase 
inhibitors; WZ 004 is used as a conditional adjuvant drug in the EU markets and AZD 9291 
is under phase III clinical studies. The parent amino-pyridine scaffold (in blue) and the 
electrophilic acrylamide groups (in grey) are highlighted. 
 
One of the therapeutic shortcomings of quinazoline-based EGFR TKIs is low in vivo 
bioavailability. This has been established from plasma concentration levels after oral 
administrations.33 The poor aqueous solubility of these compounds under physiological 
conditions is essentially rooted in the parent scaffold, quinazoline, itself. Efforts to 
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with medicinal chemistry. To date, various water solubilising groups have been 
successfully attached to the C-6 and/or C-7 positions of the quinazoline parent compound 
[see Fig. 1.5 (a)]. Most of the earliest quinazoline analogues had poor aqueous solubility 
(<1 mM) and low anti-tumour efficacy.33a, 34 Further structure–activity relationship 
optimisation studies have resulted in compounds with improved IC50 values in the 
nanomolar concentration range.33a, 34 
Figure 1.5 (a) Some solubilising groups (highlighted in blue) that are used to enhance 
the bioavailability of 4-anilinoquinazolines. 
Among the most studied solubilising groups, weakly basic groups (morpholino and 
tertiary amino groups) and/or a variety of polyalcohol alkyl chains were found to be 
suitable for increasing the aqueous solubility and anti-tumour efficacy of quinazoline 
compounds.34b, 35 When solubilising groups are attached to a α,β-unsaturated 
electrophilic acrylamide substituent in irreversible inhibitors, the anti-tumour efficacy of 
the compounds tends to vary.36 These observations can be rationalised by differences in 
nucleophilic access to the Michael acceptor due to steric hindrance. The search for 
structural analogues of quinazoline with better aqueous solubility has led to a concurrent 
investigation of the pyridopyrimidine scaffold as an alternative.22, 34b, 37 A 
pyridopyrimidine can be regarded as an aza-derivative of the quinazoline scaffold 
[structures shown in Fig. 1.5 (b)]. 
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Figure 1.5 (b) Structures of (i) 4-anilinoquinazoline derivative and (ii) aza-quinazoline 
analogues with conformational similarities. 
Pyridopyrimidines (3,4-d and 3,2-d) with similar structural conformation to quinazolines 
exhibit better aqueous solubility (>10 mM) and superior anti-tumour potency to their 
quinazoline counterparts.34b In addition, the aza-quinazoline derivatives (pyrido[3,4-
d]pyrimidines) containing α,β-unsaturated electrophilic groups (acrylamide) have 
higher reactivity to cysteine thiols in comparison to quinazoline compounds such as 
Afatinib.36b This implies that the formation of thiol adducts via a Michael addition 
reaction occurs more readily in the case of the pyridopyrimidine. In hindsight, the amide 
bond is less stable in irreversible pyridopyrimidines and this reduces the therapeutic 
efficacy of this compounds.36b, 37 Because of this, the in vivo pharmacokinetics and 
therapeutic efficacy continues to favour quinazoline-based EGFR TKIs over the aza-
quinazoline analogues. Based on the above discussion, it can be deduced that poor 
aqueous solubility is among the major therapeutic impediments that precludes full 
clinical efficacy of 4-anilinoquinazolines. Attempts improving the clinical efficacy of 4-
anilinoquinazolines has included investigating the best drug administration routes. 
 
The majority of studies have focused on oral intake and occasionally on intraperitoneal 
drug delivery.38 The best anti-tumour efficacy results have been obtained from oral 
administration, especially when the compounds were formulated into fine particulate 
‘emulsions’.38 From both practical and theoretical standpoints, these compounds have a 
good potential in lung cancer treatment. Hence, this study intends to overcome some of 
the therapeutic barriers and improve the anti-tumour efficacy of 4-anilinoquinazolines 
through the development of polymer-drug conjugates. 
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It was envisaged that sustained bio-distribution of SMKIs to the tumour 
microenvironment will minimise systemic toxicity. The commonly encountered class-
specific adverse effects from 4-anilinoquinazolines include the development of grade 3/4 
skin diseases such as rash, acne, and dryness, in combination with diarrhoea, vomiting, 
asthenia, cough, and nausea.26a Occasionally, treatment-related toxicity effects include 
liver dysfunction, intestinal lung diseases, acute respiratory distress, as well as cardiac 
failure.20a, 24b, 26b To mitigate the above adverse effects, controlled bio-distribution and 
delivery of 4-anilinoquinazoline anti-tumour agents can be achieved using polymer-
based drug carriers. This ‘Trojan horse’ approach is likely to improve the EGFR mutant 
selectivity. This design can further accommodate both the passive and molecularly 
targeted kinase inhibition of tumour cells using covalently bound polymer-drug 
conjugates.  
Relevant to this study, Wang et al.39 recently entrapped a multi-target 4-
anilinoquinazoline Vandetanib using amphiphilic block copolymer polyethylene glycol-
polylactic acid (PEG-PLA) nanospherical encapsulation. Enhanced aqueous solubility and 
anti-tumour efficacy were successfully demonstrated both in vitro and in vivo. There are 
a number of advanced concepts that have used polymer carriers to selectively deliver 
therapeutic agents to diseased sites, including tumours.40 Thus, the evolution of 
pharmacokinetics and dosage forms (also known as drug formulations) into drug 
delivery systems has the potential to achieve therapeutic benefits with minimal systemic 
toxicity. Drug formulations aimed at limiting drug access to systemic circulation were 
initiated in the late 1970s.41 A plethora of modern water soluble drug formulations can 
now be illustrated in various sophisticated performances, inspired by the Ringsdorf 
model,42 mostly emanating from the field of polymer chemistry. The drug delivery 
performances of polymeric formulations can be adjusted to conveniently minimise the 
shortcomings of the small-molecule therapeutic agents.  
From a polymer therapeutics point of view, the formulation of polymeric prodrugs can 
be designed into variable architectures. The shape, size and physicochemical properties 
of macromolecular delivery vectors can be fine-tuned to enable optimal drug solubility, 
loading capacity, pharmacokinetic disposition, as well as the controlled release of drug 
molecules.40a, 41a, 43 Many clinical benefits typifying the superior therapeutic indices 
offered by this approach have been demonstrated, over several decades. Of particular 
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interest in this study is the formulation of self-encapsulating micelle structures consisting 
of the hydrophobic 4-anilinoquinazolines and hydrophilic Poly(N-vinylpyrrolidone) 
(PVP) polymer chains (see illustration in Fig. 1.6). The micelle formation process is a self-
organising colloidal dispersion by amphiphilic structures under energetically favourable 
conditions and selective solvent medium. The targeted self-organised micelles are 
projected to sequester the anti-tumour agents in a hydrophobic core structure. The core 
structure is anticipated to be sterically stabilised under physiological conditions by the 
highly hydrated PVP shell.  
 
Figure 1.6 Illustration of the target structural composition and self-organised polymer-
drug conjugate in aqueous medium for tumouritropic delivery. 
 
In addition to the formation of a hydrated PVP core that improves the aqueous solubility 
of 4-anilinoquinazolnes, the micellar self-organising process is known to assemble into a 
spherical curvature,44 though other shapes have also been generated. The high water 
solubility of PVP is conferred by its five-membered ring lactam monomers, and this 
makes PVP a suitable drug delivery carrier under biological conditions. It is a preferred 
polymer of choice that offers a lyoprotectant feature,45 which is desirable for 
physiological applications. PVP is also a biocompatible polymer; it has been used as a 
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plasma expander.46 Beyond solubilising pharmacological agents, PVP is one of the 
hydrophilic polymers that has been investigated as drug carrier alternative to PEG.47 In 
some instances, PVP drug conjugates have demonstrated longer circulation periods, 
reduced immunogenicity, and improved anti-tumour efficacy when compared to the gold 
standard polyethylene glycol (PEG) polymer.48  
The PVP homopolymer is obtained through polymerisation of N-vinylpyrrolidone (NVP), 
normally under free radical polymerisation conditions. For the desired PVP application 
in this study, it is critical that a well-defined molecular weight, narrow molar mass 
distribution, and well-preserved end group functionalities of the polymer are obtained. 
Such merits and competencies in the reversible deactivation radical polymerisation 
(RDRP) of N-vinylpyrrolidone have been established using the reversible addition-
fragmentation chain transfer (RAFT) technique.49 This technique makes use of 
thiocarbonyl thio reagents, known as RAFT agents [see Fig. 1.7 (a)], in the presence of a 
radical initiator. The RAFT agents impart living characteristics to polymerisation 
processes between a propagating chain radical and dormant species through successive 
addition and fragmentation exchange of the radicals.49a The macromolecular design via 
the interchange of xanthates (MADIX) is a type of RAFT polymerisation that specifically 
entails the use of xanthates, and is more robust and efficient in controlling NVP 
polymerisation reactions.50 According to Destarac et al.50a, 51 the rate of addition of 
unstable propagating radicals (from less activated monomers such as NVP) to the C=S 
double bond is reduced by delocalisation of the non-bonded electron pairs of the 
xanthates. The slow exchange of radicals between the dormant and propagating chains 
enables efficient control of NVP polymerisation. The outstanding advantage of the 
RAFT/MADIX systems is the flexible design of the RAFT agents that can enable tailored 
telechelic PVP polymers with reactive end groups.  
 
Figure 1.7 (a) Generic illustration of a RAFT agent. Some polymer chain properties can 
be achieved by selection of the R and Z end groups at their α- and ω-ends, respectively.49a 
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The reactive end groups in a telechelic polymer confer various polymer characteristics 
and/or conjugation functionalities.49a For the purpose of this study, this feature has been 
employed to selectively form polymer-drug conjugates at one end of the polymer chain. 
Amides and esters are among the acid-labile linkers used in polymer-drug conjugates 
because of their ability to cleave under the acidic tumour microenvironment.52 These 
linkers differ in hydrolytic stability under acidic pH. They can therefore be explored in 
designing pH-responsive polymer-drug conjugates. Thus, aryl esters and aryl amides are 
acid-labile functional groups that have been considered for hydrolysis in a tumour 
microenvironment as well as in the lysosomal compartment. It is projected that high 
vascular density and the extended permeability between endothelial cells of tumour cells 
will enable selective accumulation and retention of the polymer-drug conjugates.53 This 
is known as the enhanced permeability and retention (EPR) effect;54 the trapped 
macromolecular prodrugs can release active anti-tumour agents at this pharmacological 
site or can be taken up by the tumour cells via endocytosis.55 
A poor metabolic clearance in tumour cells encourages an extended exposure of polymer-
drug conjugates to the acidic environment to trigger the release of trapped anti-tumour 
agents. As a result, hydrolysis of the aryl amides and aryl esters is expected to occur, 
generating free amines and hydroxyl groups from the β-propionic ester/amide of the 
polymer-drug conjugate molecule [see route (i) in Fig. 1.7 (b)]. A more complicated view 
of drug release is via a retro-Michael addition reaction to yield an α,β-unsaturated 
carbonyl moiety [see route (ii) in Fig. 1.7 (b)]. However, such reversibility is much 
slower, and is supported under mildly basic conditions.56 Hence, a different line of focus, 
reviewing β-elimination in a more favourable light for targeting the tumour environment, 
requires modification of a thiol functional group. This is not addressed in this work. 
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Figure 1.7 (b) Illustration of the target polymer-drug conjugate and modes of drug 
release. 
 
In the light of the above discussion, this overall aim of this study is to overcome some of 
the therapeutic limitations and physiological drug delivery challenges in molecularly 
targeted therapy of SMKIs. The following research objectives were then formulated: 
1. Develop a small library of 4-anilinoquinazoline anti-tumour agents. 
2. Synthesise a linear telechelic PVP by RAFT/MADIX-mediated polymerisation. 
3. Carry out the modular conjugation of PVP to 4-anilinoquinazolines via Michael 
addition. 
4. Assemble PVP-(4-phenyl amine)quinazoline conjugates into micelles. 
5. Evaluate pH-stimulated drug release and anti-tumour efficacy of polymer-drug 
conjugates in vitro. 
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Kinase inhibitors intercept aberrant signal transductions in mutant proteins and 
guarantee a differentiated cancer therapy. However, the lack of target selectivity and 
prevalence of EGFR mutations can lead to the requirement for increased drug doses and 
the possibility of severe adverse effects. Despite the ever-emerging drug resistant 
mutations, the clinical application of quinazoline-based TKIs is by far the most promising 
subclass of anti-tumour agents for NSCLC. An attempt to expedite their pharmacological 
efficacy using micellar drug delivery system is investigated in this study. A more detailed 
discussion on lung cancer studies and the mechanisms that underlie its therapeutic 
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Abstract 
This chapter addresses lung cancer, with focus on the current treatment options of lung 
tumours. A recent trend in the stratification of lung cancer patients according to EGFR 
genetic mutation in tumour cells is highlighted. This is the result of continuous efforts 
aimed to improve therapeutic responses and the overall patient survival. More 
importantly, the resurgence of 4-anilinoquinazoline molecules in the treatment of lung 




Predisposition to cancerous lung diseases is frequently the result of long-term exposure 
to and inhalation of carcinogens, genetic mutations, and occasionally infectious agents.1 
In addition, it is estimated that about 5‒10% of individuals are vulnerable to hereditary 
related epigenetic causes.2 Regardless of the cause of the disease, poor prognosis and late 
diagnosis remain critical setbacks for lung cancer patient survival.3 Acquiring drug 
resistance is another exacerbating problem that continues to pose a series of hurdles 
which must be overcome to prolong patient survival. Unfortunately, lung cancer has a 
heterogeneous tumour composition, both morphologically and genetically.4 Thus, lung 
cancer can only be strategically categorised and properly managed by different treatment 
modalities. Relevant to this observation, this chapter discusses a limited scope of the 
clinical application of 4-anilinoquinazolines in molecularly targeted kinase therapy in 
lung tumours. 
Lung cancer is presented in different progressive stages: IA, IB, IIA, IIB, IIIA, IIIB, and IV.5 
One of the common problems is that lung cancer patients are often diagnosed at advanced 
disease stages (IIIB/IV) and this creates the problem of treatment refractory tumours. On 
these occasions, most patients are considered unfit for surgical intervention and are thus 
programmed into radiotherapy and/or chemotherapy. Of late, there are emerging 
treatment options such as the use of biological agents to trigger the immune system.6 
Most of the biological approaches are however still in their experimental stages. In the 
past five years, immunotherapy has begun to be an active field,6a after the results of the 
first clinical trial was made publicly available. On the other hand, molecularly targeted 
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therapy, designed to inhibit specific protein kinase signalling pathways, has advanced 
from a mere clinical approval to a genome-based personalised medicine.4a  
 
 
The characterisation of lung tumours has recently been revised and expanded for 
thoracic oncologists.3 For a long time, therapeutic intervention of lung cancer was solely 
influenced by the histological features of tumour cells. The epithelial lung tumours were 
categorised into small cell lung cancer (SCLC, ~15%) and NSCLC (~85%).4b Following 
recent revisions, NSCLC can be subdivided further into three groups: (i) squamous cell 
carcinomas, (ii) adenocarcinomas, and (iii) large cell carcinoids [see illustration in Fig. 
2.2].3, 5 Adenocarcinomas and squamous tumour cells are the most common lung cancer 
cases. Molecularly targeted kinase therapy using small molecules finds clinical 
application in the adenocarcinoma group.  
 
Figure 2.2 Pie chart showing an estimated distribution of different types of tumours 
found in lung cancer (the NSCLC group comprises adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma).7 
Classification of lung tumours for the purpose of developing a treatment option is a 
delicate process, particularly because NSCLC tumour cells continually evolve.8 
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classified tumours. As a result, immunohistochemistry (IHC) and EGFR genetic screening 
are now used as additional new tools in tumour classification.3 The IHC staining is a 
histological companion that assists in chemical differentiation of cellular and non-cellular 
tissues, especially when clear cell morphology is not available.6 Genetic screening is 
employed in defining EGFR mutations and to stratify patients according to a specific class 
of SMKIs. For the advanced medical precision of lung cancer treatment, lung tumours are 
fully characterised using histomorphology, and chemical and genetic differentiation.3 The 
suggested treatment plans are earmarked for continuous patient biopsy during the 
course of treatment, where feasible.3  
The ability to define genetic variations in tumours of identical histomorphological 
subgroups is important for the future success of molecularly targeted therapy of kinase 
inhibitors.8a It is generally accepted that intragenic diversity among the tumour cells 
occurs via distinct pathways of genetic expressions.4a, 8b As such, a therapeutic 
intervention that targets specific protein kinases (the. EGFR TK signalling pathway) can 
inhibit the oncoprotein function and yield anti-tumour activity.9 This phenomenon has 
been reinforced by the use of 4-anilinoquinazoline compounds for clinical application in 
adenocarcinoma patients with EGFR activating mutations. NSCLC adenocarcinoma 
patients are distributed across many countries and account for >60% of all lung cancer 
cases.5 The earlier randomised clinical studies on this group have demonstrated 
inconsistent therapeutic responses; therefore, genetic variation among the patients was 
scrutinised.10 Following this initiative, lung cancer treatment using molecularly targeted 
kinase inhibition can now be used to predict >70% of favourable therapeutic responses 
in patients with EGFR mutations.11 
 
 
EGFR is a member of the human epidermal growth factor receptors (HER/ ErbB), a family 
of four oncogenic proteins, collectively known as the receptor tyrosine kinases (RTKs). 
The ErbB family consists of EGRF itself (also referred to as HER1), HER2/ErbB2, 
HER3/ErbB3, and HER4/ErbB4 homologous receptors.12 These RTKs encode a similar 
structural signature of glycoproteins, which are composed of the extracellular ligand 
binding domain, a single transmembrane lipophilic segment, and a cytoplasmic (or 
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intracellular) domain. The intracellular domain is of importance as it contains the protein 
phosphorylation kinase region with the ATP binding pocket, which is successfully used 
as a therapeutic target in oncology [see the expanded phosphorylation catalysis domain 
in Fig. 2.3 (i)].12a EGFR is found in most cells, beyond those of epithelial origin, and has 
approximately 104–105 receptors per cell.12b, 13 The EGFR gene has a full length of 170 
KDa, encoded by 28 exons of segmented amino acid sequences.14 A simplified illustration 
of four EGFR subunits (divided into colour-coded exons) is shown in Fig. 2.3 (ii). 
 
 
Figure 2.3 Colour-coded structural partitions of EGFR domains. The phosphorylation 
catalysis domain is shown in a complex with the kinase inhibitor Erlotinib, (i) enlarged 
to the left. (ii) The EGFR mutation hotspots are enlarged to the right 15 A more expanded 
view of these illustrations is discussed in later sections.  
The extracellular domain of EGFR is divided into four subdomains (I–IV; colour-coded 
orange in Fig. 2.3) and, during a normal signalling process, a sequence of highly 
modulated biochemical reactions take place. First, the subdomains I and III act as 
receptor or ligand binding sites for cell surface growth factor proteins.12a The growth 
factor proteins bind to these extracellular receptor subdomains (I and III) to initiate 
kinase activation. Following binding of the ligands, cysteine-rich subdomains (II and IV) 
mediate the EGFR dimerisation processes. The EGFR-induced dimerisation process then 
decodes conformational changes in the intracellular kinase structure (colour-coded 
green). Consequently, a highly conserved amino acid sequence Asp-Phe-Gly (DFG motif) 
within the protein phosphorylation domain authenticates ATP to access the binding 
pocket in order to begin a phosphorylation process.12 The intracellular phosphorylation 
(i) (ii) 
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of key tyrosine residues is then mediated by the protein kinases, after which a platform 
for direct protein–protein interactions with the signal transducers (SH2-proteins) is 
created. The signal transduction processes are then set to cascade a stream of 
biochemical reactions to the cell nucleus, thereby modulating cell proliferation and other 
metabolic activities.16  
 
 
A controlled phosphorylation process is achieved by the balanced catalytic activity of 
kinases and phosphatases, through opposing phosphorylation and dephosphorylation 
reactions, respectively.17 To overcome aberrant kinase phosphorylation activity, 4-
anilinoquinazoline inhibitors block the intracellular phosphorylation of EGFR TK by 
occupying the ATP binding pocket. A closer look at the bound ATP to EGFR TK is colour-
coded green in Fig. 2.4 (i); the ATP structure is shown in (iii).18 Once the pocket has been 
occupied by anti-tumour agents like Gefitinib shown in (ii), phosphorylation reactions 
and downstream signal transduction cascaded via phosphotransferase channels to the 
cell nucleus are terminated. As a result, normal cellular processes such as cell division are 
put on hold. Under these conditions, tumour cells under ATP deficiency undergo 
autophagic self-cannibalism for limited survival, before they follow a programmed cell 
death.19 In view of a so-called oncogenic addiction, these tumour cells undergo oncogenic 
shock and apoptosis when the signalling pathway has been shut off. 
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Figure 2.4 Drug-sensitive EGFR mutant (i). in complex with ATP molecule (colour-coded 
green), (ii) chemical structures of EGFR TK inhibitor Gefitinib and (iii) the endogenous 
ATP ligand are also shown next to the protein complex.18 
 
 
Personalised lung cancer therapy makes use of the differences between genetic profiles 
of tumour cells, particularly those with EGFR mutant kinases.10b, 20 In essence, lung 
tumours have abundant somatic mutations in comparison with other types of cancer, 
~150 intragenic mutations per tumour cell.4a Thus, lung tumours have a heterogeneous 
and non-synonymous composition of genetic mutations, which often imposes subtle 
structural differences in proteins (as in the EGFR kinase phosphorylation catalysis 
domain). Depending on EGFR mutations, which constitutively lead to a selective tumour 
proliferation advantage, therapeutic responses to specific conventional treatments can 
vary from one patient to another. For further clarification, the therapeutic influence of 
mutations in the EGFR catalytic domain is briefly examined [exons 18–21; see enlarged 
view in Fig. 2.5 (a)].16a It should be noted here that recent studies report drug-resistance-
inducing mutations for the newly approved 3,4-aminopyridine class of compounds;21 
however, the emphasis here will now be on the T790M and L858R mutations, which are 
well studied for 4-anilinoquinazoline compounds. 
 
(ii) Gefitinib (iii) ATP (i) 
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Figure 2.5 (a) Clinically significant mutations for 4-anilinoquinazoline EGFR TKIs. The 
mutations of interest (T790M in yellow and L858R in red) are highlighted with the more 
vivid colouring.16a  
It can be deduced that EGFR mutations can vary per a given segment of amino acid 
sequence in lung tumours [see exons 18–21 in Fig. 2.5 (a)]. In exons 18 and 19, most 
mutations are substitutions and small amino acid deletions close to the ATP binding 
pocket, and mostly drug sensitising.22 Most of these mutations (highlighted in pale 
purple) are drug sensitising mutations, but an important EGFR activating mutation is in 
exon 21. A missense mutation of a nucleotide substitution, a thymidine to guanidine 
(T→G), is known to result in further amino acid substitutions, arginine for leucine 
(L858R), in the activation loop (A-loop) of the ATP binding pocket. The EGFR L858R 
(highlighted in red) is also known as a ‘gain-of-function’ mutation because it activates the 
EGFR signalling and prolongs the ATP phosphorylation. 23 This effect has also been 
implicated in sensitising tumour cells to ATP-mimetic kinase inhibitors.23a The 
mechanisms elaborating on increased binding affinity of 4-anilinoquinazoline molecules 
in EGFR L858R have been validated through enzymatic assays and are lately supported 
by docking studies.12, 21 These studies have confirmed that mutations in the A-loop affect 
the critical protein regions involved in ATP ligand recognition. 
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Another clinically relevant missense mutation is of a cytidine for thymidine (C→T) 
nucleotide substitution, which gives rise to the development of further auxiliary 
mutations in exon 20.24 The infamous EGFR T790M mutation [highlighted with a yellow 
colour in Fig. 2.5 (a)] is caused by a substitution of the methionine for threonine amino 
acid at the gatekeeping position of the hydrophobic subpocket of the ATP. The presence 
of T790M encourages drug resistance to EGFR TKIs by causing steric clashes with the 
aniline ring of 4-anilinoquinazoline kinase inhibitors. This gatekeeping mutation restores 
the binding affinity of ATP to its binding pocket and revives a selective proliferative 
advantage to drug-sensitive tumours.25,26 Further structural illustrations of this 
secondary mutation are shown with respect to the wild-type and mutant EGFR T790M in 
Fig. 2.5 (b). The anchor positions such as hydrogen bonding between the 4-
anilinoquinazoline N-3 and the protein hinge are lost.27 
 
 
Figure 2.5 (b) Wild-type EGFR in complex with Erlotinib showing the anchoring 
hydrogen bond between 4-anilinoquinazolines and the protein hinge in the ATP binding 
pocket (i). EGFR T790M (colour-coded magenta) and its steric clash limits the aniline 
ring’s access to the hydrophobic pocket and reduces the overall optimal binding of the 
whole molecule (ii).27  
 
(i) (ii) 
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Despite the improved tumour responses achieved in recent personalised molecularly 
targeted kinase therapy,11 the presence of other oncogenic proteins such as KRAS and 
BRAF have been proposed to reduce the therapeutic responses in adenocarcinoma 
patients.28 The coexistence of EGFR mutations with other oncogenic protein mutations 
has been implicated in the primary drug resistance to 4-anilinoquinazolines (refer to Fig. 
2.6 for more oncogenic protein mutations).28a, 29 Lung cancer patients with EGFR 
mutations are universally represented in the adenocarcinoma histological group, but new 
mutation drivers have also been characterised and launched as additional therapeutic 
targets by the US FDA.30 These newly discovered genetic alterations (ROS1, MET, BRAF, 
HER2, ALK, RET, FGFR2, PDGFR, and PIK3CA) also have a number of orphan drugs under 
deveopment at different clinical stages and these are combined alongside the EGFR 
inhibitors.4a, 30b, 31 Most of these new targets (BRAF, KRAS, ROS1, and PIK3CA) do not 
contain receptors per se, but they stimulate tumour proliferation via downstream 
signalling pathways when activated by receptor growth factors, such as EGFR.32  
 
 
Figure 2.6 Approximate distributions of oncogenic protein mutations found in NSCLC 
adenocarcinoma.30b, 33 Most of these mutations are responsible for promoting selective 
tumour growth advantage but they are less statistically represented across lung cancer 









Stellenbosch University  https://scholar.sun.ac.za
Chapter 2: Literature review 
33 
A number of monoclonal antibodies have also been endorsed for clinical practice, 
especially in breast cancer.34 The clinical efficacy of these agents in lung cancer has 
remained controversial, however, as they fail to prevent phosphorylation caused by EGFR 
mutations found in the extracellular regions.35 However, necitumumab and 
pembrolizumab antibodies are currently undergoing phase III clinical trials for lung 
cancer patients.36 These antibodies have demonstrated improved overall patient survival 
when used in a combination therapy with chemotherapy regimens in squamous cell 
carcinoma patients (constituting about 20% of all lung cancer cases). The general 
problem with combination therapy involving antibodies in lung cancer treatment is 
pulmonary bleeding.37 Unlike the adenocarcinoma patients, squamous cell carcinoma 
(including large cell carcinoids) patients do not have EGFR mutations, and small-
molecule 4-anilinoquinazolines can only be used as palliatives.38 
 
 
Targeting of multiple kinase pathways by using EGFR TKIs was accidentally discovered. 
Very few such inhibitors are currently under clinical pursuit. Vandetanib is an example 
of a multi-targeting kinase inhibitor of vascular endothelial growth factor receptor 
(VEGFR-2), EGFR, and RET pro-oncogene.39 VEGFR-2 is known for stimulating 
angiogenesis and promoting tumour progression. The angiogenesis process is one of 
well-documented hallmarks of cancer.40 For tumour cells to access nutrients from the 
systemic circulation, they form new micro-vessel sprouts from the existing endothelium 
blood vessels.41 As a result of this, tumour cells can successfully proliferate, detach, and 
migrate, to establish new and distant metastasis colonies. It must be noted, however, that 
some quinazoline-based clinical drugs (shown in Fig. 2.7) are also effective angiogenic 
inhibitors.  
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Figure 2.7 Some quinazoline-based angiogenic inhibitors with multi-kinase targeting 
capabilities, clinically used against RET (Vandetanib) and VEGF-2 (Cediranib). 
Among lung tumours, squamous cell carcinomas are highly metastatic and undergo 
angiogenesis more frequently.37 The antigiogenic drug Vandetanib possesses a broader 
inhibitory profile of RTKs (VEGFR-2, EGFR, and RET). It inhibits two independent key 
pathways of VEGFR and EGFR (together with downstream signalling RET).39 The multiple 
kinase targeting capabilities of this compound might possibly delay the onset of EGFR 
kinase-mediated drug resistance or upregulation of alternative oncogene protein 
pathways. In spite of this possibility, Vandetanib doses required to elicit pharmacological 
responses are high, and compromise patient safety, perhaps due to its multi-kinase 
inhibitory effects.42 During clinical phase I trials, favourable tumour responses were 
obtained with ~600 mg/day, but drug-related toxicities were also sustained beyond 300 
mg/day.42 Other pharmacokinetic irregularities included achieving minimal steady-state 
plasma concentrations after 1 month.42b Nevertheless, the encouraging overall objective 
responses from the lung cancer patients managed to secure further clinical studies for 
Vandetanib.  
Unfortunately, poor patient survival in phase III clinical trials relegated this 4-
anilinoquinazoline’s approval from the treatment of lung cancer to medullary thyroid 
cancers with RET mutations.43 It is therefore safe to conclude that RET mutations in 
medullary thyroid cancers have persuaded the endorsement of Vandetanib by the US 
FDA.44 Late-stage thyroid tumours tend to undergo metastasis via the lymph nodes in the 
neck, close to sensory areas, which makes therapeutic intervention by radiotherapy or 
the surgeon’s scalpel very challenging. Because of the new beginnings in precision 
medicine and genomic profiling, RET mutations are also being diagnosed in ~2% NSCLC 
adenocarcinoma cases.44c, 45 The efficacy assessment of 4-anilinoquinazolines in 
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populations harbouring this mutation were not performed in earlier randomised clinical 
trials, but are now being considered for re-examination, in favour of Vandetanib.44c 
The discussion above about Vandetanib highlights SMKIs polypharmacology in 
molecularly targeted therapy. Polypharmacology generally challenges the practical 
footing and patient safety, but inhibition of multiple targets is also considered ideal for 
treatment of various cancers.46 From these multi-targeting kinase inhibitor clinical 
studies, the associated problem is drug-related systemic toxicities that are concomitant 
with either elevated doses or drug accumulation over long treatment periods.43b One way 
to overcome this limitation is to explore a more controlled drug delivery and bio-
distribution of this small molecule. Thus, the emerging application of nano-delivery in 




The subject of kinase selectivity dominates in the discovery of SMKIs; it is reviewed 
elsewhere.48 A more formal presentation of inhibitor selectivity is usually interpreted 
with reference to the biology of the kinase target. Using the DrugBank database, Wu 
assigned 25% of the US FDA-approved SMKIs to more than 10 kinase targets.48b Aligned 
with Wu’s discovery is the appreciation of a large inventory of chemical scaffolds that 
display ATP-competitive inhibition kinetics. Most ATP-competitive compounds have 
been serendipitously discovered by high-throughput screening techniques combined 
with a limited panel of kinase assays.49 Over the past decade, the high-throughput 
screening method has become less practical because of the increased availability of 
purified kinases, which are prohibitively expensive for screening a large library of 
compounds. However, this has favoured analogue synthesis (structure-informed design). 
The optimum structure–activity features required for improving 4-anilinoquinazoline 
EGFR binding affinity are summarised in Fig. 2.8.50 
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Figure 2.8 Structural basis of 4-anilinoquinazoline EGFR selectivity: the 4-aniline ring 
(colour-coded purple) occupies the hydrophobic subpocket, quinazoline (colour-coded 
blue-grey) hydrogen bonding anchors the inhibitor to the protein hinge. The C-6 and C-7 
substituents (colour-coded turquoise) can be aqueous solubilising groups or stabilise the 
overall binding affinity.50 
Beyond the structure-informed drug design, current efforts involve bioinformatics and 
molecular biology. These have added kinome-wide selectivity profiling screens for the 
small molecules to reveal structural complementarity between compounds and the 
kinase targets.51 Studies have revealed that gatekeeping amino acids are among the 
critical determinants of kinase inhibitor binding affinity.52 The gatekeeping residues 
occupy a unique region, located at the entrance of a hydrophobic subpocket that is usually 
occupied by the aniline ring of the 4-anilinoquinazolines. Thus, the identity of these 
residues can influence the optimal binding of ATP-mimetic compounds such as 
quinazoline-based kinase inhibitors.25, 51 According to Backes et al.53 small gatekeeping 
residues like methionine control the access to the hydrophobic subpocket of the wild-
type EGFR. For instance, small gatekeeping residues like threonine offer selective access 
to EGFR TKIs, while bulkier substituents like methionine impart steric impediments (as 






Anchors the inhibitor to a protein hinge via 
hydrogen bonding (N-H) with methionine 769 
Water-mediated hydrogen bonding 




to increase aqueous 
solubility and/or 
binding affinity  
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In the light of the literature discussed above, our choice of 4-anilinoquinazoline 
derivatives was that of EGFR SMKIs with known pharmacological activity [PD 153035, 
Gefitinib and Erlotinib; see Fig. 2.9 (a)]. Of note is that PD 153035 has low nanomolar 
EGFR binding affinity in enzymatic assays and poor aqueous solubility in vivo.55 Although 
PD 153035 was already discovered in 1994,55 this compound has not yet been evaluated 
against EGFR L858R/T790M mutations. Gefitinib and Erlotinib, on the other hand, show 
decreased potency, by two to three orders of magnitude, against drug resistant EGFR 
T790M in biochemical assays.24-25, 55 Pawar et al.56 have demonstrated that a 6,7-
dimethoxy structural analogue of Erlotinib is more potent than Erlotinib against EGFR 
L858R/T790M.  
 
Figure 2.9 (a) Some EGFR SMKIs with known anti-tumour pharmacological activity 
selected to model our study of 4-anilinoquinazoline compounds.24-25, 55 
Reflecting on the above three clinical drugs with high EGFR binding affinity and target 
selectivity, the 4-anilino fragment and the quinazoline skeleton attracted our interest as 
the core structural requirements for the study. For this class of compounds, it is known 
that the C-6 and C-7 positions are the optimal substitution positions to improve the 
solubility and anti-tumour efficacy. Our focus has mainly been to functionalise the C-6 
position of these compounds with a linker group that can form covalent conjugation with 
a biocompatible polymer of interest, i.e. PVP. For drug delivery purposes, the position C-
7 was intended to be used to influence the rate of drug release, should the conjugates 
have poor stability under physiological conditions. Hence, structural variations in 4-
anilinoquinazoline compounds were formulated as shown in Fig. 2.9 (b).  
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Figure 2.9 (b) Typical examples of 4-anilinoquinazoline compounds with the core 
structural resemblance to EGRF-selective clinical candidate drugs. 
 
 
The 6,7-dialkoxy-substituted 4-anilinoquinazoline derivatives are potent ATP-
competitive EGFR kinase inhibitors.55, 57 With precedence set by these solubilising 
groups, irreversible inhibitors have also been developed by attaching a Michael acceptor 
electrophile at the C-7 position.50c The acrylamides are the most studied electrophilic 
fragments for irreversible inhibition. They have been proven to efficiently overcome in 
vivo competition with endogenous ATP substrates and drug resistance associated with 
the gatekeeping mutation (EGFR T790M).58 The Parke-Davies group has demonstrated 
that the C-6 position is capable of irreversible interaction with nucleophilic cysteine 
residues.50c As a result, the C-7 position is often used for attaching water solubilising 
groups, while the C-6 position is substituted with Michael acceptor electrophiles [see Fig. 
2.10 (a)] to alkylate cysteine thiols (Cys 797) adjacent to the ATP-binding pocket.59 PD 
168393 has low plasma concentration in clinical models, while Afatinib and Dacomitinib 
are used as clinical drugs in the EU for the treatment of NSCLC adenocarcinoma.60 
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Figure 2.10 (a) Examples of EGFR cysteine targeting 4-anilinoquinazoline irreversible 
kinase inhibitors with the Michael acceptor at position C-6.  
The above irreversible inhibitors [shown in Fig. 2.10 (a)] retain high binding affinity and 
overcome the odds of a direct steric clash with gatekeeping EGFR T790M mutation.58 The 
irreversible covalent formation with the EGFR is known to prolong kinase inhibition 
activity at minimum drug doses, and improves efficacy.27, 56 In hindsight, reversible ATP-
competitive EGFR kinase inhibition activity is well tolerated by normal cells,48a but the 
irreversible covalent formation with 4-anilinoquinazoline results in indiscriminate 
tumour to non-tumour off-targeting effects. As a result, lung cancer patients under 
treatment with 4-anilinoquinazoline irreversible inhibitors experience drug-related 
toxicities due to non-selective inhibition of the wild-type EGFR.61 This problem 
underlines the need for improved targeting methods, such as the differential delivery of 
irreversibly binding anti-tumour agents.  
Irreversible covalent inhibitors are often avoided; they have been persistently rejected 
by the pharmaceutical industries when it comes to treating chronic diseases. This is 
because continuous exposure to covalent bond forming drugs is associated with 
increased risks of protein modifications, mutagen formation, and idiosyncratic immune 
responses.62 Fortunately, some reviewers have emphasised the risks and therapeutic 
benefits of covalently binding drugs, which brought about the revival of irreversible 
kinase inhibitors.63  
Our line of synthesis in this study is to develop irreversible inhibitors, but use the 
cysteine-trapping electrophilic group as a linker to the polymer. The strategy is to form a 
covalent bond to an α,β-unsaturated carbonyl electrophilic moiety via the Michael 
addition reaction.64 With this in mind, our synthetic goal is to target 4-
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anilinoquinazolines with an acrylamide or acrylate functionality, as shown in Fig. 2.10 
(b) [revisited in Chapter 03]. 
 
Figure 2.10 (b) 4-Anilinoquinazolines with acrylamide or acrylate functionality targeted 
in our synthesis. 
 
 
Lung cancer has low overall patient survival rates because it becomes symptomatic in the 
late progression stages. At the stage of primary diagnosis, lung tumours have undergone 
several genetic variations, and this presents a huge difficulty in managing lung cancer 
treatment. As a result, the treatment landscape in lung cancer is finally shifting towards 
genetically informed molecularly targeted kinase therapies. This chapter has reflected on 
the clinical application of 4-anilinoquinazoline kinase inhibitors (reversible and 
irreversible) against lung tumours. Molecularly targeted kinase therapy is a rapidly 
evolving field, with new emerging targets and anti-tumour agents alongside EGFR TKIs; 
however, the discussion has been restricted to 4-anilinoquinazoline molecules.  
Our study addresses the use of 4-anilinoquinazoline irreversible inhibitor kinase 
inhibitors to develop polymer-drug conjugates. These irreversible kinase inhibitors are 
able to form polymer conjugates under Michael addition conditions, thus creating bio-
orthogonal cleavable linkers under a suitable environment of tumour cells. Thus, the 
synthesis of SMKIs is discussed in the next chapter.  
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Abstract 
This chapter focuses on the synthesis of 4-anilinoquinazoline small molecules containing 
the electrophilic Michael acceptor (an acrylamide or an acrylate) in the C-6 position. The 
quinazolin-4(3H)-one skeleton was used as the template for the synthesis of 4-
anilinoquinazoline derivatives. The synthetic approaches and characterisation methods 
used in the preparation of quinazoline compounds are discussed. 
 
Alkaloids containing a quinazoline structure are compounds of interest for diverse 
medicinal applications.1 The 4-oxo-derivative of quinazoline, which is more correvtly 
cited as quinazolin-4(3H)-one, is an important intermediate in the synthesis of 4-
anilinoquinazoline small-molecule TKIs. The medicinal application of this skeleton has 
had some noteworthy, but rather inflexible, synthetic advances. An exhaustive review on 
different synthetic methods and the classification of quinazoline derivatives is available 
in literature.2 Among the prominent investigators who synthesised quinazolinone and 
quinazoline motifs were Niemenstowski in the late 1800s and Gabriel in early 1900s.3 
To date, the Niementowski protocol continues to be among the most attractive routes in 
the synthesis of the quinazolin-4(3H)-one moieties. This simple procedure is based on 
the thermally promoted formal condensation and cyclisation between a bifunctional 2-
aminobenzoic acid derivative and an amide (refer to Fig. 3.1).3a The quinazolin-4(3H)-
ones formed under these conditions are known to exist in tautomeric forms, which 
interconvert through a proton shift. The amidic acid and amide constitutional isomer 
forms are the most stable and commonly encountered prototropic tautomers. The 
formation of the amidic acid isomer is usually influenced by the acidic pH of the reaction 
medium, but the amide isomer is the thermodynamically more favourable isomer. Apart 
from the long-standing use of the Niementowski reaction, an appealing alternative is a 
two-step transformation process of 2-aminobenzonitrile into 4-anilinoquinazolines via a 
Dimroth-type of rearrangement reaction.4 However, a challenge to the application of this 
method is commercial scarcity of suitably substituted 2-aminobenzonitrile synthons. 
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Figure 3.1 The Niementowski synthesis of quinazolinones. The amidic acid and amide 
quinazolinone isomers are shown. 
The focus in this chapter is the preparation of 4-anilinoquinazoline moieties. Here, the 
required quinazolin-4(3H)-one intermediates were prepeared via the Niementowski 
approach. Despite the widespread application of quinazoline derivatives, most of the 
starting materials required for the synthesis of these compounds are either commercially 
unavailable or only available at significant cost. Hence, most the synthetic intermediates 
reported in this work were prepared in-house. After carefully examining the chemistry 
of quinazoline compounds, it was concluded that creating the substituted quinazolin-
4(3H)-one skeleton served as a good starting point for our synthetic studies. 
 
In line with developing polymer-drug conjugates via covalent bonding, the foremost 
evaluations of the final products would involve assessing the chemistry of the linker 
groups (the hydrolytic stability). The intention would be to establish the pharmacokinetic 
drug release profile, recovery of anti-tumour agents, and ultimately anti-tumour efficacy 
of the conjugates.5 The synthetic requirements for constructing C-6-substituted 
quinazoline derivatives were twofold: (i) the first synthetic route was directed at 
generating compounds with amide linker groups, and (ii) the other route was directed at 
compounds that would form the ester linkage. The two end products are shown in Fig. 
3.2.  
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Figure 3.2 The end products in the synthesis of polymer-bound 4-anilinoquinazoline 
anti-tumour agents. 
In view of these final products, the rate at which the consigned drug load would be 
released from the polymer chain (assembled into micelles) was also important. One way 
to control the hydrolytic cleavage of the acid-labile group on the aromatic ring was to 
perturb the overall electron density around the quinazoline ring by either adding 
electron-withdrawing or -donating groups to the C-7 position. Methoxy substituents in 4-
anilinoquinazoline anti-tumour agents are generally known to improve anti-tumour 
efficacy as electron donors.6 They have also been used to influence drug release rates in 
covalently conjugated molecules with aromatic systems by enhancing cleavage of the 
linkers in mild acidic environments.7  
Thus, 7-methoxy-substituted quinazoline derivatives were synthesised with the 
intention to promote the cleavage of quinazoline acid-labile linkers. On the contrary, 
electron-withdrawing groups were meant to slow down the rate of drug release.8 The 
chloro group was selected based on its availability as one of the synthetic intermediates 
during the synthesis of quinazolinone derivatives. However, the 7-chloroquinazolinone 
intermediates for ester derivatives were not prepared as synthetic difficulties were 
encountered in the final steps of 7-chloro-substituted 4-anilinoquinazolines. 
 
The requirement for preparing 6-aminoquinazolin-4(3H)-one derivatives could be 
achieved by either (i) applying the Niementowski protocol to 2-amino-5-nitrobenzoic 
acid and formamide, or (ii) nitration of quinazolin-4(3H)-one via electrophilic aromatic 
substitution [see Fig. 3.3 (a)].9 The synthetic plan appeared straightforward; however, 2-
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methylaniline was the starting material that was available (prepared in-house). Thus, one 
of the preliminary steps turned out to be the preparation of the 2-amino-5-nitrobenzoic 
acid precursor for the direct synthesis of 6-nitroquinazolin-4(3H)-one. 
 
Figure 3.3 (a) Synthetic pathways towards 6-nitroquinazolin-4(3H)-one via (i) the 
Niementowski protocol and (ii) electrophilic aromatic substitution. 
The planned synthetic steps of 2-amino-5-nitrobenzoic acid are shown in Fig. 3.3 (b). It 
was envisaged that aniline would be protected as the N-acetamide (1) to enable selective 
para-directed nitration, thus affording compound 2.10 Oxidation of the aryl methyl group 
of 2 followed by amide bond hydrolysis of 3 would yield the required precursor 1. 
 
Figure 3.3 (b) Attempted preparation of 5-nitrobenzoic acid from 2-methylaniline as 
starting material. (*Potential additional nitration position in compound 2.) 
With regards to the preparation plan in Fig. 3.3 (b), N-acylation of 2-methylaniline was 
carried out using acetic anhydride in acetic acid solvent, affording N-(2-
methylphenyl)acetamide (1) in good yield (94%). Unaware of the difficulties associated 
with controlling the nitration reaction for substituted acetanilide moieties, efforts to 
introduce the nitro group regioselectively at low temperatures using dilute HNO3 (40% 
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max.) were unsuccessful. The presence of activating or deactivating substituents on the 
aromatic system usually defines the reaction conditions, but the major problem here was 
finding the optimum conditions for selective nitration. Because overnitration took place, 
it was decided to follow route (ii) in Fig. 3.3 (a), using 1 as starting material, for the 
preparation of quinazolin-4(3 H)-one.9 Continuation of the synthesis is shown in Fig. 3.3 
(c). 
 
Figure 3.3 (c) Synthetic steps towards 6-nitroquinazoline-4(3H)-one (7). 
With this adjustment in the synthetic plan, transformation of the aryl methyl group into 
the carboxylic acid was accomplished through oxidation with aqueous potassium 
permanganate; it afforded compound 4 in good yield.11 The amine functionality was 
unmasked from N-acetamide with 4 N HCl solution in 96% ethanol. Next, the anthranilic 
acid (5) was converted into quinazolin-4(3H)-one (6) under the Niementowski reaction 
conditions.3a The nitration of 6 using mixed acids (96% H2SO4/99% HNO3) led to the 
regioselective placement of the nitro group at the C-6 position, to afford 6-
nitroquinazolin-4(3H)-one (7) in good yield. The 1H NMR spectroscopic data of 7 
matched the literature,12 thus confirming the expected structure. 
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It was next decided to use 4-fluoro-1-methyl-2-nitrobenzene starting material for the 7-
methoxy-substituted analogues. The attempted synthetic route is presented in Fig. 3.4 
(a). 
 
Figure 3.4 (a) Attempted synthesis of 7-methoxy-6-nitroquinazolin-4(3H)-one from 4-
fluoro-1-methyl-2-nitrobenzene as the starting material. (*Position with high likelihood 
for additional nitration.) 
The synthetic steps commenced by reducing the aryl nitro group in 4-fluoro-1-methyl-2-
nitrobenzene with tin(II)chloride under acidic conditions, affording the aniline 8 in 
excellent yield.13 The downside to tin reduction experiments was the formation of 
insoluble hydroxides in aqueous media upon the neutralisation work-up procedure. 
Luckily, primary amines were extracted at pH 10, where tin hydroxides formed reversible 
soluble complexes: Sn(OH)4(s) + 2OH
−
(aq)  ⟺ [Sn(OH)6](𝑎𝑞)
2− .14 Apart from the difficulty 
in the work-up, the synthetic process continued smoothly through the usual oxidation, 
hydrolysis, and Niementowski quinazolinone synthesis until the attempted nitration of 
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7-fluoroquinazolin-4(3H)-one (12) offered no prospect of further progress. Unlike the 
previously encountered regioselective nitration of quinazolin-4(3H)-one (6), nitration of 
12 generated a mixture of products that were insufficiently soluble for purification by 
normal chromatography. Alternative nitration reactions under ambient conditions (in 
NaNO3/NH4OAc and Ac2O/HNO3) were also unproductive. We were then forced to resort 
to using alternate purification methods, such as crystallisation. Although boiling the 
compounds in ammonium hydroxide/acetone seemed to be a promising solvent 
combination, unfortunately no reasonably pure compounds were isolated. 
A partial view of enlarged 1H NMR spectra of products of the attempted synthesis of the 
fluoro-substituted quinazolinones 12–13 is given in Fig. 3.4 (b). From the proton spectra 
of 12, the proton splitting pattern fully resembles that of the expected 7-
fluoroquinazolin-4(3H)-one. The usual first-order proton splitting of the tri-substituted 
aromatic ring was made more complex by the fluorine coupling. Beside the usual proton 
coupling in the ortho- and meta-positions, fluorine seemed to couple with every available 
proton of the quinazoline ring, including long range C-2 coupling, which is common for 
nitrogen-containing heterocycles.15 For instance, the expected doublet of doublets of H-6 
appeared as doublets of a triplet because of the differences in both ortho and meta 
aromatic chemical environments, but this was also accompanied by a fluorine coupling. 
The observed signal duplicities were equally upheld by 13C NMR spectroscopy in the 
adjacent positions to the fluoro group (C-6, C-7, and C-8 had 1JC-F = 251 Hz, 2JC-F = 24 Hz, 
and 2JC-F = 22 Hz, respectively). However, similar distinctions were impossible after the 
nitration of 12 as the overlapping peaks coalesced into one another. It was then decided 
to attempt the SNAr displacement of the fluoro group and purify the compounds of 
interest later. Unfortunately, these attempts were fruitless, and the final products were 
not successfully purified. 
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Figure 3.4 (b) 1H NMR spectra of 7-fluoroquinazoline, its transformation via the 
nitration reaction, and attempted nucleophilic displacement of the fluoro group. 
This impasse persuaded us to consider using a different starting material, or perhaps one 
with a larger halogen substituent (I>Br>Cl>F), to sterically impede nitration at the C-8 
position. It should however be mentioned here that positional selectivity of nitration is 
essentially sensitive to the nature of the substituting agent, and not necessarily to steric 
hindrances.16 Trying to merge this idea with the affordability of the starting material 
required us to create sufficient quantities of nitrated product and re-examine possible 
purification methods. For this purpose, 2-amino-4-chlorobenzoic acid was selected as the 
affordable starting material that should decisively reveal the outcome of the nitration 
reaction without additional peak splitting. The synthetic steps, analogous to in the 
preparation of 12, were followed using 2-amino-4-chlorobenzoic acid. See Fig. 3.4 (c). 
 
H2SO4/HNO3 
90 °C, 30 min. 
100 °C, 20 h 
NaOMe 
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Figure 3.4 (c) Synthesis of 7-choro-6-nitroquinazolin-4(3H)-one [15 (i)] and 7-methoxy-
6-nitroquinazolin-4(3H)-one (16). 
The Niementowski quinazolinone synthesis was once again employed to obtain 14,17 
which was then nitrated to afford a crude mixture of 15 (i) and 15 (ii) in 85–93% yield. 
Safety precautions were exercised when conducting the nitration using mixed fuming 
acids (H2SO4/HNO3) at elevated temperatures (90 °C). The synthetic scale was restricted 
to 500 mg and the product was accumulated to approximately 4 g, ground into a fine 
powder, mixed with silica gel, and then packed onto a pre-loaded column.  
Based on the earlier crystallisation attempts, it was duly noted that nitrated 
quinazolinones were partially soluble in acetone. As a result, careful choice of the mobile 
phase for chromatographic purification consisted of 2% acetone in dichloromethane 
(DCM) to 100% acetone. The eluent was continuously collected in fractions from a drip-
fed column, concentrated, and then monitored by a thin layer chromatography (TLC) 
until isolates of pure 15 (i) and 15 (ii) were obtained in yields of 67% and 11%, 
respectively. The compounds were confirmed by 1H NMR spectroscopy based on the 
splitting pattern of the benzene ring protons. For instance, for 15 (i) the benzene protons 
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appeared as distinct singlets, but doublets were observed for 15 (ii). The partial 1H NMR 
spectra displaying a crude mixture of 15 (i) and 15 (ii) prior to purification and 15 (i) 
thereafter are shown in Fig. 3.4 (d).  
 
 
Figure 3.4 (d) 1H NMR spectra showing a crude mixture of 15 (i) and 15 (ii), purified 15 
(i), and 16 after nucleophilic aromatic substitution of the chloro group with the methoxy 
group.  
Compound 15 (i) turned out to be a valuable intermediate for the preparation of 4-
anilinoquinazoline derivatives containing an electron-withdrawing chloro group in the 
ortho-position. Thus some of this material was reserved for future use, while the rest was 
utilised for further preparation of 16. According to the literature procedure,18 the 
methoxydechlorination reaction of the quinazoline activated by the nitro-group has been 
conveniently conducted under pressure in a sealed glass tube. However, we did not have 
a completely closed system and the reaction was carried out under inert conditions using 
in-house prepared sodium methoxide [2Na(s) + 2MeOH(l) →  2NaOMe(𝑙) + H2(𝑔)].  The 
reaction was heated to reflux at 100 °C and completed after 10 days. After removing 
excess methanol solvent in vacuo, the crude product was neutralised with 50% aqueous 
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acetic acid. The obtained precipitate was rinsed with cold water and dried, to afford 16 
as a pure product in an excellent yield of 97%. As was anticipated, substitution of the 
chloro group with the methoxy group was also demonstrated by the change in chemical 
environment of the aryl protons to lower frequencies (from 8.23ppm to 7.42 ppm) in the 
1H NMR spectra [see Fig. 3.4 (d)]. 
 
At this point, preparation of the quinazolin-4(3H)-one derivatives intended for use in the 
synthesis of the amide linker group was successfully completed. Their respective 
analogues with the ability to form ester bonds were then prepared. Considering that the 
6-nitroquinazolines were already available, a shortcut to the synthesis of 6-hydroxy 
analogues was via conversion of the nitro functional group (see an example in Fig. 3.5) 
to the amine. Thus, subjecting 6-aminoquinazolin-4(3H)-ones to the Sandmeyer–
Gattermann substitution reaction would potentially result in the formation of diazonium 
salts,19 which could be treated with oxygen-based nucleophiles. However, poor solubility 
of these quinazolinones and instability of the corresponding diazonium salts under the 
required experimental conditions were prohibitive factors, hence this route was 
abandoned. 
 
Figure 3.5 Proposed Sandmeyer–Gattermann type of aromatic substitution reaction for 
the synthesis of 6-hydroxyquinazolines from 6-aminoquinazoline derivatives. 
 
Because of the instability of the quinazolinone diazonium salts, the possibility of 
transforming 5-bromoanthranilate 19 (i) to a 6-bromoquinazolinone (20) was 
considered [see Fig. 3.6 (a)]. The nucleophilic displacement of the aryl bromine with 
methoxide compounds or transition metal-catalysed reactions would yield the required 
compound 21.20  
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Figure 3.6 (a) Synthesis of 6-methoxyquinazolin-4(3H)-one via aromatic nucleophilic 
substitution of 6-bromoquinazolin-4(3H)-one [19 (i)]. 
With this plan in mind, N-acetamide 17 was prepared from ethyl 2-aminobenzoate 
precursor and halogenated with molecular bromine in situ [ KBrO3(s) + HOAc(l) +
(48%) 5HBr(aq)  → 3Br2(l) +  3H2O(aq) + KOAc(aq)] to afford 18 in good yield. In order to 
avoid aqueous work-up problems associated with zwitterionic compounds, selective 
hydrolysis of the amide group under mild reaction conditions was investigated. 
Treatment of 18 with 4 N ethanolic potassium hydoxide solution provided exclusive ester 
hydrolysis within 2 h at room temperature. It turned out that the selectivity could be 
achieved to give the amine by using a 4 N ethanolic HCl solution to afford compound 19 
(i) as the only product. Further conversion of 19 (i) into 5-bromoquinazolin-4(3H)-one 
(20) was achieved in reasonably good yields. At this point, 20 was exposed to nucleophilic 
debromination conditions in an attempt to form 6-methoxyquinazoline-4(3H)-one (21). 
As in most Ullman reaction conditions,21 copper-assisted cross-coupling with oxygen-
based nucleophiles required higher temperatures and prolonged reaction periods, but 
the yields were disappointingly low. Further attempts investigated the aromatic 
Finkelstein variation method with a domino halide-exchange reaction, involving catalytic 
potassium iodide at 110 °C in dry 1,4-dioxane solvent.22 Unfortunately these attempts 
were not successful. 
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It was then decided that commercial 2-amino-5-hydroxybenzoic acid would be an 
economically viable alternative for synthesizing 6-hydroxyquinazoline, in comparison 
with the attempted 5-methoxy derivative shown in Fig. 3.6 (a). The revised synthetic 
strategy commenced with 2-amino-5-hydroxybenzoic acid under the Niementowski 
reaction conditions, affording 6-hydroxyquinazolin-4(3H)-one (22) in 76% yield [see Fig. 
3.6 (b)]. Protection of the hydroxyl group in 22 produced the acetoxyquinazolinone (23) 
in 79% yield. 
 
Figure 3.6 (b) Preparation of acetyl-protected 6-hydroxyquinazolin-4(3H)-one (23). 
According to most literature methods,23 O-acylation of hydroxy-substituted 
quinazolinones occurs under Dakin–West reaction conditions.24 Under these conditions, 
excess pyridine solvent and higher temperature (100–150 °C) were required to initiate 
acylation reactions, perhaps to account for the limited solubility of quinazolinones. In 
some cases, the acquired acetoxyquinazolinones have been further used without any 
purification.23 However, these literature conditions were not useful the obtained end 
product consisted of a mixture of compounds, probably due to mixed O- and N-acylations, 
and decompositions. 
Upon consideration of the Steglich esterification,25 we learned that 4-
dimethylaminopyridine (DMAP) significantly promotes the reaction rate by creating 
highly reactive acyl intermediates, especially if the alcohol is a poor nucleophile. 
However, our combination of catalytic DMAP and Ac2O resulted in the gelation of the 
reaction mixture, to the already poorly soluble 22. As a result, excess Ac2O and a molar 
equivalent of pyridine were used to obtain a clear solution, which was then stirred 
overnight at room temperature. Product 23 was obtained in 79% yield [see Fig. 3.6 (b)]. 
To confirm the regioselective acylation, the 1H NMR spectra of 23, its former unprotected 
hydroxyl moiety 22, and the bromoquinazolinone (20) were compared [see Fig. 3.6 (c)]. 
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It could be deduced from the spectra that the highly solvent interchangeable 
amide/amidic acid proton [4(3H) and/or 4-OH tautomers] exhibited a broad singlet in all 
the compounds in a high frequency region (11–13 ppm). In comparison, the presence of 
this exchangeable proton in 23 indicated exclusive acylation of the hydroxyl group. In 
addition, the absence of a hydroxyl peak signal at 10.2 ppm in 23 relative to 22 
unambiguously corroborated the expected functional group transformation. This 
observation was further substantiated by the existence of the methyl protons of the acetyl 
group in 23 at 2.32 ppm. The net influence of electronegativity and/or van der Waals 
deshielding effects was also evident among the compounds when the aromatic protons 
were taken into consideration. 
 
Figure 3.6 (c) 1H NMR spectra of 6-bromoquinazolin-4(3H)-one (20), and its derivatives 
6-hydroxyquinazolin-4(3H)-one (22) and 6-acetoxyquinazolin-4(3H)-one (23).  
 
Having obtained the first 6-hydroxyquinazolin-4(3H)-one intermediate, the 7-methoxy-
substituted analogue (29) was prepared next. According to the literature,26 preparation 
of this intermediate is related to the synthesis of Gefinitib, which is via selective 
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demethylation of 6,7-dimethoxyquinazolin-4(3H)-one (27), as depicted in Fig. 3.7 (a). 
Our synthesis commenced with conversion of 3,4-dihydoxybenzoic acid into methyl 3,4-
dimethoxy benzoate (24) using modified Williamson etherification conditions.27 The 
methyl 4,5-dimethoxy-2-nitrobenzoate [25 (i)] was obtained after attempting a few 
different experimental conditions for the moderately reactive aromatic molecule.28 
Besides the likely para-directed nitration, whose incoming nitro group’s inductive 
influence must sufficiently inhibit further nitrations, di-nitrated product 25 (ii) was also 
formed. The compounds were isolated by chromatographic methods. Product 25 (ii) was 
further elucidated by a combination of (1JC-H) HSQC and (2,3JC-H) HMBC NMR spectroscopic 
methods. 
 
Figure 3.7 (a) Synthesis of a 7-methoxy-substituted quinazolin-4(3H)-one derivative 
(29) via selective demethylation of 6,7-dimethoxyquinazolin-4(3H)-one (28). 
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Based on 1H NMR spectroscopic analysis, the two structures, 25 (i) and 25 (ii) were easily 
identified by peak multiplicities or signal splitting patterns. Moreover, the location of the 
second nitro substituent in 25 (ii) was also confirmed. In doing so, it was obvious that 
only one singlet could be identified in the aromatic region (except the CDCl3 solvent 
peak); thus a 1JCH correlation NMR experiment (HSQC) would conclusively identify the 
carbon to which the proton was bound. Further 2JCH and 3JCH correlations over multiple 
bonds from the HMBC were used to ascertain the two neighbouring carbons on either 
side of the aromatic ring, during which a mutual correlation between the methoxy and 
ethyl ester groups was also established. The resulting gradient selection of the HSQC and 
HMBC correlations are summarised by the interpreted structure shown in Fig. 3.7 (b).  
 
 
Figure 3.7 (b) Structural elucidation of over-nitrated 25 (ii) via JCH correlations (only 
HMBC spectroscopic analysis is displayed). 
For the purified 25 (i), tin(II)chloride was used to selectively reduce the nitro group. 
Product 26 was obtained in good yield. Cyclisation of 26 into 27 was achieved under the 
Niementwoski method with formamide. As in the conversion of isovaniliic acid from 3,4-
dimethoxybenzoic acid by acidolysis,29 the electron-rich methoxy group at the C-6 
position of 27 accepts acidic protons more readily to enable selective hydrolysis. With 
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this in mind, selective hydroxylation of the C-6 aryl methyl ether by means of methane 
sulfonic acid and the methionine salt was carried out, but with little success.26 The 
recommended experimental periods for demethylations were found to be inadequate in 
most cases and the reaction was gradually extended from 16 h to 48 h. Despite the 
meticulous experimental executions, including the freeze-pump-thaw cycles to exclude 
moisture, prolonged reaction periods resulted in over-demethylation. As a result, only 
small quantities of pure 28 were recovered. O-acylation was carried out to obtain the 
acetoxyquinazolinone 29 (i). The NMR spectroscopic analysis to determine the selectivity 
of this reaction will be discussed later, in Section 3.13, where 28 was coupled to a 4-aniline 
substrate. 
Since we were only able to obtain low quantities of pure 28 (73 mg), it was decided to 
attempt the demethylation of 6,7-dimethoxy-4-anilinoquinazolines instead.30 Thus, using 
compound 27, 6,7-dimethoxy-4-anilinoquinazoline derivatives were then prepared as 
shown in Fig. 3.7 (c). Generally, compounds 30–32 were obtained in sufficient gram 
quantities and good purity. Attempted selective hydroxydemethylation of these 
compounds under microwave conditions,30 and conventional heating, were 
unfortunately ineffective. Among these three compounds, the alkynyl aniline moiety (30) 
demonstrated high sensitivity and rapid decomposition in the attempted demethylation 
experiments. On the other hand, the halo-substituted anilines proved to be more stable 
and robust to undergo demethylation without significant decomposition. The end 
products were very impure. Chromatographic isolations and re-purification efforts were 
unsuccessful. 
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Figure 3.7 (c) Attempted microwave-assisted and conventional heating hydroxyl-
demethylation of 6,7-dimethoxy-4-anilinoquinazolines (30–32).  
As efforts to obtain 7-methoxy-substituted 6-hydroxyquinazoline derivatives were 
unrewarding thus far, it was decided to carry on with creating a library of 4-
anilinoquinazoline compounds using the available quinazolinone materials. 
 
At this point, commercially acquired aniline substrates had to be appended on the C-4 
position of quinazolinone intermediates [see Fig. 3.8 (a)]. To carry out the SNAr 
substitution with poor nucleophilic anilines, the quinazolinone C-4 position is usually 
activated by halogenation under acidic conditions using phosphorus(V) oxychloride 
(POCl3).31 In some cases, direct C-N coupling has been achieved by means of 
phosphonium-mediated reagents (pyBOP) under basic conditions.32 
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Figure 3.8 (a) The C-6-substituted quinazoline-4(3H)-ones for the preparation of 4-
anilinoquinazoline compounds. 
The formation of the quinazolinone amidic acid tautomer (4-OH) can be influenced by the 
pH of reaction medium. This allows for facile activation of the C-4 position by means of 
chlorodehydroxylation using POCl3.31 The 4-chloro intermediates from the 
nitroquinazolin-4(3H)-one derivatives [7, 15 (i), and 16] were treated with selected 
aniline substrates to undergo SNAr N-arylation and compounds 34–42 were obtained 
[see Fig. 3.8 (b)]. These intermediates (34–42) were then subjected to different reducing 
agents to obtain the C-6 amino functionality 43–51. The aminoquinazolines (43–51) 
were found amenable to form the required α,β-unsaturated olefinic amide linkers 52–58 
under Schotten–Baumann N-acylation conditions.33 The resultant acrylamide-bearing 4-
anilinoquinazolines (52–58) would then inevitably undergo Michael addition reaction 
with thiol-terminated polymers to create the desired end products. A more elaborate 
discussion on the synthesis follows in the next section. 
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Figure 3.8 (b) Generic example for creating 4-anilinoquinazolines with acrylamide 
linkers (52–58). 
 
Activation of 7-nitroquinazolin-4(3H)-one compounds (e.g. 7) for SNAr, to enable facile 
transformation into N-heteroaromatic chlorides (such as 33), was achieved with POCl3 in 
the presence of Hünig’s base. However, it must be noted that most chlorinating agents, 
including POCl3, are extremely moisture sensitive, which makes them difficult to handle. 
During the work-up, it emerged that 4-chloro-activated quinazoline derivatives are prone 
to reversible hydrolysis to their initial starting materials. Because of this instability, N-
arylation reactions were sequentially performed on freshly chlorinated products, as 
illustrated in Fig. 3.9 (a). For a quinazolinone 7, successful chlorination was confirmed 
by 1H NMR spectroscopic analysis of 33. The obtained proton spectrum unambiguously 
showed the absence of the quinazolinone proton, which is usually observed at 11.5–12.5 
ppm [see Fig. 3.6 (c)]. N-heteroaromatic chloride intermediates [15 (i) and 16] were 
then coupled with their respective aniline compounds without further characterisation. 
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Figure 3.9 (a) Synthesis of 4-anilinoquinazoline derivatives (34–36) via acid-catalysed 
SNAr with anilines.  
Upon installation of the anilines onto the N-heteroaromatic chloride (33), additional 
aromatic signals were observed in the 1H NMR spectra. The amidine C-4 protons of 34–
36 appeared rather flat on the baseline (~11.5–12.5 ppm) due to a rapid solvent 
exchange with the DMSO solvent. In addition to this, quinazoline protons generally 
exhibited a slight shift (1–1.5 ppm) in the direction of higher frequency values. An 
additional six compounds were developed from 15 (i) and 16 using the same 
experimental approach. The chemical structures of these analogues (37–42) are shown 
in Fig. 3.9 (b). 
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Figure 3.9 (b) The 6-nitro-4-anilinoquinazoline compounds (37–42) developed from 7-
chloro- and 7-methoxyquinazolin-4(3H)-ones via SNAr N-arylation.  
 
The 6-nitro-4-anilinoquinazolines (34–42) were then subjected to different Lewis acids 
in an attempt to acquire the C-6 amino functionality via reduction of the nitro group. 
Although tin(II)chloride was found to reduce the compounds selectively, the problem of 
forming stable tin(IV)hydroxides precipitates under neutral aqueous conditions 
compelled us to consider other reducing agents. Molecular hydrogenation under 
palladium catalysis was another attractive method that reduced the nitro group, followed 
by a simple filtration work-up. However, an unexpected problem with this method was 
an occasional reductive dehalogenation, probably via oxidative insertion of palladium on 
the aniline aromatic ring. Although the observed aryl dehalogenation resembled that of 
the Buchwald–Hartwig reaction,34 it usually happens at elevated temperatures in the 
presence of amine-based nucleophiles. Unfortunately, this seems to be a common 
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occurrence under mild reaction conditions as well, especially in alcohol (ethanol) 
solvents.35  
Ultimately, Fe(s)/NH4Cl in aqueous ethanol proved to be a universal reducing agent for 
compounds 34–42. Eventually, after successfully carrying out the reduction, a small 
library of the C-6 amino-substituted 4-anilinoquinazoline compounds was developed. 
Their chemical structures are shown in Fig. 3.10. Because the nitro group was converted 
to the amine, a new broad singlet integrating for two protons at 5.35–5.81 ppm was 
observed in the 1H NMR spectra of compounds 43–51. 
 
Figure 3.10 The C-6 amino-substituted 4-anilinoquinazoline compounds 43–51. 
 
According to our intended application of the polymer-bound small molecules, the C-6 
amino-substituted 4-anilinoquinazolines were treated with acryloyl chloride in the 
presence of Hünig’s base to form the acrylamides [see Fig. 3.11 (a)]. Among the 4-
anilinoquinazoline derivatives, the C-7 chloro analogues performed poorly in the 
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acylation reactions. In most cases, there was no observed reaction progress, perhaps due 
to steric effect, also known as the ortho effect.8, 36 A final library of 4-anilinoquinazolines 
with the acrylamide functional group was then created with the compounds shown in 
Fig. 3.11 (a). 
 
 
Figure 3.11 (a) Small library of 4-anilinoquinazolines with the acrylamide linker 
functionality (52–58). 
Structural elucidation of these compounds (52–58), using 1H and 13C NMR spectroscopy, 
and MS. Upon insertion of the Michael acceptor, the C-6 amino functionality was modified 
into the amide. Ordinarily, the broad aryl amine singlet at 5.35–5.81 ppm (in DMSO) 
converts to a singlet at ~10 ppm, integrating for one proton. The newly introduced α,β-
unsaturated alkene groups were observed in the range 5.8–6.5 ppm. Apart from the 
distinctive proton splitting patterns of this alkene, terminal protons were precisely 
differentiated by their J coupling values. In general, the trans coupling (J ≅ 17 Hz) was 
always larger than that of the cis (J ≅ 10 Hz) hydrogens. In addition, the molecular masses 
of the synthesised compounds were determined within the 5 ppm range by MS.37 In rare 
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cases, atoms with strong isotopic influence [79Br (50.69) and 81Br (49.31)] were observed 
displaying two parent peaks; see the mass spectrum of 53 in Fig. 3.11 (b). The 
compounds were analysed in positive ionisation mode, [M+H]+, and the isotopic peaks of 
53 clearly resembled the isotopic abundances of bromine. Occasionally, the amide bond 
cleaved during MS analysis, but a cone voltage of 15 V was used to analyse most 4-
anilinoquinazolines without additional fragmentations. 
 
 
Figure 3.11 (b) Mass spectrum of 53 showing isotopic influence in molecular mass 
determination. 
Some of the final compounds were intended for biological evaluation (anti-tumour 
efficacy) and it was critical for their chemical purities to be known. Chemical purities 
were evaluated with a Synapt ultra-performance liquid chromatography-tanderm mass 
spectroscopy (UPLC-MS) instrument at various ultraviolet (UV) wavelengths (λmax.). The 
chromatogram for 53, as an example, is shown in Fig. 3.11 (c). Good chemical purity was 
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Figure 3.11 (c) Chromatogram of 53, displaying chemical purity (λmax. 253 nm).  
 
The next efforts were then directed at creating 4-anilinoquinazoline analogues 
containing an acrylate functionality. The acetoxyquinazolinone intermediates 23 and 29 
(i) were thus used to develop the second library of 4-anilinoquinazolines. The general 
synthetic procedure for these compounds was analogous to that of the acrylamides 52–
58, except that the hydroxyl groups were deprotected through hydrolysis of the acetyl 
protecting group. A generic synthetic route towards acrylates is given in Fig. 3.12 (a). 
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Figure 3.12 (a) A generic synthetic route for the synthesis of acrylate-substituted 4-
anilinoquinazoline compounds (66–69). 
 
The 4-anilinoquinazolines (59–61) were obtained with the acetate still group intact in 
most cases after the SNAr N-arylation of activated acetoxyquinazolinones. In cases where 
small quantities of hydroxyl deprotection had occurred, a few drops of ammonium 
hydroxide were added to complete the hydrolysis process. Because there was a limited 
quantity of 28, it was decided to synthesise one 7-methoxy-substituted analogue. The 
overall set of 4-anilinoquinazolin-6-ol derivatives (62–65) is presented in Fig. 3.13 (a). 
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Figure 3.13 (a) The hydroxyl-substituted 4-anilinoquinazoline compounds (62–65). 
Most importantly, compound 65 in Fig. 3.13 (b) was synthesised from low quantities of 
the acetoxyquinazoline 29 (i), which was synthesised via selective demethylation route 
of 27 to afford 28 in poor yield (16%). The above compounds (62–65) were also analysed 
using the previously encountered NMR spectroscopic methods. In addition, 
heteronuclear NMR correlations (HSQC and HMBC) were used to acquire the full 
structural assignment of 65. Once again, the carbons with proton attachments were 
obtained from 1JCH HSQC and the carbon skeleton of the molecule was confirmed by 2,3JCH 
HMBC spectroscopic analysis. Based on these analyses, it was concluded that 
demethylation via acidolysis had occurred at the C-6 position of 6,7-
dimethoxyquinazolin-4(3H)-one (27).  
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Figure 3.13 (b) Structural elucidation of 4-analinoquinazoline (65), synthesised via 
selective demethylation route of 6,7-dimethoxyquinazolinone (27), determined using 
HSQC and HMBC NMR . 
 
At this point, it was possible to complete the synthesis of the small molecule 4-
anilinoquinazolines by sequentially attaching the acrylate functionality via O-acylation. 
Thus, the acrylate library consisted of four compounds, shown in Fig. 3.14.  
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Figure 3.14 Library of C-6 acrylate-substituted 4-anilinoquinazoline final compounds 
66–69. 
 
A library of 4-anilinoquinazoline tyrosine kinase inhibitor small molecules composed 
acrylamide and acrylate electrophilic groups was successfully developed after the 
synthesis of quinazolinone intermediates that were prepared via the Niementowski 
protocol. These intermediates exhibited poor solubility, however, except in strong acids 
or bases, and this was found to be one of the barriers to their synthetic manipulation. 
Despite this setback, the required 4-anilinoquinazoline derivatives were obtained in 
reasonable yields and high chemical purities, which then allowed for their further 
conjugation with the PVP polymer. The polymerisation and conjugation of the selected 4-
anilinoquinazoline compounds shown in Fig. 3.15 will be addressed in the next chapter. 
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Figure 3.15 The 4-anilinoquinazoline compounds selected for further studies in 
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Chapter 4: Polymerisation and synthesis 
of polymer-drug conjugates 
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This chapter addresses the synthesis of a PVP polymer by RAFT/MADIX polymerisation, 
ω-end group modification, and modular PVP conjugation with the 4-anilinoquinazoline 
small molecules. It further addresses the morphological characterisation of the 
subsequent polymer-drug conjugates using various analytical techniques. Synthesis and 
characterisation are discussed. 
 
 
The core objective was the development of polymeric-drug conjugates, i.e. polymeric 
prodrugs, for the drug delivery of 4-anilinoquinazoline kinase inhibitors to target sites. 
Therapeutic limitations of quinazoline-derived anti-tumour agents are well established,1 
but a recent advance in the treatment of lung cancer has demonstrated accelerated 
approval of kinase inhibitors that exhibit reactive toxicity properties.2 While intentions 
are to develop curative therapy and overcome drug resistance, the occurrence of adverse 
drug reactions (ADRs) has remained one of the critical challenges that requires 
immediate attention in this field.3 In view of this problem, a micellar drug delivery system 
was developed to improve the therapeutic efficacy and minimise ADRs. To achieve the 
desired delivery structure, it is critical that the polymer designed for this purpose must 
be well defined. 
 
 
A number of synthetic characteristics of reversible deactivation radical polymerisation 
(RDRP) methods, formerly referred to as controlled/living radical polymerisation (the 
three main techniques being nitrogen-mediated polymerisation (NMP), atom radical 
transformation (ATRP), and reversible addition-fragmentation chain transfer (RAFT), 
have been extensively studied.4 Their capabilities in and limitations to achieving good 
control in polymerisation of less activated vinyl monomers such as NVP have been 
established.5 Synthesis of well-defined PVP with predictable molecular weight and low 
dispersity is best controlled by the RAFT/MADIX polymerisation technique.4, 6 The 
optimal synthetic protocol for NVP polymerisations requires the following: (i) design of 
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RAFT agents (also referred to as chain transfer agents) aligned with the monomer 
reactivity, and (ii) optimization of reaction conditions.4b 
In line with this concept, Klumperman and co-workers have demonstrated the utility of 
triazole-derived RAFT agents to form good leaving groups for a variety of monomers, 
including NVP, using RAFT/MADIX polymerisations.7 Besides establishing the potential 
utility of triazole-based leaving groups, Pound et al.8 methodically explored RAFT/MADIX 
polymerisation of NVP using O-ethyl xanthates. In their studies,8 a number of unexpected 
side reactions were determined during polymerisation. One of the highlights of their 
work was establishing the optimum reaction conditions (temperature ≤ 60 °C) that are 
essential to retaining the unstable xanthate ω-end group. The xanthate end groups are 
susceptible to several chemical modifications; they readily undergo the thermally 
stimulated Chugaev elimination reaction during polymerisation, thus resulting in the 
formation of olefin-terminated PVP end groups.9 In the present study, preservation of the 
ω-end group is particularly important for the ensuing conjugation of bioactive 4-
anilinoquinazoline molecules. Informed by these developments, the RAFT/MADIX-
mediated synthesis of α,ω-heterotelechelic PVP using a triazole-based RAFT agent is 
discussed in this chapter. 
 
 
The general synthetic strategy for the preparation of triazole-based RAFT agents was 
adapted from Akeroyd et al.7 [see Fig. 4.3 (a)]. Using an alkyne moiety as the starting 
material, the but-3-yn-2-ol hydroxyl group was activated to form a tosylate leaving group 
in 70.10 Treatment of 70 with the O-ethyl xanthate salt of potassium effected the 
nucleophilic displacement of the tosylate group, at room temperature,7 affording (71) in 
good yield. At this point, the ω-end thiocarbonyl thio functionality was successfully 
substituted onto the alkyne precursor, and an azide functionality was thus required to 
create the triazole group. Therefore, a copper(II)-catalysed diazotransfer reaction 
between 1-amino-2,2-diethoxypropane and 1H-imidazole-1-sulfonyl azide was carried 
out first, affording the corresponding 3-azido-1,1-diethoxypropane (73).11 The 
copper(II)-promoted [3+2] Huisgen cycloaddition reaction was then performed between 
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the functionalised alkyne 71 and azido 73 to afford the desired RAFT agent (74) in good 
yield. More recently, Reader et al.12 highlighted the topological arrangement of 74 for 
α,ω-heterochelic functionality to favour orthogonal end group modifications. This feature 
is of interest in bio-conjugation as it allows for the chain-end-oriented binding,13 thus 
enabling one-to-one attachments in prodrug formulations. This study focused on the ω-
end functionality. 
 
Figure 4.3 (a) Outline for the preparation of a RAFT agent (74) with a triazole moiety for 
RAFT/MADIX-mediated polymerisation. The ω-end alkyne and the α-end azide groups 
(in rectangles) can be functionalised with various substrates.7  
1H NMR analysis of the RAFT agent provided the opportunity to determine the degree of 
polymerisation (DPn) and the number average molecular weight (Mn) of a polymer. For 
polymers with high end group fidelity, the number of monomers in a polymer chain can 
be determined by comparing clearly defined proton signals from the RAFT agent with 
those that can be distinguished from the repeating unit.14 Thus, 1H NMR spectroscopy 
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remains one of the most important tools for polymer characterisation. The 1H NMR 
spectrum of the RAFT agent used for the polymerisation of NVP is depicted in Fig. 4.3 
(b). Other useful techniques include relative measurements of Mn by size-exclusion 
chromatography (SEC) and more absolute measurements by mass spectrometry (MS), 
specifically matrix assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS).14-15 Owing to the common problem of thermal degradation of polymers 
during volatilisation, as well as MS sensitivity bias to dispersity,16 emphasis is now placed 
on 1H NMR and SEC analytical methods throughout our polymerisation experiments.  
 
Figure 4.3 (b) 1H NMR spectrum of the RAFT agent used for NVP polymerisation.  
 
 
The efficacy of 74 in controlling NVP polymerisation under various reaction conditions 
was determined earlier, by Klumperman and co-workers.12 It was established that NVP 
polymerisations were achieved at 60% monomer conversion at various DPns. Thus, using 
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these optimised experimental conditions, a baseline assessment of 74 for controlling 
polymerisations was revisited, as outlined in Table 4.4. 
Table 4.4 RAFT/MADIX polymerisation of NVP; experimental conditions: [RAFT agent, 
74]/[AIBN] is 4; temperature, 60 °C; solvent, THF  







1 45:1:0.25 9 nd 1007 1790 1.08 
2 45:1:0.25 15 nd 1529 2012 1.14 
3 45:1:0.25 17 nd 1524 2234 1.14 
4 45:1:0.25 24 3343 1536 2123 1.14 
5 40:1:0.25 24 3011 1361 1330 1.15 
a 𝑴𝒏,𝒕𝒉𝒆𝒐𝒓 = 𝑴𝒏,𝐑𝐀𝐅𝐓 + ([𝑴𝒏,𝐍𝐕𝐏]˳ × 𝑴𝒓,𝐍𝐕𝐏 × 𝜶) ([𝑴𝒏,𝐑𝐀𝐅𝐓(𝟕𝟒)]˳⁄ ), α = 60% estimated 
monomer (NVP) conversions.12 
b Mn determined by SEC in DMAc relative to PMMA standards  
c Mn determined by 1H NMR (𝑴𝒏,𝐍𝐌𝐑 = 𝑴𝒓,𝐍𝐕𝐏 × 𝑫𝑷𝒏) + 𝑴𝒓,𝑹𝑨𝑭𝑻(𝟕𝟒) 
 
The SEC analyses for polymerisations were obtained using a refractive index (RI) 
detector. From Table 4.4, entries 1–4, the Mn, SEC values indicate that polymerisations of 
NVP ended at reaction times of < 15 h. This conclused is based on general RDRP 
polymerisation behaviour, in which Mn increases in a linear fashion with monomer 
consumption, i.e. 𝐷𝑃𝑛 =
[M]˳−[M]𝑡
[RAFT]
. The DPn is used to define the size of a polymer by the 
number of monomer (NVP) repeat units in a polymer molecule and a closer look at 
entries 2–4 reveal no increase in Mn, SEC values. The overall efficiency of the RAFT agent 
performance in controlling NVP polymerisations was in agreement with the previously 
reported data, for which the 4-methyl-1,2,3-triazole leaving group showed improved 
living character in the presence of the radical stabilising methyl group.6, 11 The 
polydispersity indices (Ɖ ≤ 1.15) of PVP indicated narrow molecular weight distributions. 
However, it was noted that monomer conversions were lower than expected,12 and the 
consistent polydispersity values after the polymerisation reaction had stopped (beyond 
15 h) were ascribed to solvent participation in reducing the viscosity of the reaction 
medium. SEC-DRI chromatograms (DRI: differential refractive index) of PVP are shown 
in Fig. 4.4 (a). 
Stellenbosch University  https://scholar.sun.ac.za




Figure 4.4 (a) Normalised SEC-DRI chromatograms of PVP samples, entries 1–5 from 
Table 4.4.  
The 1H NMR end group analysis was used in parallel with SEC to obtain comparable 
results. The end group protons of the RAFT agent from the α-end were distinguished and 
their integral values were compared to those of identifiable NVP repeating unit [see Fig. 
4.4 (b)]. The ratios of these protons were deduced, and the experimental DPn and Mn,NMR 
were then determined. There were systemic deviations in Mn,SEC because of the 
hydrodynamic volume differences between PVP and the poly(methyl methacrylate) 
(PMMA) standards used for the calibration. Nonetheless, the thermally unstable O-ethyl 
xanthate functional group was mostly preserved throughout polymerisation reactions. 
This was established by comparing the end groups α-(f + h) and ɷ-(g) in Fig. 4.4 (b), 
which were approximated to 3:2, as expected. It was thus reckoned that modification of 
the ɷ-chain end would lead to the facile introduction of 4-anilinoquinazoline small 
molecules. 
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Figure 4.4 (b) 1H NMR spectrum of end-group functionalised PVP polymer, 75. 
 
 
In pursuit of polymer-drug conjugates, the first step of transformation involved 
conversion of the thiocarbonyl thio end group into the thiol functionality.13a, 17 A general 
presentation of the synthetic strategy is illustrated in Fig. 4.5 (a). The thiocarbonyl thio 
end groups can undergo several transformations according to the intended use of the 
final product.17 Of particular interest was creating a thiol-terminated PVP. The aminolysis 
reaction was used to achieve quantitative results. Use of different reducing agents to 
achieve similar thioamidation reactions with differing probabilities of side reactions has 
been reviewed elsewhere.17  
Hence, 75 was suspended in acetone, the solution was treated with cyclohexyl amine and 
then stirred at room temperature, to afford 76 in good yield. The bulky cyclohexyl amine 
was purposely employed with the intention to mitigate base-promoted elimination side 
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reactions. In doing so, preservation of the end group functionality during the aminolysis 
reaction was also realised. No additional purification steps were required, other than 
precipitation of the polymer in diethyl ether. 
 
Figure 4.5 (a) Transformation of O-ethyl xanthate end group into a thiol end group via 
an aminolysis reaction. 
A successful O-ethyl xanthate end group transformation was ascertained by 1H NMR; it 
was discovered that characteristic methylene protons of the O-ethyl xanthate end group 
had disappeared at 4.63 ppm [refer to Fig. 4.5 (b)]. 
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Figure 4.5 (b) 1H NMR spectra of thiol-terminated PVP (76) prepared via an aminolysis 
reaction. Disappearance of the previously distinguished O-ethyl xanthate protons has 
been highlighted by a rectangle. 
Besides using 1H NMR data, a more accurate detection of O-ethyl xanthate modification 
was obtained with SEC-UV analysis. The xanthate chromophore absorption band (SC=S, 
λmax. = 280 nm) in 75 was overlapped by the UV absorbance of 76. Because of the xanthate 
transformation into a thiol end group, no corresponding UV absorbance signal was 
observed for 76 at this wavelength [see Fig. 4.5 (c)]. 
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Figure 4.5 (c) The SEC-UV response (λmax.= 280 nm) showing transformation of a 
xanthate SC=S end group to a thiol (75 to 76). The UV responses were normalised to 
smooth the plots. 
Besides the O-ethyl xanthate transformation to a thiol group, formation of disulfide 
bridges due to a thiol oxidative coupling side reaction was expected. This was not a major 
concern as it could be lessened by performing the reaction under inert conditions or 
perhaps including phosphines, which are known to reduce alkyl disulfides.18 Other 
commonly used methods to prevent the formation of alkyl disulfides make use of the 
Ellman procedure,19 which is generally referred to as thiol-trapping in polymer 
chemistry, or capping agents. Keeping the possibility of disulphide formation in mind, 
SEC-DRI chromatograms for 75 and 76 were overlaid as shown in Fig. 4.5 (d). The RI 
response of 76 was then examined for doubling of Mn or shouldering. Nevertheless, only 
broadening of the baseline in the direction of higher molecular weight (shorter elution 
time) was observed; this gave rise to the increased poly dispersity index (Ɖ =1.20).  
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Figure 4.5 (d) SEC-DRI chromatograms of 75 and (76). Peak broadening towards shorter 
elution time suggests doubling of the PVP chain length due to disulfide formation. 
From overall polymerisation results, it appeared that PVP polymers of predetermined 
molecular weights were successfully obtained. The 1H NMR and SEC analyses 
demonstrated controlled polymerisation reactions. More importantly conservation of 
end group functionalities was also observed. Following the aminolysis reaction, it was 
further observed that 76 existed as a thiol-terminated PVP polymer. This permitted the 
facile development of polymer conjugates via 1,4-conjugated addition to the small 
molecules containing α,β-unsaturated electrophilic groups. 
 
 
In previous work,12, 20 similar conjugation reactions have been carried out under aqueous 
solution or very polar solvents, which were normally basified by organic bases. This is in 
agreement with Edwards and Pearson’s views of enhancing overall nucleophilicity.21 
Thiol groups could then exist in solution as more reactive thiolates under these 
conditions. Among the studied organic bases, Li et al.20 have demonstrated primary and 
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tertiary amines as efficient catalysts for phosphines, when preventing alkyl disulfides 
formation. In cases where alkyl disulfides have already been formed, only 30% could be 
successfully reduced under mild conditions in under 4 h, thus requiring intervention of 
thermally promoted disulphide reductions.22 On the other hand, Levison et al.23 have 
developed efficient water soluble phosphines such as tris(2-carboxyethyl)phosphine 
(TCEP) for the mild reduction of alkyl disufides under biological conditions and it works 
well without generating reactive by-products. TCEP oxidises readily in aqueous bases to 
form phosphine oxides, irreversibly,18 but its hydrogen chloride salt is very stable in air, 
which makes it easier to manipulate. 
Presented with these options, thiol-terminated PVP polymer and 4-anilinoquinazoline 
compounds were conjugated to form polymer-bound SMKIs. A modulated Michael 
addition reaction was used to form covalent bonds between these two substrates.13a, 20, 24 
A representative example of the conjugation reaction, with its conditions, is shown in Fig. 
4.6 (a). With an 1.2 molar equivalent excess of 4-anilinoquinazoline to PVP polymer in 
DMF solvent, the reaction mixture was basified with 25% NH4OH in the presence of 
TCEP·HCl as the reducing agent, to afford PVP-(4-phenyl amine)quinazoline conjugates 
in good yields. 
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Figure 4.6 (a) Preparation of covalently bonded PVP-(4-phenyl amine)quinazoline 
conjugates via the 1,4-conjugated Michael addition reaction. 
At the end of the reaction, 77 was subjected to purification by dialysis; excess 4-
anilinoquinazoline was removed. The dialysis procedure was guided by membrane 
tolerance to organic solvents according to the manufacturer’s specifications. Dialysis 
solvent composition was 10% ethanol in deionised water for the first 24 h, followed by 
100% deionised water for another 24 h. At the end of dialysis, 77 was recovered as a 
suspension in deionised water: it was frozen in liquid nitrogen and freeze-dried. 1H NMR 
analysis of 77 showed successful conjugation of polymer to a small molecule in a 1:1 ratio 
[see Fig. 4.6 (b)]. The PVP methine proton integration at 4.5 ppm was used to calculate 
the number of aromatic protons (1:9) that corresponded to 4 anilinoquinazoline and a 
triazole. Moreover, disappearance of the Michael acceptor olefin signals at 5.80–6.60 ppm 
further confirmed positive conjugation. 
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Figure 4.6 (b) 1H NMR spectra showing end group analysis for the PVP-(4-phenyl 
amine)quinazoline conjugate (77). 
The 1H NMR results were further confirmed by SEC analysis using both a RI detector and 
the UV wavelength corresponding to 4-anilinoquinazoline. Thus, an ultraviolet-visible 
(UV-Vis) scan was performed in N,N-dimethylacetamide (DMAc) to determine the 
absorption bands (λmax.) of the conjugated 4-anilinoquinazoline. The absorption bands of 
77 showed two absorption bands at approximately 290 nm and 350 nm, as shown in Fig. 
4.6 (c). 
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Figure 4.6 (c) UV-Vis spectrum of the PVP-(4-phenyl amine)quinazoline conjugate (77). 
The absorption band at λ = 350 nm was then selected for the SEC-UV analysis of the 
conjugates in DMAc (λmax. ~260 nm), where the solvent interference was considered 
minimal. The SEC-UV chromatogram of 77 obtained is shown in Fig. 4.6 (d). Two 
additional conjugates (78 and 79) were added for comparison purposes. The chemical 
structures are shown in Section 4.8 of this chapter. A closer look at the SEC-UV 
chromatograms revealed minor peaks close to the baseline, which could suggest that the 
conjugates were interacting with the SEC column.  
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Figure 4.6 (d) SEC-UV chromatograms (λmax = 350 nm) of PVP-(4-phenyl 
amine)quinazoline conjugates (77, 78, and 79) in DMAc solvent. 
Besides having these SEC-UV results in hand, SEC-DRI results were also obtained. The 
chromatograms shouldering towards higher molecular weight positively indicated 
successful conjugation. All the SEC analyses were performed at a concentration of 1.310-
3 M and the obtained Mn values are as shown in Fig. 4.6 (e). In the light of these results, 
it was considered useful to attempt to induce particle self-assembly in a selective solvent 
and then assess the resultant aggregation morphologies.  
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Figure 4.6 (e) SEC-DRI chromatograms of PVP-(4-phenyl amine)quinazoline conjugates 
(77, 78, and 79). 
 
 
The self-organising behaviour of amphiphilic conjugates was studied in aqueous 
solutions. To initiate self-assembly, a complete dissolution of the conjugates (e.g. 77) was 
investigated in different aprotic solvents; DMSO was determined as a common solvent. 
Thus, the conjugates were dissolved in DMSO and solvent composition was changed by 
gradual addition of a more selective aqueous solvent. The high miscibility of DMSO with 
water proved to be instrumental, as DMSO was easily displaced through dialysis in 
deionised water. 
These amphiphilic conjugates were expected to arrange themselves into organised 
assemblies of micelles.25 Thus, a solution of 77 was prepared in DMSO (1 mg/mL) and 
serially diluted with deionised water in a drop-wise fashion, while swirling, into different 
concentrations. The particle size distribution of resulting turbid colloidal suspensions 
were then analysed by a dynamic light scattering (DLS) technique. DLS measures the 
scattered light intensity from a laser passing through the colloidal solution as a function 
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of time (Brownian motion) and this is correlated to the hydrodynamic size of the particles 
by the Stokes–Einstein equation.26 The obtained DLS results showing particle size 
distribution of the conjugates at different concentrations are shown in Fig. 4.7 (a). It was 
determined that in the concentration range 10-6 to 10-5 M, the conjugates self-organised 
into uniformly distributed sizes of 123–130 nm, while at 10-4 M concentration the 
conjugates seemed to generate more than one aggregate state. 
 
Figure 4.7 (a) Particle size distribution plots of PVP-(4-phenyl amine)quinazoline 
conjugates (77) obtained by DLS. 
With the promising DLS data showing narrowly dispersed (Ɖ = 0.21) particle 
distributions, we decided to characterise the shape of the aggregates. Thus, imaging the 
particles by scanning transmission electron microscopy (STEM) and confocal microscopy 
(CM) were considered. Thus, sample preparations for STEM were done at a concentration 
of 3×10-5 M and immobilised on carbonised copper grids (3) for drying. The self-
organised polymer-drug conjugates were expected to retain their aqueous morphological 
state because PVP exhibits both cryoprotectant and lyoprotectant properties.27 The 
sample preparation methods involved freeze-drying, slow solvent evaporation at room 
temperature, and drying under vacuum at 37 °C. Unfortunately, the particle sizes and 
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morphology determinations of all samples viewed using STEM were generally 
unsuccessful due to a lack of imaging contrast and resolution. It was then realised that 
the use of confocal fluorescence imaging microscopy may be worthwhile. 
The 4-anilinoquinazoline derivatives are known fluorescent kinase inhibitors for 
confocal microscopy imaging,28 but they require high UV excitation energy [see the UV-
Vis spectrum in Fig. 4.6 (c)]. They could be expected to fluoresce in the blue to green 
region. Although this property is not favourable for imaging at the Central Analytical 
Facility (CAF) at Stellenbosch University, due to the unavailability of a UV laser, 
attempted imaging of the conjugates (e.g. 77) was nonetheless carried out, using the 
violet laser at 405 nm. A vague auto-fluorescence in the green region was seen.  
It was decided to study the structure of the self-assembled particles in the presence of 
Nile red, a common lipophilic fluorophore dye used in cell imaging.29 Its fluorescence 
(excitation at 515–560 nm and emission >590 nm) properties are influenced by the 
existence of the hydrophobic and hydrophilic environment in self-organised particles.29 
The dye tends to accumulate in the hydrophobic environment. Hence, this lipophilic 
behaviour was used to successfully image quinazoline conjugates with the violet laser. 
In preparation of CM samples, solutions of conjugate were made up in the presence of 1 
mol% Nile red and again immobilized on a carbonised copper grid at room temperature. 
The dried samples were then visualised using two wavelength regions (violet-blue and 
golden-red), independently. Each imaging wavelength captured individual fluorescences 
(of conjugates or of Nile red). These independent images overlapped. The overlaid images 
were then used to reveal the morphology of the self-assembled particles according to 
composition. The violet to blue region wavelength captured the auto-fluorescence of 
polymer-drug conjugates, while the golden-red region filmed the Nile red fluorescence. 
These two visuals were then overlaid to define the shape of the self-assembled particles.  
With reference to the 3D images shown in Fig. 4.7 (b), the overall spherical colloidal 
dispersion of the particles is demonstrated by image (i) with the yellow dot at the centre. 
The images (ii) and (iii) are the result of auto-fluorescence of 4-anilinoquinazolines and 
Nile red, respectively. It can be deduced from these images [(ii) and (iii)] that self-
assembled particles were unambiguously observed according to their composition. 
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Indeed, merging of the two independent fluorescence colours from (ii) and (iii) produced 
the yellow colour which is observed in image (iv), also seen in image (i). Various visual 
perspectives were also explored [(v) and (vi)] and cross-sectioning was utilised to show 
preferential accumulation of Nile red inside the hydrophobic core segment of the 4-
anilinoquinazolines. This was more visible in image (v). Overall, the images 
demonstrated the anticipated self-assembling behaviour of the amphiphilic polymer-
drug conjugates in solution to form spherical micelles. CM measurements of the particle 




Figure 4.7 (b) Confocal microscopy imaging of self-assembled PVP-(4-phenyl 
amine)quinazoline conjugate (77) stained with Nile red. The particles were visualised as 
follows: (i) a broader perspective of self-assembled particles showing circular shapes in 
2D, (ii) autofluorescence of conjugates, (iii) fluorescence by Nile red, and (iv)–(vi) 
overlaid images, through fluorescence at different wavelengths, ~450–600 nm.  
The very same sample, on a copper grid, was carefully used for further imaging by STEM, 
but without success. It was hoped that the Nile red stain at the centre of these globular 
i ii ii
iv v vi 
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particles would enhance the relative contrast and result in an improved view of the 
particles. However, ultimately, the different imaging modes were exhausted and 
increased magnifications that were meant to enhance the resolution often resulted in 
focus loss and blurred images. Selected STEM images are shown in Fig. 4.7 (c). 
 
Figure 4.7 (c) Selected STEM images of self-assembled PVP-(4-phenyl 
amine)quinazoline conjugates. 
Furthermore, qualitative methods such as 1H NMR analysis were instrumental in 
demonstrating the self-organising effect of the particles into micelles in both DMSO and 
water solvents. The illustrative behaviour of the conjugates in solutions involved the 
disappearance of characteristic peaks assigned to the hydrophobic core (4-
anilinoquinazolines) while only the outer hydrophilic segments (PVP chain) were 
selectively revealed after micelle formation. An example of this observation is depicted 
by the 1H NMR spectra in Fig. 4.7 (d). The two spectra demonstrate polymer-drug 
conjugates in unimolecular arrangement and micelle aggregation state in DMSO solvent.  
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Figure 4.7 (d) The influence of the aggregation state of PVP-(4-phenyl 
amine)quinazoline conjugates (77, 78, and 79) on the appearance of 1H NMR spectra in 
different solvents (DMSO and water). 
After using all the above-mentioned analytical methods (DLS, CM, STEM, SEC, and 1H 
NMR), the strengths and weakness of each method were identified during 
characterisation of the conjugates. Eventually, this enabled us to logically establish, 
finally, the morphology of the aqueously dispersed particles. The particle size 
distribution and dispersity were obtained from DLS and the shape of the particles was 
visualised by CM imaging. 
 
 
RDRP of NVP using the RAFT/MADIX technique on a triazole-based RAFT agent was 
utilised to successfully obtain well-defined PVP polymers. These PVP polymers 
demonstrated highly controlled polymerisation with low dispersity values (Ɖ ≤1.15) and 
DMSO-d6 
D2O 
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well-preserved end group functionalities. Transformation of the O-ethyl xanthate was 
performed by an aminolysis reaction to form thiol-terminated PVP, which was then 
coupled to 4-anilinoquinazoline conjugates via an 1,4-conjugated Michael addition 
reaction. The formed conjugates were then dissolved in DMSO and dialysed in water to 
induce micelle formation. The morphology of the self-assembled particles was 
established using various analytical tools. Eventually, a total of eight PVP-(4-phenyl 
amine)quinazoline conjugates were prepared and formulated into micellar structures. 
See Fig. 4.8. A preliminary drug release and anti-tumour efficacy study of the two 
conjugates (highlighted on cleavable linkers) was performed in vitro. This, and the effect 
of the linker chemistry in drug release and the biological efficacy of these conjugates will 
be discussed in Chapter 05. 
 
Figure 4.8 PVP-(4-phenyl amine)quinazoline conjugates realised in this study. The R 
group represents the PVP polymer chain. The difference between the two test conjugates 
is highlighted on the linker group. 
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This chapter describes a study on drug release and biological evaluation of two 
amphiphilic polymer-drug conjugates. These conjugates comprised a PVP polymer 
attached to cytotoxic 4-anilinoquinazoline anti-tumour agent through acid-labile linkers 
(an ester and an amide). The drug release profiles of the active ingredient were studied 
under various pH conditions. Based on the outcome of this study, pH-selective drug 
release profiles showing favourable chemical stabilities were obtained. The second part 
of this chapter focuses on the biological assessment of anti-tumour efficacy in carcinoma 
cells. These preliminary biological studies demonstrated comparable anti-tumour 
efficacy between conjugated molecules and ‘free 4-aniliniloquinazolines’, with similar 
mechanisms of anti-tumour activity. 
 
Formulation of polymer-drug conjugates into a pH-responsive micellar delivery system 
to target a tumour microenvironment has promising therapeutic potential for cancer 
treatment.1 This type of colloidal drug carrier system is known to have tumouricidal 
effects that are underlined by enhanced bio-distribution and release of cytotoxic agents 
in the acidic environment of tumour cells.2 While this has proven to be explicitly 
tumouritropic,3 it also offers an interesting opportunity to improve target specificity of 
the SMKIs. Because of these features, micelle formulations for drug delivery has the 
potential to overcome a number of therapeutic barriers found in conventional 
molecularly targeted cancer therapy. 
In assembling these conjugates, emphasis was placed on the critical role that each 
component plays in influencing the anti-tumour efficacy.4 Thus, the hydrolytic stability of 
the linkers (ester and amide) and anti-tumour efficacy of two conjugates were evaluated 
under physiologically relevant conditions, and will be discussed.  
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Drug release profiles of the conjugates were established in vitro by measuring the 
hydrolytic stability of the linker groups under a set of conditions. During the process, self-
assembled micelle conjugates were subjected to conditions mimicking the endosomal pH 
(5.6) and normal physiological pH (7.4) over a period of 24 h. A typical reaction showing 
hydrolysis of the acid-labile ester linker is shown in Fig. 5.2 (a). 
 
 
Figure 5.2 (a) Hydrolysis of the acid-labile ester linker in PVP-(4-phenyl 
amine)quinazoline conjugate (79) at pH 5.6. 
In conducting the hydrolysis of self-assembled PVP-(4-phenyl amine)quinazoline 
conjugates, a 0.1 M potassium acetate buffer was prepared to a predetermined pH of 5.6 
using the Henderson–Hasselbalch equation:5 𝑝𝐻 = p𝐾𝑎 + 𝑙𝑜𝑔
[A⁻]
[HA] 
. The buffering effect 
is well known to result from a reversible reaction equilibrium, when the concentrations 
of the proton donor and its conjugate base are equal. Thus, equimolar (0.2 M) solutions 
of acetic acid (pKa = 4.75) and potassium acetate were prepared using deionised water, 
HOAc (11.55 mL/L), and KOAc (19.6 g/L), in separate volumetric flasks. To achieve a 0.1 
M buffer concentration and the desired pH, HOAc (35.8 mL) and KOAc (264.2 mL) 
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solutions were mixed to a volume of 300 mL and then diluted to a final volume of 600 mL 
using deionised water. Based on the above equation, the pH is dependent on the ratio of 
buffer components. The solutions were mixed under mechanical stirring to ensure 
homogeneity. The buffer solutions (2300 mL) were then equilibrated to a constant 
temperature (37 °C). To initiate the hydrolysis process, preconditioned dialysis 
membranes [Float-A-Lyzer G2; pore size rating/molecular weight cut-off (MWCO) 500–
1000] were charged with freshly prepared conjugates (1.0×10-3 M) then immersed into 
equilibrated buffer solutions under gentle stirring (200 rpm). 
The amount of the drug released was followed quantitatively using UV-Vis analysis (λmax. 
= 350 nm). The initial absorbance intensities were recorded as [A˳] corresponding to time 
t˳ = 0 h, and the reaction progress was monitored at regular time intervals of ~2 h for 10 
h, then 18 h, and 24 h. The recorded absorbance values were measured against a blank 
buffer solution. It was projected that as the hydrolysis occurred, the released small 
molecules would diffuse from the semi-permeable membrane (Float-A-Lyzer G2) into the 
dialysate across the concentration gradient. This procedure thus allowed for selective 
molecular separation, during which hydrated PVP polymer was trapped inside the 
membrane as the free 4-anilinoquinazoline chromophores diffused into the solution. The 
analytical samples were withdrawn from dialysis membranes with a seleable screw-cap. 
The reactions were interrupted to measure the absorbance. By applying the Beer–
Lambert law in our UV-Vis analyses,6 the measured absorbance values were expected to 
decrease as the molar concentration of the chromophores decreased. A decrease in the 
absorbance during hydrolysis at the acidic pH of 5.6 was observed for both the ester and 
the amide bonds. One example to illustrate the decreasing absorbance of 79 as 63 is 
released into the dialysate solution is shown in Fig. 5.1 (b). 
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Figure 5.2 (b) UV-Vis spectra of 79 showing decreasing UV absorbance during hydrolysis 
as 63 is released into the buffer solution at pH 5.6. 
The dialysate was changed three times to ensure the movement of 4-anilinoquinazolines 
from the dialysis membrane into the buffer solution against the concentration gradient. 
Then 0.1 M potassium phosphate buffer solutions at pH 7.4 were prepared using a 
method similar to that used to prepare the acetate buffers at pH 5.6. While acetate ions 
have strong buffering capacity under acidic conditions. (buffer range = pKa±1.0), the 
phosphate buffers have pKa 7.21, and work well from pH 5.8–8.0.7 The overall hydrolysis 
drug release studies at pHs 5.6 and 7.4 were plotted as a function of time, as shown in 
Fig. 5.2 (c). 
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Figure 5.2 (c) Drug release profiles of polymer-drug conjugates showing the amide and 
ester linker group hydrolysis at pH 5.6 and 7.4. 
With reference to the pre-established multiple aggregation states of PVP-(4-phenyl 
amine)quinazolines for the concentration of 10-3 M, the UV-Vis spectroscopic absorbance 
for the amount of released 4-anilinoquinazoline chromophores was calculated as the 
percentage of drug released (  % 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =
([A˳]−[A𝑡] )
[A˳] 
× 100). It can be observed 
from Fig. 5.2 (c) that the hydrolysis reactions were sensitive to the reaction pH. It was 
evident that both linker groups showed high chemical stability at pH 7.4, while they were 
hydrolysed within ~12 h at the endosomal pH of 5.6. This confirmed that the two linkers 
were suitable for the selective delivery of compounds into acidic tumour environments. 
More importantly, they hydrolyse within the cell cycle doubling time of tumour cells.8 
The observed pH sensitivity profiles were also attributable to the proton-trapping ability 
of the 4-anilinoquinazoline interior, i.e. the hydrophobic core of the formed micelles. The 
proton-trapping effect exhibited by the hydrophobic core was expected to stimulate 
hydrolytic cleavage of the conjugates and micelle dissociation. In some micelle-based 
drug delivery systems, the pH-trapping effect has been induced by incorporating 
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poly(histidine) or imidazole rings to form the basic hydrophobic core in amphiphilic 
block polymers.9 In our case, the ester linker group was cleaved earlier (after ~5 h), but 
the amide bond hydrolysis was much slower (~12 h). 
The hydrolytic products of PVP-(4-phenyl amine)quinazoline conjugates at pH 5.6 were 
analysed by MS. This experiment was also in line with the earlier hypothesis in Chapter 
02, namely, that β-propionic ester/amide linker groups are likely to undergo hydrolytic 
cleavage instead of β-elimination under acidic conditions. To confirm this hypothesis, two 
additional reactions were performed at pH 5.6 [3-mg-scale polymer-drug conjugates in 1 
mL acetate buffer solution at 37 °C in reaction flasks]. After 24 h, crude hydrolytic 
products were dialysed in deionised water for 12 h, and dialysates were collected and 
freeze-dried. Using liquid chromatography-mass spectroscopy (LC-MS) analytical 
technique, the identity of released compounds is usually confirmed by matching the 
retention time and m/z of the known molecules with the hydrolysed compounds. 
Unfortunately, only the MS results were successfully obtained as the samples bound 
strongly to the column packing, perhaps due to PVP polymer contamination. MS results 
of the dialysates showed m/z values which were consistent hydrolysis [see structures of 
63 and 44 in Fig. 5.2 (d)]. These results verified our hypothesisnone agreed with the 
β-elimination reaction. However, the overall concentration of compounds was very low 
and no purification was performed before MS analysis. 
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Figure 5.2 (d) MS results of 63 and 44 obtained from hydrolysis of 79 and 82, 
respectively at pH 5.6. Experimental [M+H]+ values are highlighted in pale yellow and the 
calculated m/z values are shown under the chemical structures. 
The overall drug release results showed the successful recovery of 4-anilinoquinazolines 
under an acidic pH of 5.6, which favours selective tumouritropic drug delivery. With the 
obtained chemical stability at the physiological pH of 7.4, micellar-encupsulated anti-
tumour agents were expected to have prolonged plasma half-life in vivo. The MS results 
further confirmed that drug release was solely as a result of hydrolytic cleavage. Because 
of hydrolytic cleavage, active ingredients obtained from polymer-drug conjugates were 
expected to inhibit EGFR kinase activity via a reversible ATP-competitive mechanism. It 
was thus considered suitable to carry out in vitro biological assessment of the anti-
tumour efficacy of selected PVP-(4-phenyl amine)quinazolines. Bioassays were 
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The anti-tumour activities of PVP-(4-phenyl amine)quinazoline conjugates (77 and 78) 
and 4-anilinoquinaolines (45, 54, 64, and 68) were evaluated on wild-type and EGFR 
mutant epithelial cells (A431 and H1975, respectively). These human epidermoid 
carcinoma cell variants are known to possess a large number of EGFRs and are 
universally used to study the EGFR overexpression in protein kinase activities.10 EGFR 
phosphorylation activity is highly overexpressed in A431 carcinomas, while H1975 cells 
carry mutant EGFR L858R/T790M.10c Both cell lines are found in lung tissues of NSCL 
patients with adenocarcinoma. They were used to determine the efficacy of conjugates 
against EGFR phosphorylation and drug resistance which is induced by secondary 
mutations.  
In assessing the anti-tumour efficacy of 4-anilinoquinazolines in cell cultures, the 
CellTiter-Glo luminescent cell viability assay was used. Thus, the polymer-drug 
conjugates (77 and 78) and 4-anilinoquinazolines (45, 54, 64, and 68) were dissolved in 
DMSO in the concentration range 14 nM to 30 µM, along with the conventional drugs 
Gefitinib, Afatinib, WZ 004, and Osimertinib as the reference compounds (see Table 5.3). 
The free PVP polymer, DMSO solvent, and staurosporine were used as negative controls. 
The preconditioned cells (A431 and H1975) were treated with EGFR kinase inhibitors 
and incubated for 96 h prior to luminescence measurements. Based on bioassay 
protocols, inhibition of EGFR kinase activity was correlated to the reduction of cell 
proliferation by quantifying the amount of ATP in cells.11 The presence of metabolic 
activity in cells usually requires ATP, whose measurable luminescent signal is directly 
proportional to the number of viable cells per culture.12 Measurements were carried out 
in duplicate and cell seeding (150 cells/well) was replicated in at least two plates. The 
luminescence signal intensity was recorded on a Perkin Elmer Envision microplate 
reader at 500 ms integration time for which the Z’-factor ≥0.5 was obtained. The 50% of 
maximum effective concentration (EC50) values of the compounds were determined 
using the Quatro Software suite. 
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Table 5.3 EC50 determination of PVP-(4-phenyl amine)quinazoline conjugates and small 
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R*S = PVP polymer chain 
With reference to the EC50 values in Table 5.3, entries 1–4, it can be seen that the 
standard drugs maintained low micromolar EGFR kinase inhibition on both wild-type 
and mutant EGFR over 4 days of incubation. During this period, cells experiencing no 
EGFR inhibition were expected to grow exponentially with respect to their doubling cell-
cycle times. Under such conditions (see the negative control in entry 5) the maximum 
concentration value (30 µM) was obtained, demonstrating that no measurable effective 
dose was obtained. Looking closely at Gefitinib (entry 1) showed a diminishing anti-
tumour activity against mutant EGFR L858R/T790M. In previous studies,13 this effect has 
been ascribed to the T790M steric clash in the hydrophobic region of the ATP binding 
pocket. The T790M is common for 4-anilinoquinazoline reversible kinase inhibitors, but 
Afatinib (entry 2) is an irreversible kinase inhibitor, which has been proven by good 
efficacy against both EGFR variants. This is attributed to the acrylamide functionality that 
forms covalent bonds with the Cys 797 thiol of the EGFR target.14 Although Afatanib 
received the first FDA approval in 2013 against NSCLC adenocarcinoma patients with 
EGFR T790M, it is still considered as an experimental drug due to dose-limiting adverse 
effects.15 The third generation amino pyrimidine irreversible inhibitors,16 entries 3 and 
4, demonstrated superior efficacy over 4-anilinoquinazolines on EGFR L858R/T790M. 
Proceeding to entries 6–8, it is evident that polymer-bound conjugate (77) and the small 
molecules (64 and 68) exhibited threefold lower anti-tumour activities on wild-type 
EGFR in comparison to Gefitinib (entry 1). Based on the hydrolysis reaction profiles, it 
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was determined that active anti-tumour agents released from polymer conjugates are 
expected to display reversible kinase inhibition efficacies that are similar to Gefitinib.17 
It was however disappointing to see the ester conjugate (77) displaying no activity 
against mutant EGFR. In view of this outcome, it was hypothesised that the reduced anti-
tumour efficacy for the acrylate derivative (68) was also attributable to the cleavage of 
ester functionality, thus averting the compound’s mode of action from irreversible to 
reversible kinase inhibition mechanisms. The loss of acrylate functionality leading to less 
potent substrates in irreversible kinase inhibition has also been observed by Denny and 
co-workers.18 One of the reasons why the acrylate functionality was used in our studies 
was to achieve the release of cytotoxic anti-tumour agents with a lesser hydrolytically 
stable ester linker group, should the amides have unfavourable physiological stability. 
Looking at entries 9–12, the polymer-drug conjugate 78 demonstrated a better anti-
tumour inhibitory profile on both EGFR cell variants. From drug release studies, it could 
be suggested that the conjugates of the amide linker group had better sustained release 
profiles, thus ensuring sizeable drug doses over prolonged periods, in comparison with 
the ester linkers. On the other hand, the free amine 45 had notably low anti-tumour 
activity; it was considered to be an outlier among the other amino compounds (78 and 
54). It was however interesting to note that polymer-drug conjugate 78 exhibited similar 
anti-tumour activity profiles to the gold standard ATP-competitive Gefitinib (entry 1). Of 
even further interest was to note that compound 54 displayed good anti-tumour efficacy 
on wild-type and double mutant EGFR. The anti-tumour efficacy of this C-6 acrylamide-
substituted quinazoline (54) was similar to that of Afatinib (entry 2). Afatinib is traded 
under the name Gilotrif® after its second FDA approval in 2016 as a front-line treatment 
option for advanced squamous cell lung cancer.19 These results (with polymer-drug 
conjugate 78 and the free drug 54) warrant further investigation of the amide-based 
polymer-drug conjugates. 
Based on the bioassay results, it was significant to obtain anti-tumour activity for the 
polymer bound 4-anilinoquinazoline molecules. The active ingredients released from the 
conjugates have demonstrated comparable bioactivity profiles with their small-molecule 
counterparts (except 45) possessing the same anti-tumour inhibitory mechanism. One of 
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the outstanding results was that the anti-tumour efficacy of the amide-linked polymer-
drug conjugate (78) resembled that of Gefitinib, which was anticipated to have the same 
mechanism of kinase inhibition. Moreover, acrylamide-bearing 54 also displayed a 
similar irreversible kinase inhibition pattern to Afatinib, the first quinazoline-based drug 
against squamous cell lung cancer. Although anti-tumour agents released from the 
conjugates were expected to have improved anti-tumour efficacy, it must be emphasised 
that the present bioassay experiments do not address the effects of limited solubility and 
bioavailability of 4-anilinoquinazolines, as all the compounds were solubilized in DMSO 
solvent.  
 
The two PVP-(4-phenyl amine)quinazoline conjugates composed of the PVP polymer and 
4-anilinoquinazoline anti-tumour agents linked by the acid-labile groups (ester and 
amide) were evaluated in vitro. Based on the obtained drug release profiles, polymer-
drug conjugates demonstrated selective hydrolysis at acidic pH, which is a requirement 
for targeting tumour cells. Furthermore, MS analysis of the dialysates supported an acid-
catalysed hydrolysis mechanism, thus ascribing the active ingredients released from the 
polymer conjugates to a reversible EGFR kinase inhibition mechanism. Finally, the 
bioassay assessments of the polymer conjugates on EGFR kinase inhibition in A431 cells 
and double-mutant EGFR L858R/T790M in H1975 cells revealed anti-tumour efficacy 
that corresponds to reversible EGFR kinase inhibition. Attempts to upgrade the 
conjugates into irreversible EGFR kinase inhibitors will be briefly addressed in the 
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Chapter 6: Experimental methods and 
characterisation data  
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This chapter contains description of experimental procedures that were used during the 
course of synthesis of small molecules and polymerisation reactions. Descriptive 





Analytical grade solvents and reagents were purchased from Sigma Aldrich and dried 
using conventional distillation prior to use. Unless stated otherwise, moisture sensitive 
reactions were performed under an inert nitrogen atmosphere. Stabiliser free NVP was 
distilled under reduced pressure and α,α´-azobisisobutyronitrile (AIBN) radical initiator 
was recrystallized twice from ethanol, dried under high vacuum and kept under argon 
atmosphere. 
Preparative column chromatography separations were performed on a silica gel column 
(70–230 mesh size, ASTM, Fluka). Reactions and separations were monitored by TLC on 
pre-coated aluminium silica gel plates (60F254 Merck) and the developed TLCs were 
viewed under UV lamp (254 nm) or visualised after staining. The melting points were 
recorded using the open capillary method on a Lasany melting point apparatus. Only the 
compounds with definite melting points, which did not undergo decomposition before 
melting, were recorded. Organic solvents were evaporated on a Büchi rotary evaporator 
equipped with a diaphragm pump and aqueous solvents were removed on a lyophilizer 
after they were frozen in liquid nitrogen. Polymer-drug conjugates were dialysed using 
the Spectra/Por Float-A-Lyzer G2, biotech grade, cellulose ester membrane with screw-
on caps and MWCO 500-1000. 
b) Instrumentation 
The nuclear magnetic resonance (NMR) spectroscopy (1H and 13C, 1JC-H HSQC, 2,3JC-H 
HMBC) data were recorded on Varian Unity Inova spectrometers. All the spectra were 
obtained on a 5 mm dual broad band PFG probe at 25 °C. The chemical shifts (δ) were 
reported in ppm relative to internal solvent peaks. The coupling constant (J) values were 
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assigned in hertz (Hz), and the standardised signals splitting abbreviations have been 
used throughout the text. 
The average molar masses (Mn) and polydispersity indices (Ɖ) of PVP homopolymer were 
obtained by size exclusion chromatography (SEC), at the Polymer Science Laboratories, 
Stellenbosch University. A 100 µL injection volumes of PVP samples (2 mg/mL) were 
analysed at a flow rate of 1 mL/minute at λmax. 280 nm or 350 nm with DMAc as a mobile 
phase, which was calibrated with PMMA standards. The SEC set up consisted of a Waters 
717 auto-sampler coupled to a Shimadzu LC-10AT pump, PSS GRAM (50 × 8.0 mm, 10 
µm) guard-column, PSS GRAM (300 × 8.0 mm, 10 µm, 100 Å) column and a Waters 
differential refractometer (Waters 2414) in a series with a dual wavelength UV detector 
(Waters 2487). 
The size distributions were recorded by intensity, Z-average diameter and polydispersity 
index (Đ), on Dynamic Light Scattering using a Malvern Zetasizer Nano ZS 100. The 
samples were measured in triplicates and the data was generated using the Zeta Sizer 
software. Imaging of the self-assembled polymer-drug conjugates was performed on 
scanning transmission electron microscope (STEM) and confocal microscope, using Zeiss 
Evo MA15VP and Carl Zeiss LSM 780 fluorescence microscope, respectively. The UV-VIS 
chromatograms were recorded by Specord 210 plus UV VIS and the absorbance 
wavelengths were obtained in nanometers (nm).  
The mass spectra were recorded on a Waters Synapt G2 UPLC-MS instrument using the 
positive ionization mode (ESI+) at a cone voltage of 15 volts. The chemical purity of the 
compounds were also determined on the Waters Synapt G2 UPLC-MS that is equipped 
with an Acquity UPLC/UV detector, a Phenomenex kinetix phenyl hexyl column, and a 
programmable binary elution system at a mobile phase flow rate of 0.4 mL/min. The 
mobile phase consisted of a 1% formic acid:acetonitrile (A:B) and a snapshot showing the 
solvent system is provided in the supporting information. All the NMR spectroscopy, LC-
MS, STEM and confocal analyses were carried out at the CAF, Stellenbosch University. 
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Compound 1 was prepared by acylation of 2-methylaniline as reported by 
Steck and Fletcher.1 A solution of 2-methylaniline (1.89 g, 17.7 mmol), acetic 
anhydride (Ac2O, 4 mL), and acetic acid (AcOH, 5 mL) was warmed to 50 °C 
with stirring for 1 h. The reaction was then quenched by emptying the flask contents into 
ice water (~30 mL), and white prismatic needles crushed out of the aqueous solution. 
The aqueous solution was decanted and the prismatic needles were then filtered, rinsed 
with cold water, and dried to afford pure compound 1 in 94% yield (2.49 g). The melting 
point was 96–98 °C [lit.2 105–108 °C]; 1H NMR (300 MHz, DMSO) δ 9.26 (br s, 1H), 7.39 
(d, J = 7.6 Hz, 1H), 7.25–6.98 (m, 3H), 2.19 (s, 3H), 2.05 (s, 3H); 13C NMR (75 MHz, DMSO) 
δ 168.5, 136.9, 131.9, 130.6, 126.2, 125.4, 125.3, 23.7, 18.3. The 1H NMR spectrum 
resembled literature data.3 
 
2-Acetamidobenzoic acid (4) 
Compound 4 was synthesized by following the literature procedure with 
minor modifications to the reaction conditions.1 The N-(2-
methylphenyl)acetamide (1.30 g, 8.71 mmol), KMnO4 (1.85 g, 11.7 mmol), 
and MgSO4 (1.27 g, 10.1 mmol) were dissolved in water (100 mL) with 
stirring at a room temperature. The reaction was warmed to 75 °C under continuous 
stirring until the vigorous bubbling of the reaction had subsided. The reaction 
temperature was then raised to 90 °C for 3 h during which the purple solution (KMnO4) 
changed colour to a brown suspension (MnO2). The brown suspension was filtered off 
while still hot and the MnO2 cake was rinsed with hot water (~50 mL) in order to obtain 
a clear aqueous filtrate. The filtrate was cooled into the ice-bath and titrated to pH 4 using 
32% HCl. The aqueous solution was decanted and the remaining white needles were 
dried to obtain a pure product in 81% yield (1.27 g). The melting point was 181–183 °C 
[lit.4 184–186 °C]; 1H NMR (300 MHz, DMSO) δ 13.55 (br s, 1H), 11.05 (s, 1H), 8.46 (dd, J 
= 7.5, 1.0 Hz, 1H), 8.00–7.93 (m, 1H), 7.61–7.51 (m, 1H), 7.14(ddd [appeared as dt], J1 = J2 
=7.9, 1.2 Hz, 1H), 2.13 (s, 3H);13C NMR (75 MHz, DMSO) δ 168.9, 167.9, 140.2, 133.4, 
130.5, 122.0, 119.4, 115.9, 24.0. The 1H NMR spectrum matched literature data.5 
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2-Aminobenzoic acid (5) 
A solution of 4 (1.80 g, 10.1 mmol) in 96% ethanolic HCl (10 mL, 4 N) was 
heated to reflux at 80 °C for 2 h.1 At the end of the reaction, the solution 
was concentrated in vacuo to obtain a brown HCl salt product. The salt was 
recrystallized from ethanol to obtain 5 as a beige powder in 76% yield (1.56 g). The 
melting point was 144–146 °C [lit.6 145 °C]; 1H NMR (300 MHz, DMSO) δ 8.50 (br s, 2H), 
7.68 (dd, J = 8.1, 1.7 Hz, 1H), 7.21 (ddd, J = 8.5, 5.7, 1.7 Hz, 1H), 6.73 (dd, J = 8.5, 1.2 Hz, 
1H), 6.50 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 170.0, 152.0, 134.2, 
131.6, 116.8, 115.0, 110.0. Alternative hydrolysis with 4 N KOH in 96% ethanol gave the 




Preparation of compound 6 was carried out by following the literature 
method.8 2-Aminobenzoic acid (2.50 g, 18.2 mmol) was added to 
formamide (15 mL) at room temperature and the reaction mixture was 
stirred at 130 °C for 24 h. The reaction contents were poured into ice-cold water (~120 
mL) and the product was allowed to precipitate out of the solution. The precipitate was 
recovered by filtration, rinsed with cold water, and 4-hydroxyquinazoline precipitate 
was isolated in 91% yield after drying (2.41 g). The melting point was 215–217 °C [lit.9 
214–216 °C]; 1H NMR (400 MHz, DMSO) δ 12.24 (s, 1H), 8.12 (dd, J = 7.9, 1.2 Hz, 1H), 8.09 
(s, 1H), 7.84–7.78 (m, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.55–7.48 (m, 1H);13C NMR (101 MHz, 
DMSO) δ 161.4, 149.4, 146.0, 135.0, 127.9, 127.4, 126.5, 123.3. The 1H NMR spectra was 
in agreement with the literature data.8  
 
6-Nitroquinazolin-4(3H)-one (7) 
Preparation of compound 7 was carried out by following the 
literature procedure.10 Quinazolin-4(3H)-one (500 mg, 3.42 mmol) 
was dissolved in mixed fuming acids (1:1 by volume, H2SO4/HNO3; 4 
mL) and the reaction mixture was stirred at 90 °C for 45 min. The reaction was quenched 
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by pouring the hot reaction mixture into ice-cold water (~50 mL) and the yellow 
precipitate was formed. The precipitate was collected by filtration, rinsed with cold water 
and dried to obtain 6-nitroquinazolin-4(3H)-one (0.60 g) as a yellow powder in 91% 
yield. The melting point was 273–275 °C [lit.11 275–276 °C]; 1H NMR (400 MHz, DMSO) δ 
11.41 (br s, 1H), 8.80 (d, J = 9.0 Hz, 1H), 8.55 (dd, J = 9.0, 2.7 Hz, 1H), 8.34 (s, 1H), 7.87 (d, 
J = 9.0 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 160.8, 149.3, 143.0, 136.8, 129.5, 127.7, 123.8, 
122.6; MS (ESI+) m/z 192.0403 was calculated for C8H5N3O3 [M + H]+ and 192.0429 (-2.60 




Synthesis of compound 8 was performed by adapting to the literature 
procedure,13 with minor modifications. A solution of 4-fluoro-2-
nitrotoluene (2.60 g, 16.8 mmol) and SnCl2 (14.7 g, 77.7 mmol) in 96% ethanolic HCl (2 
N) was maintained at 60 °C with stirring for 2 h. The solvent was then removed in vacuo 
and the residue was diluted with water (10 mL) and DCM (30 mL), and then basified to 
pH 10 with 4 N aqueous KOH. The product was extracted from the milky white aqueous 
solution into DCM (3 × 30 mL), after which the organic extract was dried over MgSO4, and 
concentrated to obtain the crude product. The product was purified by chromatography 
to afford a pale yellow liquid in 99% yield (2.08 g). 1H NMR (400 MHz, CDCl3) δ 6.96 (ddd 
[appeared as dt] 4J H-H  = 0.7, 3JH-H  = 3JF-H = 8.0 Hz, 1H), 6.42–6.34 (m, 2H), 3.67 (br s, 2H), 
2.11 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.7 (d, 1JC-F= 242.4 Hz), 146.1, 131.4, 117.9, 
105.0 (d, 2JC-F = 21.2 Hz), 101.9 (d, 2JC-F = 26.3 Hz), 16.9. The 1H NMR closely resembled 
the literature data.14 
 
N-(5-Fluoro-2-methylphenyl)acetamide (9) 
Compound 9 was prepared from compound 8 (2.00 g, 16.0 mmol) by 
adapting to the procedure used in the synthesis of compound 1.1 The N-
(5-fluoro-2-methylphenyl)acetamide was obtained in 91% yield (2.43 g). The melting 
point was 134–136 °C [lit.15 133–135 °C]; 1H NMR (300 MHz, CDCl3) δ 7.78–7.69 (m, 1H), 
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7.17–7.02 (m, 2H), 6.83–6.72 (m, 1H), 2.22 (br s, 6H); 13C NMR (75 MHz, CDCl3) δ 168.3, 
162.9 (d, 1JC-F = 267.8 Hz), 136.8, 131.1, 123.2, 111.5 (d, 2JC-F = 24.0 Hz), 109.9 (d, 2JC-F = 
25.5 Hz), 24.5, 17.1. The 1H NMR data was in agreement with literature data.16 
 
2-Acetamido-4-fluorobenzoic acid (10) 
In a similar manner to the synthetic procedure reported for compound 
4,1 compound 10 acid was prepared from acid hydrolysis of N-(5-fluoro-
2-methylphenyl)acetamide (2.01 g, 12.0 mmol). 2-Acetamido-4-
fluorobenzoic acid 10 was obtained as an off-white powder in 82% yield (1.93 g). The 
melting point was 208–209 °C [lit.1 209–209.5 °C]; 1H NMR (600 MHz, DMSO) δ 11.63 (s, 
1H), 8.34 (dd, 3JH-F = 12.3 Hz, 4JH-H = 2.7 Hz, 1H), 8.05 (dd, 3JH-H = 8.8 Hz, 3JH-F = 6.9 Hz, 1H), 
6.95 (ddd [appeared as dt] , 3JH-H = 3JH-F = 8.4 Hz, 4JH-H = 2,7 Hz, 1H), 2.15 (s, 3H); 13C NMR 
(151 MHz, DMSO) δ 169.4 (2C), 165.5 (d, 1JC-F = 249.2 Hz), 143.5 (d, 3JC-F = 13.0 Hz), 134.2 
(d, 3JC-F = 11.2 Hz), 109.8 (d, 2JC-F = 21.1 Hz, 2C), 106.0 (d, 2JC-F = 28.7 Hz), 25.1. The 1H 
NMR data was in agreement with the literature.5 
 
2-Amino-4-fluorobenzoic acid (11) 
Compound 10 (2.02 g, 10.3 mmol) was treated in a similar fashion to 
synthesis of compound 5 under acidic medium to afford 11 as a beige 
powder in 74% yield (1.18 g). The melting point was 193–194 °C [lit.1 
192.5–193 °C]; 1H NMR (600 MHz, DMSO) δ 7.73 (ddd, [appeared as td] 3JH-H =11.9, 3JH-F = 
7.2 Hz, 4JH-H = 2.6 Hz, 1H), 6.87 (br s, 2H), 6.51 (dd, JH-F = 11.9 Hz, 4JH-H = 2.6 Hz, 1H), 6.31 
(ddd, [appeared as dt, 3JH-F =11.9 Hz, 3JH-H = 7.2 Hz, 4JH-H = 2.6 Hz, 1H); 13C NMR (100 MHz, 
DMSO) δ 171.8, 169.5 (d, 1JC-F = 240.1 Hz), 156.3 (d, 3JC-F = 13.1 Hz), 136.9 (d, 3JC-F = 11.5 
Hz), 105.1 (d, 2JC-F = 22.0 Hz), 104.0, 103.8 (d, 2JC-F = 24.0 Hz). 
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Compound 12 was obtained in 83% yield (1.76 g) following treatment 
of compound 11 (2.01 g, 12.9 mmol) with formamide (25 mL) as in the 
preparation of 6.8 The melting point was 258–259 °C [lit.17 260.1–261 
°C]; 1H NMR (600 MHz, DMSO) δ 12.33 (br s, 1H), 8.18 (ddd [appeared as dt], 3JH-H =8.4, 
3JH-F = 6.4, 4JH-H = 2.4 Hz , 1H), 8.13 ( br d, J = 2.9 Hz, 1H), 7.44 (dd, 3JH-F = 10.1 Hz, 4JH-H = 
2.5 Hz, 1H), 7.38 (ddd [appeared as dt], 3JH-H =3JH-F = 8.7 Hz, 4JH-H = 2.5 Hz, 1H); 13C NMR 
(75 MHz, DMSO) δ 167.7 (d, 1JC-F = 250.7 Hz), 160.5, 151.2 (d, 3JC-F = 13.1 Hz), 147.3, 129.4 
(d, 3JC-F = 10.8 Hz), 120.1, 115.8 (d, 2JC-F = 24.2 Hz), 112.8 (d, 2JC-F = 22.7 Hz). The 1H NMR 
spectrum matched the literature data.12 
 
7-Chloroquinazolin-4(3H)-one (14) 
In a similar fashion to a preparation of 6,8 compound 14 was obtained 
from treatment of 2-amino-4-chlorobenzoic acid (2.03 g, 11.7 mmol) 
with formamide (25 mL). A free flowing light-brown powder of 14 was 
obtained in 87% yield (1.84 g). The melting point was 249–250 °C [lit.18 249–252 °C]; 1H 
NMR (400 MHz, DMSO) δ 12.37 (br s, 1H), 8.12 (s, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 
2.1 Hz, 1H), 7.54 (dd, J = 8.5, 2.1 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 160.8, 149.2, 148.3, 
140.0, 128.9, 128.2, 126.3, 122.0. The 1H NMR data resembled the literature.12 
 
7-Chloro-6-nitroquinazolin-4(3H)-one [15 (i)] 
Using the same procedure for the synthesis of 6-nitoquinazolin-
4(3H)-one (7),10 compound 15 (i) was obtained from nitration of 7-
Chloroquinazoline (500 mg, 2.78 mmol) in fuming HNO3/H2SO4 (4 
mL) for 1 h at 80°C. Due to multiple products formation for this particular nitration 
reaction, further purification was performed by means of chromatography to afford 15 
(i) as a light yellow product in 67% overall yield. The melting point was 222–224 °C [lit.19 
300–303 °C];  1H NMR (300 MHz, DMSO) δ 12.79 (br s, 1H), 8.67 (s, 1H), 8.31 (s, 1H), 8.01 
(s, 1H); 13C NMR (75 MHz, DMSO) δ 160.8, 149.2, 148.3, 140.0, 128.9, 128.2, 126.3, 122.0. 
The NMR data was identical to one reported in the literature.20 
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7-Chloro-8-nitroquinazolin-4(3H)-one [15 (ii)] 
The compound was isolated as a by-product from preparation of 15 (i) 
above at an estimated quantitative yield of 11%. The melting point was 
230–232 °C; 1H NMR (300 MHz, DMSO) δ 12.84 (br s, 1H), 8.28 
(overlapping s, 1H), 8.28 (overlapping d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.7 Hz, 
1H); 13C NMR (75 MHz, DMSO) δ 159.8, 156.3, 154.6, 150.5, 126.0, 119.8, 116.2, 115.9. 
 
7-Methoxy-6-nitroquinazolin-4(3H)-one (16) 
Under inert reaction conditions, Na(s) (0.51 mg, 22.2 mmol), was 
added to a freshly dried methanol (MeOH, 40 mL) reaction flask, 
placed in the ice-bath. After all the sodium had dissolved, the NaOMe 
solution was degassed, transferred to a reaction flask containing 15 (i) (500 mg, 2.22 
mmol), and the reaction mixture was heated to reflux at 100 °C. After 10 days, excess 
MeOH was removed in vacuo and the concentrate was quenched with ice cold water, and 
neutralised with 50% aqueous AcOH (20 mL) to form a yellow precipitate. The 
precipitate was filtered, rinsed with cold water, and dried to obtain a pure product in 
97% yield (476 mg). Decomposition occurred during melting point determinations [lit.21 
287 °C]; 1H NMR (300 MHz, DMSO) δ 12.50 (br s, 1H), 8.51 (s, 1H), 8.23 (s, 1H), 7.42 (s, 
1H), 4.04 (s, 3H); 13C NMR (75 MHz, DMSO) δ 160.1, 156.5, 153.6, 149.3, 138.8, 124.2, 
115.7, 111.0, 57.8. The 1H NMR data was in agreement with the literature.20 
 
Ethyl 2-acetamidobenzoate (17) 
Compound 17 was synthesized from ethyl 2-aminobenzoate (5.05 g, 
29.9 mmol) by utilizing the same procedure that has been reported in 
the preparation of 1. Ethyl 2-acetamidobenzoate was obtained as a 
crystalline precipitate in 94% yield (5.90 g). The melting point was 62–64 °C [lit.22 63–65 
°C]; 1H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.88 (dd, J = 7.9, 
1.6 Hz, 1H), 7.60–7.54 (m, 1H), 7.20–7.12 (m, 1H), 4.29 (q, J = 7.1 Hz, 2H), 2.09 (s, 3H), 
1.30 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 168.9, 167.5, 140.1, 134.2, 130.9, 123.5, 
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121.6, 118.5, 61.6, 25.0, 14.4. The 1H NMR spectrum was in agreement with the literature 
data.23 
 
Ethyl 2-acetamido-5-bromobenzoate (18) 
To a suspension of ethyl 2-acetamidobenzoate (4.68 g, 28.4 mmol) and 
KBrO3 (3.02 g, 18.9 mmol) in acetic acid (80 mL) was added 48% HBr 
(5 mL) using a dripping funnel over 15 minutes. The reaction was 
stirred at a room temperature during which a permanent orange 
precipitate was formed. The reaction was continued for another 15 min before the flask 
contents were emptied into ice-cold water (250 mL). The yellow precipitate was filtered 
and the residual bromine was washed off with 10% Na2S2O4 (50 mL) to afford 18 as a 
white precipitate in 83% yield (6.72 g). The measured melting point was 128–130 °C 
[lit.24 120 °C]; 1H NMR (300 MHz, DMSO) δ 10.49 (s, 1H), 8.14 (d, J = 8.9 Hz, 1H), 7.97 (d, 
J = 2.5 Hz, 1H), 7.77 (dd, J = 8.9, 2.5 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 2.12 (s, 3H), 1.33 (t, J 
= 7.1 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 169.0, 166.2, 139.1, 136.7, 132.9, 123.9, 120.8, 
115.1, 62.0, 24.9, 14.4. The 1H NMR spectrum was in agreement with the literature data.24 
 
Ethyl 2-amino-5-bromobenzoate [19 (i)] 
Compound 19 was obtained as result of selective amide hydrolysis 
in 18 (2.55g, 8.91 mmol) by adapting to acidic reaction conditions 
reported in preparation of compound 5,1 but this time at 50 °C. After 
chromatographic purification, compound 19 was produced in 94% yield (2.04 g). The 
melting point was 83–83 °C [lit.25 80–81 °C]; 1H NMR (300 MHz, DMSO) δ 7.77 (d, J = 2.5 
Hz, 1H), 7.38 (dd, J = 8.9, 2.5 Hz, 1H), 6.79 (d, J = 8.9 Hz 1H), 6.09 (s, 4H), 4.25 (q, J = 7.1 
Hz), 1,29 (t, J = 7.1 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 166.6, 150.7, 136.8, 132.7, 119.5, 
111.0, 105.4, 60.8, 14.6. The 1H NMR spectrum was identical to that of the literature 
data.25 
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2-Acetamido-5-bromobenzoic acid [19 (ii)] 
This compound was obtained as result of selective ester group hydrolysis 
of 18 under mild (50 °C) basic conditions Thus, ethyl 2-acetamido-5-
bromobenzoate (1.03 g, 3.61 mmol) was dissolved in 4 N ethanolic KOH 
solution (15 ml) and the reaction was stirred at 50 °C for 2 h. The excess 
solvent was then removed in vacuo, the crude product was then diluted with cold water 
(30 mL), acidified to pH 5 with 4 N HCl, before it was extracted into DCM (3 × 40 mL). The 
organic extracts were dried over MgSO4, concentrated and the crude product was 
purified by chromatography. Compound 19 (ii) was obtained as a white solid in 71% 
yield (0.66 g). The melting point was 220–221 °C [lit.25 219–221 °C]; 1H NMR (300 MHz, 
DMSO) δ 10.96 (s, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.03 (d, J = 2.5 Hz, 1H), 7.75 (dd, J = 9.0, 2.5 
Hz, 1H), 2.13 (s, 3H); 13C NMR (75 MHz, DMSO) δ 169.1, 168.5, 140.4, 136.9, 133.5, 122.6, 
119.3, 114.4, 25.4. The 1H NMR spectrum matched the literature data.25 
 
6-Bromoquinazolin-4(3H)-one (20) 
Compound 20 was prepared from ethyl 2-amino-5-bromobenzoate 
(2.01 g, 8.24 mmol) and formarmide (20 mL) using similar 
experimental conditions reported for 6,8 but at 140 °C. Compound 20 
was obtained as a light brown powder in 81% yield (1.58 g). The melting point was 268–
270 °C [lit.26 273–274°C]; 1H NMR (300 MHz, DMSO) δ 12.44 (br s, 1H), 8.19 (d, J = 2.3 Hz, 
1H), 8.14 (d, J = 3.1 Hz, 1H), 7.96 (dd, J = 8.7, 2.3 Hz, 1H), 7.62 (d, J = 8.7 Hz, 1H); 13C NMR 
(75 MHz, DMSO) δ 160.1, 148.2, 146.5, 137.6, 130.1, 128.4, 124.7, 119.7. The 1H NMR data 
corresponded to literature.26 
 
6-Hydroxyquinazolin-4(3H)-one (22) 
Compound 22 was prepared from 2-amino-5-hydroxybenzoic acid 
(2.00 g, 13.1 mmol) by adapting to a synthetic method for compound 
6.8 Compound 22 was obtained as a grey powder in 76% yield (1.61 
g). The melting point was 214–218 °C [lit.12 300 °C]; 1H NMR (300 MHz, DMSO) δ 12.03 
(br s, 1H), 10.06 (s, 1H), 7.90 (d, J = 3.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.9 Hz, 
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1H), 7.26 (dd, J = 8.8, 2.9 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 160.9, 158.5, 156.6, 142.6, 
129.3, 124.1, 109.2 (2C). The 1H NMR  spectrum was identical to that reported in the 
literature.12 
 
4-Oxo-3,4-dihydroquinazolin-6-yl acetate (23) 
6-Hydroxyquinazolin-4(3H)-one (1.50 g, 9.26 mmol) was dissolved 
in Ac2O (15 mL), pyridine (4 mL) was added and the reaction 
mixture was stirred at a room temperature overnight. The reaction 
was quenched by emptying the reaction contents into ice-water (30 mL). The formed 
precipitate was filtered, rinsed with cold water and dried to obtain a beige precipitate in 
79% yield (1.49 g). The melting point was 220–222 °C; 1H NMR (300 MHz, DMSO) δ 12.33 
(br s, 1H), 8.10 (s, 1H), 7.83 (br d, J = 2.6 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.61–7.56 (m, 
1H), 2.31 (s, 3H); 13C NMR (75 MHz, DMSO) δ 169.7, 160.7, 149.0, 147.0, 145.6, 129.3, 




To a suspension of, K2CO3 (11.2 g, 81.3 mmol) in acetone (120 mL) 
placed over the ice bath was added 3,4-dihydrobenzoic acid (5.00 g, 
32.5 mmol) and then methyl iodide (7.40 mL, 119 mmol) in a drop-
wise fashion with stirring. The reaction was continued at 50 °C for 3 h, before excess 
K2CO3 was filtered off and the organic solvent removed in vacuo to obtain a yellow viscous 
liquid. The viscous liquid was diluted with DCM (40 mL) and washed with 10% Na2S2O4 
(40 mL) and then water (40 mL × 2). The organic extract was dried over MgSO4, and 
evaporated in vacuo to afford a colourless liquid. Chromatographic purification afforded 
81% yield of methyl-3,4-dimethoxybenzoate (5.13 g), which solidified upon storage. The 
melting point was 60–62 °C [lit.28 58–60 °C]; 1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 8.4, 
2.0 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 3.96 (overlapping s, 3H), 3.95 
(overlapping s, 3H), 3.92 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 162.1, 148.2, 143.8, 118.8, 
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117.9, 107.2, 105.5, 51.3 (2C), 47.2. The 1H NMR spectrum was in agreement with the 
literature.29 
 
Methyl 4,5-dimethoxy-2-nitrobenzoate [25 (i)] 
A reaction flask containing methyl 3,4-dimethoxybenzoate (1.06 g, 
5.92 mmol) was placed in the ice bath and to this was added 65% 
HNO3 (8 mL) in a drop-wise fashion over 10 min. The reaction was 
continued for another 20 min and the final temperature of the ice bath was 6 °C. The 
reaction mixture was poured into the ice-water (150 mL) and the resulting precipitate 
was filtered, rinsed with cold water and dried to obtain a yellow powder. The crude 
product was suspended in DCM and purified by chromatography to yield 25 (i) in 26%. 
The melting point was 142–143 °C [lit.30 127–128 °C]; 1H NMR (400 MHz, CDCl3) δ 7.45 
(s, 1H), 7.08 (s, 1H), 3.98 (overlapping s, 3H), 3.97 (overlapping s, 3H), 3.91 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 166.5, 152.7, 150.6, 141.5, 121.8, 111.0, 107.2, 56.9, 56.8, 53.5; 
MS (ESI+) m/z 264.1872 was calculated for C10H11NO6 [M+Na]+ and 264.1872 was 
determined experimentally.  
 
Methyl 4,5-dimethoxy-2,3-dinitrobenzoate [25 (ii)] 
The over-nitration by-product was isolated with an estimated yield of 11% 
(0.15 g). The melting was 131–133 °C [lit.31 133–134 °C]; 1H NMR (400 
MHz, CDCl3) δ 7.41 (s, 1H), 4.03 (s, 6H), 3.91 (s, 3H); 
13C NMR (100 
MHz, CDCl3) δ 163.5, 155.7, 144.2, 122.4, 114.2, 63.0, 57.4, 54.0; 
1JC-H 
HSQC NMR (400, CDCl3) δ (7.41, 114.1), (4.05, 62.9), (4.03, 57.27), (3.91, 53.9); 
2,3JC-H HMBC NMR (400, CDCl3) δ (7.41; 163.5), (7.41, 155.5), (7.41, 144.1), (7.41, 
135.5), (7.41, 122.4}, (4.03, 144.1), (4.03, 155.6), (3.90,153.5); MS (ESI+) m/z 
309.1648 was calculated for C10H10N2O8 [M+Na]
+ and 309.1661 (-3.17 ppm) was 
determined experimentally. 
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Methyl 2-amino-4,5-dimethoxybenzoate (26) 
Compound 26 was synthesized from compound 25 (i) (0.35 g, 1.45 
mmol) by adapting to the literature procedure described for 
preparation of compound 8.13 Chromatographic purification of the 
crude afforded a desired compound in 87% yield (0.27 g). The melting point was 128–
130 °C [lit.32 130–132 °C]; 1H NMR (600 MHz, CDCl3) δ 7.29 (s, 1H), 6.14 (s, 1H), 5.57 (br 
s, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.82 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 170.8, 157.4, 
149.7, 143.2, 115.3, 104.7, 102.0, 59.0, 58.4, 53.9; MS (ESI+) m/z 212.0917 was calculated 
for C10H13NO4 [M+H]+ and 212.0915 (0.90 ppm) was determined experimentally. The 1H 
NMR was identical to the one reported in the literature.33 
 
6,7-Dimethoxyquinazolin-4(3H)-one (27) 
Compound 27 was acquired from methyl 2-amino-4,5-
dimethoxybenzoate (0.40 g, 1.56 mmol) using the literature method 
reported in the synthesis of compound 6.8 6,7-Dimethoxyquinazolin-
4(3H)-one was obtained as a beige powder (0.28 g, 84% yield). The melting point was 
294–296 °C [lit.33 300–302 °C]; 1H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 7.99 (s, 1H), 
7.44 (s, 1H), 7.13 (s, 1H), 3.90 (s, 3H), 3.87 (s, 3H); 13C NMR (75 MHz, DMSO) δ 160.5, 
154.9, 149.0, 145.3, 144.3, 116.1, 108.5, 105.4, 56.4, 56.2. The 1H NMR was identical to 
the literature report.33 
 
6-Hydroxy-7-methoxyquinazolin-4(3H)-one (28) 
Demethylation procedure was carried out according to Knesl et al.34 
with degassing modification to the procedure. Thus, methane sulfonic 
acid (4 mL) was added to 6,7-dimethoxyquinazolin-4(3H)-one (0.50 g, 
2.43 mmol) and D,L-methionine (0.40 g, 2.50 mmol) and the contents were subjected to 
three cycles of freeze-pump-thaw degassing. The reaction mixture was heated to reflux 
at 120 °C with stirring for 48 h, then cooled to a room temperature and the contents were 
poured into ice-cold water (20 mL). It was then slowly neutralized with 40% aqueous 
NaOH solution over the ice bath, the resultant pale grey precipitate was filtered, washed 
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with cold water and dried to afford 28 in 16% yield (73 mg). The melting point was 214–
216 °C [lit.33 300 °C]; 1H NMR (300 MHz, DMSO) δ 11.67 (br s, 1H), 9.78 (br s, 1H), 7.88 
(s, 1H), 7.36 (s, 1H), 7.07 (s, 1H), 3.88 (s, 3H); 13C NMR (75 MHz, DMSO) δ 160.5, 154.4, 
147.2, 144.2, 143.4, 116.5, 109.1, 108.6, 56.3. The 1H NMR data was in agreement with 
the literature.33 
 
7-Methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate [29 (i)] 
A crude sample of 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
demethylation experiments (1.00 g, 5.21 mmol) was dissolved in 
pyridine (2.5 mL) and Ac2O (5 mL, 52.8 mmol) and the resulting 
suspension was stirred at a room temperature overnight. The reaction was quenched by 
adding flask contents into ice-cold water (50 mL). The floating impurities were decanted 
off and the settled precipitate was then filtered, rinsed with ice-cold water, and dried to 
obtain a free flowing light-brown powder. Chromatographic purification of the O-
acylated compounds on a silica gel column using gradient elution of 5% acetone in DCM 
to 100% acetone produced two positively identified products as 29 (i) and 29 (ii).  
Campound 29 (i) was obtained as a beige solid in approximated quantitative yield of 14% 
(163 mg). The melting point was 298–300 °C [lit.33 303–305 °C]; 1H NMR (300 MHz, 
DMSO) δ 12.20 (s, 1H), 8.09 (s, 1H), 7.75 (s, 1H), 7.28 (s, 1H), 3.92 (s, 3H), 2.30 (s, 3H); 
13C NMR (75 MHz, DMSO) δ 169.1, 160.4, 156.5, 149.3, 146.4, 139.3, 119.5, 116.1, 109.6, 
56.9, 20.9. The 1H NMR data was identical to those reported in the literature.33 
 
4-Oxo-3,4-dihydroquinazoline-6,7-diyl diacetate [29 (ii)] 
One of the collected fractions proved this compound to be a by-product 
constituting about 3% quantitative yield. 1H NMR (300 MHz, DMSO) 
δ 12.40 (br s, 1H), 8.13 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 2.34 
(overlapping s, 3H), 2.32 (overlapping s, 3H); 13C NMR (75 MHz, 
DMSO) δ 168.8, 168.4, 160.2, 148.0, 147.5, 146.7, 141.3, 122.1, 121.3, 120.9, 20.9 
(2C). 
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A general method for synthesis of 6,7-dimethoxy-substituted 4-anilinoquinazolines (30–
32). 
A representative procedure for the synthesis of 6,7-dimethoxy-
(4-anilino)quinazolines is described.35 Under inert atmospheric 
conditions, a suspension of 6,7-dimethoxyquinazolin-4(3H)-one 
(500 mg, 2.43 mmol), chlorobenzene (5 mL) and Hunig’s base 
(0.42 mL, 2.43 mmol)was kept in the ice bath. To this cooled suspension was dispensed 
POCl3 (10 mL) through the dripping funnel in a drop wise fashion under continuous 
stirring for 0.5 h. The reaction mixture was then heated to reflux at 80 °C for 3 h and 
excess POCl3 and the solvent were distilled off at 60 °C under vacuum. The resultant beige 
solid was dried further under high vacuum for 1 h. This semi-dried product was dissolved 
in isopropyl alcohol (IPA, 30 mL) and a suitable aryl amine (1.3 molar equivalents) was 
then added. The reaction mixture shortly precipitated before turning into a solution at 60 
°C with stirring. The reaction was continued for 2 h during which a permanent precipitate 
rematerialized. The precipitate was cooled, filtered, rinsed with cold IPA (15 mL) and 




Compound 30 was obtained as a white precipitate in 76% 
yield (0.56 g). The melting point was 182–184 °C [lit.36 290–
292 °C]; 1H NMR (300 MHz, DMSO) δ 9.49 (s, 1H), 8.51 (s, 1H), 
8.00 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.83 (s, 1H), 7.41 (dd 
[appeared as a t], J1 = J2 = 8 Hz, 1H), 7.25–7.19 (m, 2H), 4.20 (s, 1H), 3.97 (s, 3H), 3.94 (s, 
3H); 13C NMR (75 MHz, DMSO) δ 156.6, 154.8, 153.2, 149.4, 147.5, 140.3, 129.3, 126.8, 
125.2, 123.0, 122.2, 109.3, 107.7, 102.2, 84.0, 81.0, 56.7, 56.3; MS (ESI+) m/z 306.1237 
was calculated for C18H15N3O2 [M+H]+and 306.1237 was determined experimentally; LC 
chemical purity was 98.4%.  
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Compound 31 was obtained as a white precipitate in 85% yield 
(0.74 g). The melting point was 173–174°C [lit.37 188–189 °C]; 
1H NMR (300 MHz, DMSO) δ 9.53 (s, 1H), 8.53 (s, 1H), 8.17–8.13 
(m, 1H), 7.91–7.86 (m, 1H), 7.83 (s, 1H), 7.36 (dd [appeared as 
a t], J1 = J2 = 8 Hz, 1H), 7.30–7.25 (m, 1H), 7.21 (s, 1H), 3.97 (s, 3H), 3.94 (s, 3H); 13C NMR 
(75 MHz, DMSO) δ 156.4, 154.8, 153.1, 149.5, 147.6, 141.8, 130.8, 126.0, 124.4, 121.6, 
121.0, 109.4, 107.7, 102.2, 56.7, 56.3; MS (ESI+) m/z 360.0342 was calculated for 
C16H14BrN3O2 [M+H]+ and 360.0339 (0.3 ppm) was determined experimentally; LC 
chemical purity was 96.3%. 
 
N-(3-Chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine (32) 
Compound 32 was obtained as a white precipitate in 90% yield 
(0.73 g). The melting point was 196–198 °C [lit.38 273–275 °C]; 
1H NMR (300 MHz, DMSO) δ 8.78 (s, 1H), 7.74 (s, 1H), 7.36 (dd, 
J = 6.8, 2.6 Hz, 1H), 7.09–7.00 (m, 2H), 6.68 (dd [appeared as a 
t], 3JH-F = 3JH-H = 9.2 Hz, 1H), 6.44 (s, 1H), 3.20 (s, 3H), 3.18 (s, 3H); 13C NMR (75 MHz, 
DMSO) δ 155.7, 154.1, 152.3, 148.7 (d, 1JC-F = 252.7 Hz), 146.8, 136.5, 123.1, 122.0, 121.9, 
118.6 (d, 2JC-F = 25.2 Hz), 116.2, (d, 2JC-F = 21.8 Hz) 108.5, 106.9, 101.4, 55.9, 55.6. The 1H 
NMR was in agreement with the literature data. 38 MS (ESI+) m/z 334.0753 was calculated 
for C16H13ClFN3O2 [M+H]+ and 334.0751 (0.20 ppm) was determined experimentally; LC 
chemical purity was 99.1%.  
 
General synthesis of the 6-nitro(4-anilino)quinazoline derivatives (34–42) 
The synthesis of 6-nitro(4-anilino)quinazoline derivatives was carried out according to a 
described representative procedure in general synthesis of compounds 30–32. A once off 
NMR analysis was performed on the crude intermediate, 4-chloro-6-nitroquinazoline 
(33), as presented next. All of the resulting 6-nitro(4-anilino)quinazoline compounds 
were obtained as bright yellow powdery precipitates. 
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The intermediate 33 was analysed without quantifying the yield. 1H 
NMR (400 MHz, DMSO) δ 8.78 (d, J = 2.6 Hz, 1H), 8.52 (dd, J = 9.0, 2.7 
Hz, 1H), 8.29 (s, 1H), 7.84 (d, J = 9.0 Hz, 1H); 13C NMR (101 MHz, DMSO) 
δ 160.9, 153.6, 149.7, 145.6, 129.7, 128.9, 123.4, 122.6. The 1H NMR data was in 
agreement with the values reported in literature.39 
 
N-(3-Ethynylphenyl)-6-nitroquinazolin-4-amine (34) 
Compound 34 was obtained in 76% yield (0.58 g). The melting 
point was 232–234 °C [lit.40 271–272 °C]; 1H NMR (300 MHz, 
DMSO) δ 10.42 (s, 1H), 9.62 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 
8.52 (dd, J = 9.0, 2.4 Hz, 1H), 8.04–8.01 (m, 1H), 7.94–7.91 (m, 
1H), 7.91–7.88 (m, 1H), 7.42 (dd [appeared as a t], J1 = J2 = 9.0 Hz, 1H), 7.31–7.25 (m, 
1H), 4.23 (s, 1H); 13C NMR (75 MHz, DMSO) δ 159.1, 158.0, 153.5, 145.0, 139.2, 
130.0, 129.5, 127.9, 127.1, 125.9, 123.6, 122.3, 121.2, 114.8, 83.7, 81.3. The 1H NMR 
spectrum closely resembled the reported the literature data.40 
 
N-(3-Bromophenyl)-6-nitroquinazolin-4-amine (35) 
Compound 35 was afforded in 85% yield (0.77 g). The melting 
point was 244–246 °C [lit.40 282–283 °C]; 1H NMR (300 MHz, 
DMSO) δ 11.95 (s, 1H), 9.90 (d, J = 2.2 Hz, 1H), 9.02 (s, 1H), 8.76 
(dd, J = 9.2, 2.3 Hz, 1H), 8.17 (d, J = 9.2 Hz, 1H), 8.08 (m, 1H), 
7.84–7.79 (m, 1H), 7.56–7.51 (overlapping m, 1H); 7.47 (overlapping dd, J1 = J2 = 8.0 Hz, 
1H); 13C NMR (75 MHz, DMSO) δ 160.4, 154.7, 146.1, 138.9, 131.2, 129.6, 129.5, 127.1, 
124.2 (2C), 123.6, 122.2, 121.7, 114.3. The 1H NMR spectrum closely resembled the 
literature data.40 
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Compound 36 was obtained in 90% yield (0.75 g). The melting 
point was 254–256 °C [lit.40 289–281 °C]; 1H NMR (300 MHz, 
DMSO) δ 12.13 (br s, 1H), 9.91 (d, J = 2.3 Hz, 1H), 9.02 (s, 1H), 
8.76 (dd, J = 9.3, 2.1 Hz, 1H), 8.18 (d, J = 9.3 Hz, 1H), 8.07 (dd, J 
= 6.9, 2.4 Hz, 1H), 7.79 (ddd, 3JH-H = 9.3, 4JH-F = 4.4, 4JH-H = 2.6 Hz, 1H), 7.57 (dd [appeared 
as a t], 3JH-F = 3JH-H = 9.3 Hz, 1H);13C NMR (75 MHz, DMSO) δ 160.5, 156.2 (d, 1JC-F = 246.3 
Hz), 154.5, 146.1, 134.4, 129.8, 126.8, 125.5, 124.4, 123.9, 122.2, 119.9 (d, 2JC-F = 19.6 Hz), 




Compound 37 was obtained in 73% yield (0.53 g). The 
melting point was 216–218 °C; 1H NMR (300 MHz, DMSO) δ 
10.30 (s, 1H), 9.42 (d, J = 5.3 Hz, 1H), 8.73 (d, J = 5.4 Hz, 1H), 
8.07–7.96 (m, 2H), 7.86 (m, 1H), 7.58–7.34 (m, 1H), 7.34–7.22 
(m, 1H), 4.20 (s, 1H); 13C NMR (75 MHz, DMSO) δ 158.7, 158.5, 152.3, 144.6, 139.0, 130.8, 
129.5, 129.4, 128.1, 125.8, 123.4 (2C), 122.4, 113.8, 83.7, 81.3; MS (ESI+) m/z 325.0487 




Compound 38 was obtained in 69% yield (0.58 g). The melting 
point was 222–224 °C; 1H NMR (300 MHz, DMSO) δ 10.34 (s, 
1H), 9.43 (s, 1H), 8.77 (s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.88–
7.84 (m, 1H), 7.43–7.34 (m, 2H); 13C NMR (75 MHz, DMSO) δ 
158.6, 158.4, 152.3, 144.7, 140.4, 131.0, 130.9, 129.5, 127.5, 125.1, 123.4, 121.7, 121.6, 
113.8. 
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Compound 39 was obtained in 83% yield (0.65 g). The melting 
point was 244–246 °C; 1H NMR (300 MHz, DMSO) δ 10.37 (br 
s, 1H), 9.39 (s, 1H), 8.74 (s, 1H), 8.13 (dd, J = 6.8, 2.4 Hz, 1H), 
8.09 (s, 1H), 7.81–7.75 (m, 1H), 7.47 (dd [appeared as a t], 3JH-
H = 3JH-F = 9.0 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 158.6, 158.4, 155.9 (d, 1JC-F = 240.8 Hz), 
152.2, 144.6, 135.9, 130.9, 129.5, 124.6, 123.4, 123.3, 119.6 (d, 2JC-F = 19.0 Hz), 117.4 (d, 
2JC-F = 21.8 Hz), 113.7. MS (ESI+) m/z 353.0003 was calculated for C14H7Cl2FN4O2 [M+H]+ 
and 353.000 (-0.3 ppm) was experimentally found. 
 
N-(3-Ethynylphenyl)-7-methoxy-6-nitroquinazolin-4-amine (40) 
Compound 40 was obtained in 75% yield (0.54 g). The 
melting point was 178–180 °C [lit.41 213–218 °C with 
decomposition]; 1H NMR (300 MHz, DMSO) δ 10.11 (br s, 1H), 
9.26 (s, 1H), 8.68 (s, 1H), 8.03 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 
7.48 (s, 1H), 7.43 (dd [appeared as a t], J1 = J2= 7.9 Hz, 1H), 7.26 (d, J = 7.7 Hz, 1H), 4.22 (s, 
1H), 4.07 (s, 3H); 13C NMR (75 MHz, DMSO) δ 158.4, 157.9, 154.9, 153.9, 139.2, 129.5, 
127.7, 125.6, 123.3 (2C), 122.3 (2C), 110.2, 108.5, 83.8, 81.2, 57.6. The 1H NMR data was 
in agreement with the published data.42 
 
N-(3-Bromophenyl)-7-methoxy-6-nitroquinazolin-4-amine (41) 
Compound 41 was obtained in 61% yield (0.52 g). The melting 
point was 188–190 °C [lit.21 206–207.5 °C]; 1H NMR (300 MHz, 
DMSO) δ 10.11 (s, 1H), 9.25 (s, 1H), 8.69 (s, 1H), 8.17 (s, 1H), 
7.90–7.85 (m, 1H), 7.49 (d, J = 3.4 Hz, 1H), 7.44–7.27 (m, 2H), 
4.06 (s, 3H); 13C NMR (75 MHz, DMSO) δ 158.2, 157.8, 155.0, 153.8, 140.8, 139.2, 130.8, 
126.9, 124.8, 122.3, 121.6, 121.2, 110.1, 108.5, 57.6. The 1H NMR spectrum was in 
agreement with literature data.42 
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Compound 42 was obtained in 78% yield (0.62 g). The melting 
point was 238–240 °C [lit.17 292–293 °C]; 1H NMR (300 MHz, 
dmso) δ 10.09 (s, 1H), 9.17 (s, 1H), 8.64 (s, 1H), 8.13 (dd, J = 6.8, 
2.6 Hz, 1H), 7.81–7.73 (ddd, 3JH-H = 9.1 Hz, 4JH-F = 4.3 Hz, 4JH-H 
=2.7 Hz, 1H), 7.43 (dd [appeared as a t], J = 8.3 Hz, 2H), 4.04 (s, 
3H);13C NMR (75 MHz, DMSO) δ 157.5, 157.1, 155.0 (d, 1JC-F = 246.0 Hz), 154.3, 153.0, 
138.4, 135.5, 123.5, 122.2, 121.5, 118.6 (d, 2JC-F = 20.6 Hz), 116.5 (d, 2JC-F = 21.8 Hz), 109.4, 
107.6, 56.9. The 1H NMR spectrum was in agreement with the literature values.17 
 
A representative procedure for the C-6 nitro reduction in 4-anilinoquinazolines (43–51) 
A general reaction for the transformation of the C-6 nitroquinazolin-4(3H)-ones 
functionality to the amine is described: To a suitable 6-nitro(4-anilino)quinazoline (50–
200 mg), iron powder and ammonium chloride salt (Fe(s)/NH4Cl, 5 molar equivalents 
each) were added and the reaction mixture was suspended in ethanol (2–5 mL). The 
suspension was heated to reflux at 70 °C with stirring for 5 h, during which the yellow 
suspension changed colour to a reddish-brown solution [iron(III)]. At the end of the 
reaction, the contents were filtered by suction over celite and doubled-filter paper and 
the residue was further rinsed with ethyl acetate to obtain a light yellow solution. The 
filtrate was dried over MgSO4, concentrated in vacuo and purified by chromatography to 
obtain the C-6 aminoquinazolin-4(3H)-ones as yellow precipitates. These amines often 
underwent decomposition during melting point determinations. 
 
N4-(3-Ethynylphenyl)quinazoline-4,6-diamine (43) 
Compound 43 was obtained in 42% yield (75.9 mg). 1H NMR 
(300 MHz, DMSO) δ 9.40 (s, 1H), 8.37 (s, 1H), 8.08 (s, 1H), 
7.94–7.88 (m, 1H), 7.54 (d, J = 4.7 Hz, 1H), 7.38 (d, J = 7.9 Hz, 
1H), 7.36–7.33 (m, 1H), 7.26 (dd, J = 8.9, 2.3 Hz, 1H), 7.18–
7.15 (m, 1H), 5.61 (br s, 2H), 4.17 (s, 1H); 13C NMR (75 MHz, DMSO) δ 156.3, 150.1, 147.8, 
143.1, 140.7, 129.3, 129.2, 126.4, 124.7, 124.2, 122.6, 122.1, 117.1, 101.4, 84.2, 80.8; MS 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 6 Experimental methods and .characterisation data  
143 
 
(ESI+) m/z 261.1135 was calculated for C16H12N4 [M+H]+ and 261.1132 (-0.30 ppm) was 
determined experimentally; LC chemical purity was 99.0%. 
 
N4-(3-Bromophenyl)quinazoline-4,6-diamine (44) 
Compound 44 was obtained in 69% yield (126 mg). 1H NMR 
(300 MHz, DMSO) δ 9.45 (s, 1H), 8.39 (s, 1H), 8.24 (d, J = 1.9 
Hz, 1H), 7.91–7.86 (m, 1H), 7.56 (d, J = 8.9 Hz, 1H), 7.35 (d, J = 
2.5 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.28–7.20 (m, 2H), 5.63 (br 
s, 2H); 13C NMR (75 MHz, DMSO) δ 156.1, 150.0, 147.9, 143.2, 142.2, 130.7, 129.2, 125.6, 
124.3, 123.9, 121.6, 120.5, 117.2, 101.3; MS (ESI+) m/z 315.0240 was calculated for 
C14H11BrN4 [M+H]+ and 315.0247 (-0.70 ppm) and (317.0227 for 81Br) were determined 
experimentally; LC chemical purity was 98.7%. 
 
N4-(3-Chloro-4-fluorophenyl)quinazoline-4,6-diamine (45) 
Compound 45 was obtained in 63% yield (114 mg). 1H NMR 
(300 MHz, DMSO) δ 9.47 (s, 1H), 8.37 (s, 1H), 8.21 (dd, J = 6.9, 
2.6 Hz, 1H), 7.87–7.80 (m, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.41 (dd 
[appeared as a t], J1 = J2 = 9.2 Hz, 1H), 7.32 (d, J = 2.2 Hz, 1H), 
7.26 (dd, J = 8.8, 2.3 Hz, 1H), 5.63 (br s, 2H); 13C NMR (75 MHz, 
DMSO) δ 156.1, 154.9 (d, JC-F =241.8 Hz), 150.0, 147.9, 143.1, 137.8, 129.2, 124.3, 123.2, 
122.2, 122.1, 119.2 (d, 2JC-F =21.3 Hz), 117.0 (d, 2JC-F =21.1 Hz), 101.2; MS (ESI+) m/z 
289.0650 was calculated for C14H10FClN4 [M+H]+ and 289.0665 (-1.50 ppm) was 
determined experimentally; LC chemical purity was 98.1%. 
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Compound 46 was obtained in 48% yield (106 mg). 1H NMR 
(300 MHz, DMSO) δ 9.60 (s, 1H), 8.40 (s, 1H), 8.04 (s, 1H), 
7.88 (d, J = 8.2 Hz, 1H), 7.75 (s, 1H), 7.61 (s, 1H), 7.41–7.34 
(m, 1H), 7.19 (d, J = 7.5 Hz, 1H), 5.81 (br s, 2H), 4.18 (s, 1H);13C 
NMR (75 MHz, DMSO) δ 156.4, 151.4, 143.9, 143.0, 140.4, 
129.3, 128.1, 127.1, 126.7, 124.9, 122.8, 122.2, 116.2, 104.0, 84.1, 81.0; MS (ESI+) m/z 
295.0745 was calculated for C16H11ClN4 [M+H]+ and 295.0747 (-0.20 ppm) was 
determined experimentally; LC chemical purity was 93.3%.  
 
N4-(3-Bromophenyl)-7-chloroquinazoline-4,6-diamine (47) 
Compound 47 was obtained in 63% (116 mg) yield. 1H NMR 
(300 MHz, DMSO) δ 9.66 (s, 1H), 8.42 (s, 1H), 8.20 (s, 1H), 7.86 
(d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.61 (s, 1H), 7.33 (dd [appeared 
as a t], J1 = J2 = 8.1 Hz, 1H), 7.28–7.23 (m, 1H), 5.83 (s, 2H); 13C 
NMR (75 MHz, DMSO) δ 156.3, 151.2, 144.0, 142.8, 141.9, 130.8, 128.0, 127.2, 126.0, 
124.2, 121.6, 120.8, 116.2, 103.9; MS (ESI+) m/z 348.9850 was calculated for 
C14H10BrClN4 [M+H]+ and 348.9849 (0.1.0 ppm), and [82Br]C14H10BrClN4 350.9830 were 
determined experimentally; LC chemical purity was 92.4%. 
 
7-Chloro-N4-(3-chloro-4-fluorophenyl)quinazoline-4,6-diamine (48) 
Compound 48 was obtained in 80% (138 mg) yield. 1H NMR 
(300 MHz, DMSO) δ 9.68 (s, 1H), 8.39 (s, 1H), 8.17 (dd, J = 6.9, 
2.6 Hz, 1H), 7.83–7.77 (m, 1H), 7.76 (s, 1H), 7.58 (s, 1H), 7.42 
(dd [appeared as a t], 3JH-F = 3JH-H = 9.0 Hz, 1H), 5.83 (s, 2H); 13C 
NMR (75 MHz, DMSO) δ 156.3, 151.9 (d, 1JC-F = 247.5 Hz), 144.0, 142.9, 137.4, 134.0, 128.1, 
127.2, 123.6, 122.5,  119.3 (d, 2JC-F = 19.1 Hz), 116.8 (d, 2JC-F = 21.8 Hz), 116.1, 103.8; MS 
(ESI+) m/z 323.0261 was calculated for C14H9Cl2FN4 [M+H]+ and 323.0258 (0.30 ppm) 
was determined experimentally. 
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Compound 49 was obtained in 66% yield (90.7 mg). 1H NMR 
(300 MHz, DMSO) δ 9.36 (s, 1H), 8.40 (s, 1H), 8.25–8.20 (m, 
1H), 7.88–7.82 (m, 1H), 7.41 (s, 1H), 7.30 (dd [appeared as a 
t], J1 = J2 = 8.0 Hz, 1H), 7.23–7.17 (m, 1H), 7.11 (s, 1H), 5.37 (s, 
1H), 4.21 (s, 1H), 3.97 (s, 3H); 13C NMR (151 MHz, DMSO) δ 156.4, 154.3, 152.4, 147.1, 
146.7, 140.6, 129.2, 126.4, 124.6, 122.5, 122.1, 110.1, 107.6, 105.8, 84.1, 80.8, 56.3; MS 
(ESI+) m/z 291.1240 was calculated for C15H13BrN4O [M+H]+ and 291.1241 (0.10 ppm) 
was determined experimentally.  
 
N4-(3-Bromophenyl)-7-methoxyquinazoline-4,6-diamine (50) 
Compound 50 was obtained in 74% (68.1 mg) yield; 1H NMR 
(300 MHz, DMSO) δ 9.36 (s, 1H), 8.40 (s, 1H), 8.23–8.20 (m, 
1H), 7.89–7.83 (m, 1H), 7.41 (s, 1H), 7.33–7.27 (m, 1H), 7.22–
7.18 (m, 1H), 7.11 (s, 1H), 5.37 (br s, 2H), 3.97 (s, 3H); 13C NMR 
(75 MHz, DMSO) δ 155.4, 153.2, 150.7, 145.4, 142.5, 139.0, 130.7, 125.2, 123.6, 121.6, 
120.2, 111.0, 106.3, 101.3, 56.3; MS (ESI+) m/z 345.0340 was calculated for C15H13BrN4O 




Compound 51 was obtained in 76% yield (69.4 mg). 1H NMR 
(300 MHz, DMSO) δ 9.39 (s, 1H), 8.38 (s, 1H), 8.19 (dd, 4JH-F = 
6.9 Hz, 4JH-H = 2.6 Hz, 1H), 7.81 (ddd, 3JH-H = 9.1 Hz, 4JH-F = 4.3 Hz, 
4JH-H  =2.7 Hz, 1H), 7.43–7.35 (m, 2H), 7.10 (s, 1H), 5.38 (br s, 
2H), 3.97 (s, 3H); 13C NMR (75 MHz, DMSO) δ 155.5, 153.2, 151.5 (d,  1JC-F = 255.6 Hz), 
150.7, 145.3, 139.0, 138.0, 122.9, 121.8, 118.9 (d, 2JC-F = 20.3 Hz), 117.0 (d, 2JC-F = 18.8 Hz), 
110.9, 106.4, 101.3, 56.3. The 1H NMR data was in agreement with literature values.17 
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General amidation and insertion of the C-6 acrylamide linker fragment (52–58) 
The appendage of C-6 acrylamide functionality to 4-anilinoquinazoline compounds is 
described: Under inert conditions, a suitable C-6 amino-substituted 4-anilinoquinazoline 
compound (50–100 mg scale) was added into DMF (1.5–2.5 mL) solvent and to this was 
added Hünig’s base (3 molar equivalents). The solution was cooled into the ice bath and 
acryloyl chloride (1.2 molar equivalents) was introduced in a drop wise via syringe. The 
reaction was then allowed to slowly warm to a room temperature as the ice melted. After 
2 h, the reaction was loaded onto the column for chromatographic purification. The 
following products were obtained as yellow solids; 
 
N-[4-(3-Ethynylanilino)quinazolin-6-yl]prop-2-enamide (52) 
Compound 52 was obtained in 58% (35 mg). The melting 
point was 204–206 °C;1H NMR (300 MHz, DMSO) δ 10.50 
(s, 1H), 9.89 (s, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.57 (s, 1H), 
8.04–8.00 (m, 1H), 7.93–7.85 (m, 2H), 7.80 (d, J = 8.9 Hz, 
1H), 7.39 (dd [appeared as a t], J1 = J2 = 7.1 Hz, 1H), 7.23–7.18 (m, 1H), 6.54 (dd, J = 17.0, 
10.0 Hz, 1H), 6.35 (dd, J = 17.0, 2.1 Hz, 1H), 5.84 (dd, J = 10.0, 2.1 Hz, 1H), 4.19 (s, 1H); 13C 
NMR (75 MHz, DMSO) δ 163.8, 157.9, 153.7, 147.2, 140.2, 137.0, 132.0, 129.3, 128.9, 
127.9, 127.7, 127.1, 125.5, 123.3, 122.2, 115.9, 112.8, 84.0, 81.0; MS (ESI+) m/z 315.1240 
was calculated for C19H14N4O [M+H]+ and 315.1241 (0.10 ppm) was determined 
experimentally; LC chemical purity was 96.9%. 
 
N-[4-(3-Bromoanilino)quinazolin-6-yl]prop-2-enamide (53) 
Compound 53 was afforded in 63% yield (74 mg). The 
melting point was 250–252 °C; 1H NMR (400 MHz, DMSO) 
δ 10.49 (s, 1H), 9.91 (s, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.57 
(s, 1H), 8.16 (d, J = 1.8 Hz, 1H), 7.89 (dd, J = 9.0, 2.1 Hz, 1H), 
7.85 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.33 (dd [appeared as a t], J1 = J2 = 8.0 Hz, 
1H), 7.30–7.24 (m, 1H), 6.51 (dd, J = 17.0, 10.1 Hz, 1H), 6.33 (dd, J = 17.0, 1.9 Hz, 1H), 5.82 
(dd, J = 10.1, 1.9 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 164.0, 158.0, 153.8, 147.5, 141.9, 
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137.3, 135.0, 132.2, 131.0, 129.2, 128.2, 127.9, 126.5, 124.9, 121.8, 121.5, 116.1; MS (ESI+) 
m/z 369.03454 was calculated for C17H13BrN4O [M+H]+ and 369.0352 (0.2 ppm) and 
371.0334 for [82Br] were determined experimentally; LC chemical purity was 98.8%. 
 
N-[4-(3-Chloro-4-fluoroanilino)quinazolin-6-yl]prop-2-enamide [54 (i)] 
Compound 54 (i) was obtained in 74% (88 mg) yield. The 
melting point was 230–232 °C [lit.43 258–261 °C]; 1H NMR 
(300 MHz, DMSO) δ 10.52 (s, 1H), 9.95 (s, 1H), 8.81 (d, J = 
1.9 Hz, 1H), 8.57 (s, 1H), 8.14 (dd, J = 6.9, 2.5 Hz, 1H), 7.89 
(dd, 4JH-F = 9.0, 4JH-H = 2.1 Hz, 1H), 7.83–7.76 (m, 2H), 7.42 (dd [appeared as a t], 3JH-F = 3JH-
H = 9.0 Hz, 1H), 6.53 (dd, J = 17.0, 10.0 Hz, 1H), 6.35 (dd, J = 17.0, 2.0 Hz, 1H), 5.85 (dd, J = 
10.0, 2.0 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 163.8, 157.8, 155.5 (d, JC-F = 242.0 Hz), 
152.2, 147.1, 137.1, 132.0, 129.0, 128.0, 127.67, 124.2, 123.1, 123.0, 119.3 (d, 2JC-F = 18.5 
Hz), 117.1 (d, 2JC-F = 21.7 Hz), 115.8, 112.6; MS (ESI+) m/z 343.0756 was calculated for 
C17H12ClFN4O [M+H]+ and 343.0746 (2 ppm) was experimentally determined; LC 




The by-product 54 (ii) was isolated from the reaction 
above in sacrificial quantities (7 mg) due to a quick 
addition of acryloyl chloride. The melting point was 110–
112 °C; 1H NMR (300 MHz, DMSO) δ 10.69 (s, 1H), 9.15 (s, 
1H), 8.56 (d, J = 0.5 Hz, 1H), 8.19 (dd, J = 9.2, 2.3 Hz, 1H), 8.10 (d, J= 8.8 Hz, 1H), 7.67 (dd, 
3JH-F = 6.6, 4JH-H = 2.6 Hz, 1H), 7.50 (dd [appeared as a t], 3JH-F = 3JH-H = 9.0 Hz, 1H), 7.35 
(ddd, 3JH-H = 8.9, 4JH-F = 4.3, 4JH-H = 2.6 Hz, 1H), 6.47 (dd, J = 17.0, 9.9 Hz, 1H), 6.42–6.49 (m, 
2H), 6.23 (dd, J = 16.7, 10.0 Hz, 1H), 5.85 (overlapping dd, J = 10.0, 2.1 Hz, 1H), 5.83 
(overlapping dd, J = 10.0, 2.1 Hz, 1H) ; 13C NMR (75 MHz, DMSO) δ 166.0, 164.3 (2C), 160.8, 
158.5 (d, 1JC-F = 241.7 Hz), 153.7, 149.5, 139.5, 137.6, 131.8, 131.0, 130.18, 129.8, 129.3, 
129.0, 128.6, 122.1, 120.8 (d, 2JC-F = 20.3 Hz), 118.3 (d, 2JC-F = 19.9 Hz), 111.7. MS (ESI+) 
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Compound was obtained in 71% yield (41.9 mg). The melting 
point was 178–180 °C; 1H NMR (300 MHz, DMSO) δ 9.77 (s, 
1H), 9.63 (s, 1H), 8.94 (s, 1H), 8.49 (s, 1H), 7.68 (d, J = 8.2 Hz, 
1H), 7.60 (s, 1H), 7.32–7.22 (m, 2H), 6.95 (d, J = 7.6 Hz, 1H), 
6.75 (dd, J = 17.0, 10.2 Hz, 1H), 6.32 (dd, J = 17.0, 2.0 Hz, 1H), 5.81 (dd, J = 10.2, 1.9 Hz, 
1H), 4.19 (s, 1H) 4.02 (s, 3H); 13C NMR (75 MHz, DMSO) δ 164.0, 157.6, 155.8, 154.7, 
149.5, 144.3, 139.9, 132.2, 128.7, 127.6, 127.1, 123.3, 122.1, 120.3, 117.2, 109.5, 107.1, 
83.7, 81.3, 56.7. The 1H NMR was in agreement with the the literature.44 
 
N-[4-(3-Bromoanilino)-7-methoxyquinazolin-6-yl]prop-2-enamide (56) 
Compound 56 was obtained in 67% yield (38.7 mg). The 
melting point was 222–224 °C;  1H NMR (300 MHz, DMSO) δ 
9.79 (s, 2H), 8.96 (s, 1H), 8.56 (s, 1H), 8.18–8.15 (m, 1H), 7.89–
7.84 (m, 1H), 7.38–7.22 (m, 3H), 6.76 (dd, J = 17.0, 10.2 Hz, 1H), 
6.32 (dd, J = 17.0, 2.0 Hz, 1H), 5.81 (dd, J = 10.2, 2.0 Hz, 1H), 4.03 (s, 3H); 13C NMR (75 
MHz, DMSO) δ 164.0, 157.6, 155.8, 154.7, 149.5, 144.3, 139.9, 132.2, 128.7, 127.6, 127.1, 
123.3, 122.1, 120.3, 117.1, 109.5, 107.1, 56.7.  
 
N-[4-(3-Chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]prop-2-enamide (57) 
Compound 57 was obtained in 80% yield (46.8 mg). The 
melting point was 218–220 °C; 1H NMR (300 MHz, DMSO) δ 
9.82 (overlapping s, 1H), 9.79 (overlapping s, 1H), 8.94 (s, 1H), 
8.54 (s, 1H), 8.13 (dd, J = 6.9, 2.5 Hz, 1H), 7.85–7.76 (m, 1H), 
7.41 (dd, J = 16.8, 7.7 Hz, 1H), 7.30 (s, 1H), 6.76 (dd, J = 17.0, 
10.2 Hz, 1H), 6.32 (dd, J = 17.0, 1.9 Hz, 1H), 5.81 (dd, J = 10.2, 1.9 Hz, 1H), 4.03 (s, 3H); 13C 
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NMR (75 MHz, DMSO) δ 164.0, 157.3, 155.8, 154.4, 152.0 (d, 1JC-F = 222.4 Hz), 149.4, 137.2, 
132.1, 127.8, 127.5, 124.0, 122.9, 119.2 (d, 2JC-F = 18.1 Hz) 117.0, 116.7 (d, 2JC-F = 20.0 Hz), 
109.3, 107.2, 56.7; MS (ESI+) m/z 373.0862 was calculated for C18H14ClFN4O2 [M+H]+ and 
373.0860 (0.2 ppm) was found experimentally. 
 
N-[7-Chloro-4-(3-ethynylanilino)quinazolin-6-yl]prop-2-enamide (58) 
Compound 58 was obtained in 33% yield (38.8 mg). 1H 
NMR (300 MHz, DMSO) δ 10.15 (s, 1H), 9.99 (s, 1H), 8.84 
(s, 1H), 8.63 (s, 1H), 8.05–8.02 (m, 1H), 7.99 (s, 1H), 7.92–
7.87 (m, 1H), 7.42 (dd [appeared as a t], J1 = J2 = 7.9 Hz, 
1H), 7.27–7.22 (m, 1H), 6.66 (dd, J = 17.0, 10.2 Hz, 1H), 6.36 (dd, J = 17.1, 1.9 Hz, 1H), 5.87 
(dd, J = 10.2, 1.9 Hz, 1H), 4.21 (s, 1H); 13C NMR (75 MHz, DMSO) δ 164.3, 157.7, 155.6, 
148.6, 139.7, 134.8, 132.9, 131.4, 129.4, 128.4, 128.3, 127.5, 125.6, 123.4, 122.2, 121.8, 
114.5, 83.9, 81.1. 
 
Synthesis of acetoxy(4-anilino)quinazoline derivatives (59–61) 
Synthesis of compounds 59–61 was carried out according to the general procedure that 
has been described for the synthesis of compounds 30–32. The appropriate 
acetoxyquinazoline derivatives at 150–500 mg scale were used to obtain the following 
compounds; 
 
4-(3-Ethynylanilino)quinazolin-6-yl acetate (59) 
Compound 59 was obtained in 56% yield (437 mg). The 
melting point was 210–212 °C; 1H NMR (300 MHz, DMSO) δ 
9.93 (s, 1H), 8.65 (s, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.11 (s, 1H), 
7.97–7.92 (m, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.69 (dd, J = 9.0, 2.4 
Hz, 1H), 7.41 (dd [appeared as a t], J1 = J1 = 7.6 Hz, 1H), 7.23 (dd, J = 7.6, 1.1 Hz, 1H), 4.21 
(s, 1H), 2.37 (s, 3H); 13C NMR (75 MHz, DMSO) δ 169.8, 157.9, 154.7, 148.5, 148.2, 139.9, 
129.8, 129.4, 129.0, 127.3, 125.3, 123.1, 122.2, 115.8, 115.4, 84.0, 81.1, 21.2. 
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4-(3-Chloro-4-fluoroanilino)quinazolin-6-yl acetate (60) 
Compound 60 was obtained in 64% yield (515 mg). The melting 
point was 235–237 °C; 1H NMR (300 MHz, DMSO) δ 11.92 (s, 
1H), 8.99–8.96 (m, 1H), 8.88 (s, 1H), 8.18–8.03 (m, 2H), 8.00–
7.92 (m, 1H), 7.83–7.73 (m, 1H), 7.62–7.50 (m, 1H), 2.39 (s, 3H); 
13C NMR (75 MHz, DMSO) δ 169.6, 160.1, 154.1 (d, 1JC-F = 249.2 Hz), 151.4, 150.0, 137.5, 
134.4, 131.9, 127.0, 125.8, 125.7, 122.2, 119.6 (d, 2JC-F = 18.2 Hz), 117.6 (d, 2JC-F = 22.5 Hz), 
114.9, 21.2. 
 
4-(3-Ethynylanilino)-7-methoxyquinazolin-6-yl acetate (61) 
Compound 61 was obtained in 54% yield (115 mg). The 
melting point was 238–340 °C ; 1H NMR (300 MHz, DMSO) δ 
11.61 (s, 1H), 8.93 (s, 1H), 8.89 (s, 1H), 7.91 (s, 1H), 7.79 (d, J 
= 8.1 Hz, 1H) 7.59 (s, 1H), 7.54–7.44 (m, 1H), 7.44–7.37 (m, 
1H), 4.29 (s, 1H), 4.00 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, DMSO) δ 168.9, 159.3, 157.9, 
151.4, 140.7, 140.0, 137.7, 129.9, 129.6, 127.8, 125.5, 122.5, 119.2, 107.7, 101.7, 83.4, 
81.8, 57.4, 20.7. 
 
Hydrolysis of the C-6 acetoxy (4-anilino)quinazoline compounds (62–65) 
The common hydrolysis procedure for the acetoxy(4-anilino)quinazolines was carried 
out in alcohol solutions (IPA or EtOH) under basic reaction conditions. The acetoxy 
protected compounds (100–300 mg scale) in ethanol (5 mL) were treated with 
ammonium hydroxide (25% NH4OH, 1.5 mL) solution and the reaction was kept at 40 ˚C 
with stirring for 2 h. At the end, excess solvent was removed in vacuo and the crude 
products were diluted with ice-cold water (10 mL), neutralised with 2 N HCl aqueous 
solutions and extracted into ethyl acetate (3 × 20 mL). The organic extracts were then 
dried over MgSO4 and purified by chromatographic methods in order to afford the 
following C-6 hydroxy-substituted 4-anilinoquinazoline compounds; 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 6 Experimental methods and .characterisation data  
151 
 
4-(3- Ethynylanilino)quinazolin-6-ol (62) 
Compound 62 was obtained in 57% yield (130 mg). The 
melting point was 228–230 °C;1H NMR (300 MHz, DMSO) δ 
10.11 (s, 1H), 9.55 (s, 1H), 8.49 (s, 1H), 8.10 (br s, 1H), 7.96–
7.91 (m, 1H), 7.79 (d, J = 2.5 Hz, 1H), 7.69 (d, J = 9.0 Hz, 1H), 
7.43 (dd, J = 9.0, 2.5 Hz, 1H), 7.37 (overlapping dd [appeared as a t], J1 = J2 = 8.1 Hz, 1H), 
7.20 (d, J = 7.6 Hz, 1H), 4.19 (s, 1H); 13C NMR (75 MHz, DMSO) δ 157.1, 156.1, 151.8, 144.5, 
140.4, 129.8, 129.3, 126.8, 125.0, 124.7, 122.8, 122.2, 116.8, 105.5, 84.1, 80.9; MS (ESI+) 




Compound 63 was obtained in 85% yield (141 mg). The 
compound underwent decomposition 1H NMR (300 MHz, 
DMSO) δ 10.13 (s, 1H), 9.59 (s, 1H), 8.51 (s, 1H), 8.28–8.24 (m, 
1H), 7.96–7.89 (m, 1H), 7.80 (d, J = 2.5 Hz, 1H), 7.70 (d, J = 9.0 
Hz, 1H), 7.45 (dd, J = 9.0, 2.5 Hz, 1H), 7.34 (dd [appeared as a t], J1 = J2 = 8.0 Hz, 1H), 7.29–
7.21 (m, 1H); 13C NMR (75 MHz, DMSO) δ 156.9, 156.2, 151.7, 144.6, 141.9, 130.8, 129.9, 
126.0, 124.8, 124.2, 121.6, 120.8, 116.8, 105.4; MS (ESI+) m/z 316.0080 was calculated 




Compound 64 was obtained in 64% yield (179 mg). 
Decomposition occurred during melting point determination; 
1H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.62 (s, 1H), 8.49 (s, 
1H), 8.24 (dd, J = 6.9, 2.5 Hz, 1H), 7.90–7.82 (m, 1H), 7.77 (d, J = 
2.3 Hz, 1H), 7.70 (d, J = 8.9 Hz, 1H), 7.49–7.38 (m, 2H); 13C NMR (75 MHz, DMSO) δ 156.9, 
156.18, 151.7 (d, JC-F = 254.3 Hz), 144.5, 137.4, 137.4, 129.9, 124.8, 123.5, 122.5, 119.2 (d, 
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2JC-F = 18.4 Hz), 117.1, 116.7 (d, JC-F  = 21.6 Hz), 105.4; MS (ESI+) m/z 290.0491 was 
calculated for C14H9ClFN3O [M+H]+ and 290.0491 was determined experimentally. 
 
4-(3-Ethynylanilino)-7-methoxyquinazolin-6-ol (65) 
Compound 65 was obtained in 71% yield (58 mg). The 
melting point was 240–242 °C; 1H NMR (300 MHz, DMSO) δ 
9.67 (s, 1H), 9.41 (s, 1H), 8.48 (s, 1H), 8.09 (s, 1H), 7.95–7.88 
(m, 1H), 7.81 (s, 1H), 7.37 (dd[appeared as a t], J1 = J2 = 8.1Hz, 
1H), 7.21 (s, 1H), 7.17 (d, J = 7.6 Hz, 1H), 4.17 (s, 1H), 3.98 (s, 3H); 13C NMR (75 MHz, 
DMSO) δ 156.5, 154.3, 152.5, 147.2, 146.7, 140.6, 129.3, 126.4, 124.7, 122.5, 122.1, 110.1, 
107.6, 105.9, 84.1, 80.8, 56.4; MS (ESI+) m/z 292.1080 was calculated for C17H13N3O2 
[M+H]+ and 292.1082 (-0.20 ppm) was determined experimentally; LC chemical purity 
was 97.3%. 
 
General esterification and insertion of the C-6 acrylate linker (66–69) 
The acrylate derivatives of 4-anilinoquinazoline compounds were prepared using a 
procedure similar to synthesis of compounds 52–58. The following compounds were 
obtained following chromatographic purifications; 
 
4-(3-Ethynylanilino)quinazolin-6-yl prop-2-enoate (66) 
Compound 66 was obtained in 81% yield (97.8 mg); The 
melting point was 174–176 °C; 1H NMR (300 MHz, 
DMSO) δ 9.79(s, 1H), 8.67 (s, 1H), 8.43 (d, J = 2.4 Hz, 1H), 
8.09 (m, 1H), 7.96–7.91 (m, 1H), 7.88 (d, J = 9.0 Hz, 1H), 
7.75 (dd, J = 9.0, 2.4 Hz, 1H), 7.42 (dd [appeared as a t], J1 = J2 = 7.9 Hz, 1H), 7.26–7.21 (m, 
1H), 6.64 (dd, J = 17.4,1.6 Hz, 1H), 6.58–6.47 (m, 1H), 6.25 (dd, J = 10.0, 1.6 Hz, 1H), 4.20 
(s, 1H); 13C NMR (75 MHz, DMSO) δ 164.8, 157.9, 154.8, 148.3, 148.2, 139.8, 134.8, 130.0, 
129.4, 128.8, 127.8, 127.3, 125.2, 123.0, 122.3, 115.8, 115.3, 83.9, 81.1; MS (ESI+) m/z 
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316.1080 was calculated for C19H13N3O2 [M+H]+ and 316.1073 (-0.70 ppm) was 
determined experimentally. 
 
4-(3-Bromoanilino)quinazolin-6-yl prop-2-enoate (67) 
Compound 67 was obtained in 79% yield (92.4 mg). The 
melting point was 184–186 °C  1H NMR (300 MHz, DMSO) 
δ 9.81 (s, 1H), 8.70 (s, 1H), 8.43 (d, J = 2.4 Hz, 1H), 8.26–
8.23 (m, J = 1.8 Hz, 1H), 7.95–7.86 (m, 2H), 7.76 (dd, J = 9.0, 
2.3 Hz, 1H), 7.76 (dd [appeared as a t], J1 = J2 = 7.9 Hz, 1H), 7.33–7.28 (m, 1H), 6.65 (dd, J 
= 17.2, 1.4 Hz, 1H), 6.52 (dd, J = 17.3, 10.0 Hz, 1H), 6.25 (dd, J = 10.1, 1.4 Hz, 1H); 13C NMR 
(75 MHz, DMSO) δ 164.7, 157.8, 154.7, 148.3, 148.3, 141.3, 134.9, 130.9, 130.0, 128.9, 
127.8, 126.6, 124.5, 121.7, 121.0, 115.8, 115.3; MS (ESI+) m/z 370.0186 was calculated 
for C17H12BrN3O2 [M+H]+ and 370.0186 and 372.0165 [82Br] were determined 
experimentally. 
 
4-(3-Chloro-4-fluoroanilino)quinazolin-6-yl prop-2-enoate (68) 
Compound 68 was obtained in 72% yield (85.3 mg). The 
melting point was 158–160 °C; 1H NMR (300 MHz, DMSO) δ 
9.84 (s, 1H), 8.67 (s, 1H), 8.39 (d, J = 2.4 Hz, 1H), 8.22 (dd, J = 
6.9, 2.6 Hz, 1H), 7.97–7.88 (d, J = 6.9 Hz, 1H), 7.87–7.80 (m, 1H), 
7.75 (dd, J = 9.0, 2.4 Hz, 1H), 7.45(dd [appeared as a t], 3JC-F = 3JH-H =  9.0 Hz, 1H), 6.65 (dd, 
J = 17.2, 1.6 Hz, 1H), 6.52 (dd, J = 17.2, 10.0 Hz, 1H), 6.25 (dd, J = 10.0, 1.6 Hz, 1H);13C NMR 
(75 MHz, DMSO) δ 164.7, 162.6, 157.7, 154.7, 152.2 (d, 1JC-F = 242.3 Hz), 148.3, 136.8, 
134.9, 130.0, 128.9, 127.8, 123.9, 122.8, 119.2 (d, 2JC-F = 20.6 Hz), 117.2 (d, 2JC-F = 21.0 Hz), 
115.7, 115.2; MS (ESI+) m/z 344.0597 was calculated for C17H11ClFN3O2 [M+H]+ and 
344.0595 (0.20 ppm) was determined experimentally; LC chemical purity was 98.0%. 
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4-(3-Ethynylanilino)-7-methoxyquinazolin-6-yl prop-2-enoate (69) 
Compound 69 was isolated in 84% yield (49.5 mg). The 
melting point was 158–160 °C; 1H NMR (300 MHz, DMSO) δ 
9.62 (s, 1H), 8.63 (s, 1H), 8.41 (s, 1H), 8.08 (s, 1H), 7.91 (d, J = 
7.5 Hz, 1H), 7.46–7.35 (m, 2H), 7.21 (d, J = 7.6 Hz, 1H), 6.67–
6.52 (m, 2H), 6.25 (d, J = 10.0 Hz, 1H), 4.20 (s, 1H), 3.95 (s, 3H); 13C NMR (75 MHz, DMSO) 
δ 164.1, 157.4, 155.9, 155.3, 150.7, 140.0, 139.3, 135.1, 129.4, 127.3, 127.0, 124.9, 122.7, 
122.2, 116.7, 109.2, 108.9, 84.0, 81.0, 56.9; MS (ESI+) m/z 346.1186 was calculated for 
C20H15N3O3 [M+H]+ and 346.1181 (0.50 ppm) was determined experimentally. LC 
chemical purity was 94.5%. 
 
 
The RAFT agent used in this study has already been prepared used in our research group 
and the necessary steps required for synthesis were as described next.45  
 
But-3-yn-2-yl 4-methylbenzene-1-sulfonate (70) 
Preparation of compound 70 was carried out according to a modified 
literature procedure.46 A suspension of KOH (3.20 g, 84.2 mmol) and tosyl 
chloride (5.25 g, 27.6 mmol) in THF (60 mL) solvent was placed in ice-bath, 
under inert atmosphere. But-3-yn-2-ol (1.61 g, 22.9 mmol) was added in one 
portion via syringe to the suspension with stirring. The reaction mixture was 
then allowed to slowly warm to a room temperature as the ice-melted and it 
was stopped after 2 h. The resultant white precipitate and excess KOH were filtered off 
and the solvent was removed from the rotary evaporator. The concentrate was diluted 
with Diethyl ether (Et2O, 30 mL), and washed with ice-cold water (3 × 25 mL), dried over 
MgSO4, filtered and the product was recovered as a colourless oil. The recovered product 
was purified further by means of a column chromatography using 30% EtOAc/Hex eluent 
to obtain 70 in 84% yield (5.16 g). 1H NMR (300 MHz, CDCl3) δ 7.86–7.80 (m, 2H), 7.38–
7.32 (m, 2H), 5.18 (qd, J = 6.7, 2.2 Hz, 1H), 2.46 (s, 3H), 2.43 (d, J = 2.2 Hz, 1H), 1.59 (d, J = 
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6.7Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 144.9, 133.8, 129.7 (2C), 128.0 (2C), 79.9, 75.5, 
67.4, 22.6, 21.7. The 1H NMR data was in agreement with that reported in the literature.46 
 
S-But-3-yn-2-yl O-ethyl carbonodithioate (71) 
A preparation procedure for compound 71 was carried out according to a 
literature procedure.47 Tosyl butynyl (2.50 g, 11.1 mmol) and potassium O-ethyl 
carbonodithioate (4.10 g, 25.1 mmol) were dissolved in THF (60 mL) and the 
reaction was stirred at room temperature for 12 h covered with aluminium foil. 
The resulting precipitate was filtered off, the filtrate was concentrated and 
diluted with ice-cold water (60 mL). The product was then extracted into DCM (3 × 60 
mL), dried over MgSO4, and filtered. The organic solvent was evaporated in vacuo and the 
crude product was purified by column chromatography to obtain a pale yellow oil in 88% 
(1.71 g).47 1H NMR (300 MHz, CDCl3) δ 4.68 (dq, J = 6.9, 2.4 Hz, 2H), 4.48 (q, J = 7.2 Hz, 
1H), 2.35 (d, J = 2.4 Hz, 1H), 1.63 (d, J = 6.9 Hz, 3H), 1.44 (m, t, J = 6.9 Hz 3H); 13C NMR (75 
MHz, CDCl3) δ 212.1, 82.9, 71.5, 70.1, 35.0, 21.2, 13.8. The 1H NMR data matched that 
reported in the literature.47 
 
1 H-Imidazole-1-sulfonyl azide hydrochloride (72) 
The azide transfer agent was a necessary precursor for the next azide 
compound that was synthesized immediately hereafter. Thus, preparation of 
this azide transferring agent was carried out in a step-by-step procedure as 
described by Goddard-Borger.48 The resultant product was obtained as a white powder 
in 41% yield (8.59 g). 1H NMR (300 MHz, D2O) δ 9.21–9.19 (m, 1H), 7.91–7.87 (m, 1H), 
7.49–7.46 (m, 1H). The 1H NMR spectra resembled the one reported in the literature.48 
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Preparation of the azido compound 73 was performed according to the 
literature procedure using 1H-imidazole-1-sulfonyl azide hydrogen 
chloride at 1.2 molar equivalents excess to the amine at 1.01 g scale (4.04 
mmol).48 Following a chromatographic purification of the product using 
hexane as an eluent, pale-yellow oil was obtained in 98% yield (565 mg). 1H NMR (300 
MHz, CDCl3) δ 4.62 (br t, J = 5.6 Hz, 1H), 3.75–3.61 (m, 2H), 3.59–3.46 (m, 2H), 3.39 (br t, 
J = 6.8 Hz, 2H), 1.95–1.85 (m, 2H), 1.23 (t, J = 7.0 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 100.5, 
61.9 (2C), 47.5, 33.2, 15.3 (2C). The 1H NMR was in agreement with that reported in the 
literature.48 
 
S-{1-[1-(3,3-Diethoxypropyl)-1H-1,2,3-triazol-4-yl]ethyl} O-ethyl carbonodithioate (74) 
A triazole-based RAFT agent was synthesised according to a published 
procedure by the Klumperman’s research group with minor 
modifications.47 3-Azido-1,1-diethoxypropane (2.00 g, 11.6 mmol) was 
added to CuSO4·5H2O (292 mg, 1.17 mmol), sodium ascorbate (620 mg, 3.13 
mmol) in DMF (2 mL). The reaction mixture was placed in the ice-bath and 
S-but-3-yn-2-yl O-ethyl carbonodithioate (2.23 g, 12.8 mmol) was added in 
a drop-wise manner via a syringe. The reaction was allowed to warm to a 
room temperature and stirring was continued for 1.5 h. The ambient colour 
transition from the hydrated copper blue to the yellow and finally the permanent light 
brown colour were observed as the reaction progressed. The reaction mixture was 
filtered and purified over a silica gel column to afford colourless oil in 91% yield (3.85 g). 
1H NMR (300 MHz, CDCl3) δ 7.44 (s, 1H), 5.01 (q, J = 7.2 Hz, 1H), 4.57 (q, J = 7.1 Hz, 2H), 
4.39 (t, J = 5.5 Hz, 1H), 4.37 (t, J = 7.1 Hz, 2H), 3.65–3.50 (m, 2H), 3.46–3.35 (m, 2H), 2.14 
(dt, J = 7.1, 5.5 Hz, 2H), 1.74 (d, J = 7.2 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.0 Hz, 
7H); 13C NMR (75 MHz, CDCl3) δ 213.2, 148.1, 121.5, 100.3, 69.9, 62.2 (2C), 46.2, 40.9, 
34.4, 20.2, 15.3 (2C), 13.8. The 1H NMR was in agreement with that reported in the 
literature.45 
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Polymerisation procedure for PVP was also carried out by selecting optimal conditions 
reported by Reader et al.45 in which polymerisation exhibited the most controlled system 
with low polydispersity. Thus, NVP (5.00 g, 45.0 mmol), AIBN (44 mg, 0.27 mmol) and 
RAFT agent (373 mg, 1.07 mmol) were dissolved in 1,4-dioxane (5 mL) solvent. The 
reaction mixture was subjected to three freeze-pump-thaw cycles and polymerisation 
reaction was conditioned at 60 °C for 24 h. At the end, the reaction was stopped by 
precipitating the polymer into Et2O and the solvent was decanted. The precipitate was 
then dissolved into DCM under stirring and precipitated back into Et2O. The procedure 
was repeated three times before the polymer was dried under high vacuum at a room 
temperature to obtain a white powder. The 1H NMR data corresponded to that reported 
in the literature.45 
 
 
Under inert conditions, a PVP polymer (2.50 g, 1.59 mmol) was dissolved into acetone 
(10 mL) and cyclohexylamine (730 µL, 6.37 mmol) was added to the solution and the 
reaction was stirred at a room temperature for 5 h. At the end of the reaction, Et2O was 
once again used to precipitate the thiol-terminated polymer and the solvent was 
decanted. The precipitated polymer was dissolved back into dichloromethane, stirred 
and precipitated again into Et2O solvent. The procedure was repeated three times before 
a thiol-terminated PVP polymer was dried under high vacuum at a room temperature. 
The product was obtained as a white powder in 96% yield (2.27 g). 
 
 
In a screw top V-vial was added a PVP polymer (50mg, 0.03 mmol), TCEP·HCl (10.0 mg, 
0.03 mmol), and a suitable 4-aniliquinazoline compound (~12.5 mg, 1.1 molar 
equivalents) were dissolved to 1 mL with DMF solvent. To this solution was added 20% 
NH4OH (10 µL) and the reaction mixture was stirred at a room temperature for 16 h. At 
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the end, the resultant solution was purified by dialysis using 10% ethanol in deionised 
water over 24 h and then 100% deionised water for another 24 h. The aqueous samples 
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This chapter contains the concluding remarks based on the research outcomes of the 
objectives of the study. Recommendations for further improving the anti-tumour efficacy 




In this research study, polymer-drug conjugates of 4-anilinoquinazoline small-molecule 
EGFR tyrosine kinase inhibitors and PVP, covalently bound by an acid-labile linker group, 
were developed. A small library of 4-anilinoquinazoline compounds with a α,β-
unsaturated carbonyl moiety (acrylamides and acrylates) at the C-6 position were 
synthesised. These quinazoline-based anti-tumour agents, commonly used for clinical 
application in adenocarcinoma lung cancer, were then conjugated to a pre-defined thiol-
terminated PVP polymer using the Michael addition reaction, thus affording PVP-(4-
phenyl amine)quinazoline conjugates. 
The resultant amphiphilic polymer-drug conjugates were assembled into a spherical 
micellar drug delivery system. The drug release profiles for these formulations were 
realised under physiological and acidic conditions, and the hydrolytic stability of the 
covalent linker groups was established. A high degree of drug release selectivity in an 
acidic environment was obtained, to favour the tumouritropic drug delivery aspect of pH-
sensitive micelle formulations. Based on the results of our studies, the mode of the EGFR 
kinase inhibition mechanism in the present formulation of polymer-bound 4-
anilinoquinazoline was determined to be reversible and ATP-competitive in nature. 
Preliminary in vitro biological assays strongly demonstrated the influence of the 
inhibition mechanisms to be a determinant factor for the anti-tumour efficacy of 4-
anilinoquinazolines. Hence, the polymer-drug conjugates exhibited anti-tumour 
activities that were comparable to the corresponding small molecules (reversible 
inhibitors). The conjugates also shared reduced anti-tumour efficacy profiles with the 
respective small molecules against drug-resistance-inducing secondary mutation EGFR 
T790M.  
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In general, compounds carrying the acrylamide Michael acceptor showed excellent anti-
tumour activity and the β-thiopropionamide polymer conjugate showed good anti-
tumour activity in comparison with Gefitinib. Due to the sustained EGFR kinase inhibition 
by the irreversible inhibitors, their anti-tumour potency proved superior to reversible 
inhibitors, irrespective of the present formulation of the micelles. Based on the overall 
outcome of this work, further developments in the chemistry of the present conjugates 
are planned, as described in the next section. 
 
 
In consideration of the potential advantages offered by the polymer-drug conjugates, a 
number of modifications to the present formulation are proposed for further 
investigation. First, the potency of the conjugates must be enhanced to the level or beyond 
that of the irreversible EGFR kinase inhibitors. In doing so, the criteria of this 
modification should take into account the mutation status of the EGFR target. At present, 
double mutant EGFR L858R/T790M tumour cells can be overcome by irreversible kinase 
inhibitors,1 but the newly acquired mutant EGFR T790M/C797S is very likely to be 
circumvented by the allosteric inhibitors.2 Given this scenario, the first attempt would 
involve upgrading the PVP-(4-phenyl amino)quinazoline conjugates to irreversible EGFR 
kinase inhibitors. Thus, generating the α,β-unsaturated Michael acceptor under 
physiologically relevant acidic conditions would generally be the universal reaction of 
interest.  
Among the three broadly categorised elimination mechanisms (E1, E1cb, E2) that can 
generate an olefin adjacent to a carbonyl group, the E1cb has recently been used by the 
research group of Tautonas as an alternative and very attractive for reversible-covalent 
inhibition.3 Unfortunately, generating the Michael acceptor under the reported E1cb 
elimination conditions requires an α,β-unsaturated olefin that is substituted with an 
electron-withdrawing group in the α-position of the carbonyl. Moreover, the authors 
have reported this system to undergo reversible cleavage under physiological 
conditions,3a which is unfavourable for our present conjugation design. Thus, in the near 
future, we intend to explore a modified Reich olefin formation reaction using the 
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sulfoxides. This is a largely under-exploited reaction, relative to making use of the well-
known seleneoxides.4 To apply this reaction to our design, the current set up can 
potentially be modified as shown in Figure 7.2 (a). 
 
Figure 7.2 (a) Modification of β-thiopropionamide conjugate linker group by oxidation 
of the thioether. For a simplified presentation, only the last NVP monomer and the amide 
linker are shown in full. 
The selective mono-oxidation of polymer-drug conjugate [Fig. 7.2 (a)] presents a 
versatile chemistry that can be exploited in many forms, including a change in drug 
release mechanism.5 The proposed retro-Michael addition reaction [see Fig. 7.2 (b)] is 
perceived to proceed via simultaneous elimination of the vicinal substituents on the 
alkane skeleton, being S=O and H, via a cyclic transition state that involves abstraction of 
a β-proton in a syn fashion to form the α,β-unsaturated olefin.4 The same β-elimination 
mechanisms leading to the formation of olefins using sulfoxides are well distinguished in 
other reactions, such as the Morin rearrangement.6 This reaction is an ideal case of 
intramolecular E2 elimination for which (i) acrylamide (covalent-irreversible) and/or 
(ii) sulfenic acid (covalent-reversible) functionalities could be formed. In the former case 
of (i), β-elimination via abstraction of the more acidic proton in the α-position to the 
carbonyl (electron-withdrawing group) is a more favourable kinetic product under 
physiological conditions.5  
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Figure 7.2 (b) Proposed β-eliminative cleavage products of modified PVP-(4 phenyl 
amine)quinazoline conjugates under acidic tumour microenvironment. 
The latter case (ii) represents a thermally promoted E2 reaction in which NVP loses its β-
proton to form a sulfenic acid terminated product.4b, 7 Thermally promoted E2 reactions 
have been observed for seleneoxides at room temperature in acidic media,7 but they are 
generally substituent sensitive. Nevertheless, sulfenic acid exhibits electrophilic 
character and can undergo condensation with cysteine to form disulfide bonds.8 It is often 
regarded as a transient oxidation state to the formation of disulfides under physiologic 
conditions. The biggest challenge will however be the hydrolytic cleavage of the amide 
bond of the linker group. Hence, careful execution of these experiments is very critical, 
and this would perhaps lead to a different choice of the linker group. The reactions similar 
to the retro-Michael eliminations have been applied in time-delayed fragrance delivery 
systems of the enone functionality in different skeletons such as damascone.9 In a 
biological setting, the formation of the more bioactive Brefeldin A, an α,β-unsaturated 
antibiotic lactone, has been speculated to form via syn elimination of the sulfoxide 
analogues.10 
Presented with the most recent EGFR C797S,11 it must be appreciated that this mutation 
is resistant to irreversible EGFR kinase inhibitor drugs with electrophilic Michael 
acceptors. This has opened a new opportunity for the discovery of more electrophilic 
agents that can form a covalent bond with the serine (–OH) in tumour cells. The aliphatic 
serine (–OH, pKa >13) has almost the same nucleophilicity as water and is relatively inert 
to the Michael acceptors under acidic conditions.12 We thus also intend to explore the E1 
reaction using 2-thioethanol derivatives as solubilising groups for quinazoline-based 
kinase EGFR kinase inhibitors. The thioethanol functionality has a potential to form 
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highly reactive thiiranium ion intermediate [refer to Fig. 7.12 (c)] in a stepwise fashion 
in an acidic environment,13and it can be used to target a number of cellular nucleophiles 
such as cysteine thiols (SH) and serine (OH). It can also be viewed as poly(alcohol) chain 
mimicry for enhancing the aqueous solubility.14 This new functionality can potentially 
expand the use of 4-anilininoquinazoline compounds against lung adenocarcinoma 
patients that accrue both EGFR L858R/T790M and EGFR C797S mutations. It is expected 
that further anti-tumour efficacy of the modified PVP-(4-phenyl amine)quinazoline 
conjugates will also be achieved. 
 
Figure 7.2 (c) Proposed new linker group for reversible-covalent (EGFR C797S) or 
irreversible-covalent inhibition (EGFR T790M), depending on targeted nucleophile. 
This is the end of the current work on the synthesis of polymer-bound SMKIs. An outline 
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